

**Purinergic Signaling during Rat Embryonic  
Development**

by

**Kwok Kuen CHEUNG**

**Department of Anatomy and Developmental Biology  
University College London**

**A thesis submitted to the University College London  
in partial fulfillment of the requirements for the degree of  
Doctor of Philosophy  
in  
Neurosciences**

**September 2003**

## **Abstract**

Adenosine 5'-triphosphate (ATP) has been shown to be an important extracellular signaling molecule that mediates various physiological activities via the P2 (P2X and P2Y) receptors. However, information on the expression patterns of the P2 receptors during mammalian embryogenesis is limited. We therefore examined the expression patterns of different P2 receptor subtypes in rat embryos. In the hindbrain neural tube, the P2X<sub>3</sub> receptor was transiently expressed at embryonic day E11 in the cranial motor neurons and the outgrowing axons. ATP significantly inhibited neurite outgrowth from neural tube explants. P2X<sub>3</sub> receptors were also prominently expressed in sensory ganglia at this early stage and were coexpressed with P2X<sub>2</sub> receptors in E16.5 embryos. Other P2X receptor subtypes were observed in different brain regions such as subventricular zones, the site of postnatal neurogenesis. In addition, the P2Y receptor expression was detected in the somites and subsequently in the developing skeletal muscle but was downregulated as development proceeded. While the P2Y<sub>1</sub> receptor was no longer expressed in the adult skeletal muscle, the expression of P2Y<sub>2</sub> receptor was present, although restricted in the satellite cells and the P2Y<sub>4</sub> receptor showed reduced expression in adult skeletal muscle. Likewise, the expression of the P2Y receptors was initially expressed throughout the myocardium (E12) but was gradually restricted to the trabeculated myocardium (E14-18). Studies on Ca<sup>2+</sup> influx showed that

particular P2 receptor subtypes of P2X<sub>2</sub>, P2X<sub>4</sub>, P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptors responded to nucleotides in E14 cardiomyocytes. P2X<sub>7</sub> receptor expression was detected in developing pancreatic islet cells and later coexpressed with glucagon in  $\alpha$ -cells. In addition, transient expression of the P2X<sub>7</sub> receptor in insulin-expressing cells was observed in the embryonic, but not in adult, islet cells. Together, the results indicated that widespread and dynamic expression of P2 receptors was found in the three-germ layer-derived embryonic tissues, particularly in some transient embryonic structures during development, which suggested they may be important in embryonic organogenesis

## **Acknowledgements**

The opportunity for exposure to research on purinergic signaling has gained me valuable knowledge and experience, which are crucial to my research career in the future. For this, I would first like to express my gratitude sincerely to my principal supervisor, Prof. Geoffrey Burnstock, who has guided me into critical thinking and key skills in scientific writing. His enthusiastic attitude on scientific research, and his endless effort in proposing purinergic signaling though encountering resistance over several decades, has undoubtedly set an example for me of how a scientist should be. In addition, I would also like to thank my second supervisor Dr Jonathan Clarke for his sincere advice on my project.

Many thanks are due to my fellows in the Autonomic Neuroscience Institute including for their help and support. Special thanks are due to Mrs Annie Evans, Dr. Chrystalla Orphanides, Dr. Robson Coutinho-Silva and Dr. Mina Ryten for their friendship and constant support and encouragement.

I would also like to thank my flatmates in Langton Close and the Finsbury Park Congregation of the Chinese Church in London for being with me during my stay in London. I would also like to take this opportunity to acknowledge Prof. Woody Chan and

the colleagues in Department of Anatomy, CUHK, who provided me with invaluable advice and technical assistance essential during the course of my project. My thanks are also due to Prof Andrew Copp and his groups in the Institute of Child Health, UCL, for their technical support. I would also like to express my sincere thanks to Henry and Janice for their constant support.

I am deeply grateful to my churchmates in Shatin Free Methodist Church in Hong Kong for their prayers. Last but not least, I wish to record my indebtedness to my brothers and sisters, particularly my mother and my wife, for their encouragement, consideration and love.

## Abbreviations

2MeSADP	2-Methylthio- adenosine 5'-diphosphate
2MeSATP	2-Methylthio- adenosine 5'-triphosphate
ADP	Adenosine 5'-diphosphate
AMP	Adenosine 5'-monophosphate
ATP	Adenosine 5'-triphosphate
ATP $\gamma$ S	Adenosine 5'-O-(3-thio)triphosphate
BzATP	2',3'-O-(4-benzoylbenzoyl)- Adenosine 5'-triphosphate
CNS	Central Nervous System
E	Embryonic day
FLIPR	Fluorometric Imaging Plate Reader
IgG	Immunoglobulin G
IP3	Inositol triphosphate
KN62	1-(N,O-bis[5-isoquinolinesulphyl]-N-methyl-L-tyrosyl)-4-phenylpiperazine
MAPK	Mitogen Activated Protein Kinase
MRS2179	2'-deoxy-N <sup>6</sup> -methyladenosine-3',5'-bisphosphate
NANC	Nonadrenergic noncholinergic
NF023	8,8'-(carbonylbis(imino-3,1-phenylene carbonylimino)bis(1,3,5-naphthalenetrisulfonic acid))
P	Postnatal day
PGP9.5	Protein Gene Product 9.5
PKC	Protein Kinase C
PLC	Phospholipase C
PNS	Peripheral Nervous System
PPADS	Pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid
RT-PCR	Reverse Transcriptase-Polymerase Chain Reaction
Shh	Sonic Hedgehog
TNP-ATP	2',3'-O-(2,4,6-trinitrophenyl)- Adenosine 5'-triphosphate
UDP	uridine 5'-diphosphate
UTP	uridine 5'-triphosphate
$\alpha\beta$ -meATP	$\alpha\beta$ -methylene ATP
$\beta,\gamma$ -meATP	$\beta,\gamma$ -methylene ATP

# OUTLINE OF CONTENTS

Abstract-----	ii
Acknowledgement-----	iv
Abbreviations-----	vi
Outline of Contents-----	vii

## Chapter I Introduction

<b>I.1 Brief historical perspective on purinergic signaling-----</b>	<b>1</b>
I.1.a    ATP as an extracellular signaling molecule -----	1
1.1.b    Source and mechanisms of ATP release-----	4
<b>I.2 Purinergic receptors-----</b>	<b>5</b>
<i>I.2.a Classification of purinoceptors-----</i>	<i>6</i>
<i>I.2.b P2X receptor-----</i>	<i>6</i>
<i>I.2.b.i P2X<sub>1</sub> receptor-----</i>	<i>9</i>
<i>I.2.b.ii P2X<sub>2</sub> receptor-----</i>	<i>10</i>
<i>I.2.b.iii P2X<sub>3</sub> receptor-----</i>	<i>12</i>
<i>I.2.b.iv P2X<sub>4</sub> receptor-----</i>	<i>13</i>
<i>I.2.b.v P2X<sub>5</sub> receptor-----</i>	<i>15</i>

<i>I.2.b.vi</i>	<i>P2X<sub>6</sub> receptor</i>	-----17
<i>I.2.b.vii</i>	<i>P2X<sub>7</sub> receptor</i>	-----18
<i>I.2.c</i>	<i>P2Y receptors</i>	-----20
<i>I.2.c.i</i>	<i>P2Y<sub>1</sub> receptor</i>	-----21
<i>I.2.c.ii</i>	<i>P2Y<sub>2</sub> receptor</i>	-----22
<i>I.2.c.iii</i>	<i>P2Y<sub>4</sub> receptor</i>	-----23
<i>I.2.c.iv</i>	<i>P2Y<sub>6</sub> receptor</i>	-----24
<i>I.2.c.v</i>	<i>P2Y<sub>11</sub> receptor</i>	-----25
<i>I.2.c.vi</i>	<i>P2Y<sub>12</sub> receptor</i>	-----26
<i>I.2.c.vii</i>	<i>P2Y<sub>13</sub> receptor</i>	-----27
<i>I.2.c.viii</i>	<i>P2Y<sub>14</sub> receptor</i>	-----27
<b>I.3</b>	<b>Purinergic signaling during embryonic development</b>	-----28
<i>I.3.a</i>	<i>Brief introduction on mammalian embryonic development</i>	-----28
<i>I.3.a.i</i>	<i>From zygote to bilaminar germ disc</i>	-----28
<i>I.3.a.ii</i>	<i>Gastrulation</i>	-----29
<i>I.3.a.iii</i>	<i>Somite formation and development of urogenital system and limb</i>	-----30
<i>I.3.a.iv</i>	<i>Neurulation and neural crest migration and differentiation</i>	-----32



<i>I.3.a.v</i>	<i>Development of cardiovascular system</i>	33
<i>I.3.a.vi</i>	<i>Development of respiratory and gastrointestinal system</i>	34
I.3.b	Purinergic signaling during embryonic development	35
<b>I.4</b>	<b>Objective of studies</b>	39
Tables		41

## **Chapter II Localization of P2X<sub>3</sub> receptors and coexpression with P2X<sub>2</sub> receptors during rat embryonic neurogenesis**

<b>Abstract</b>	44
<b>Introduction</b>	46
<b>Materials and Methods</b>	51
<i>Tissue preparation</i>	51
<i>Immunohistochemistry</i>	52
<i>Immunofluorescence double labeling</i>	53
<i>Photomicroscopy</i>	55
<i>Data analysis</i>	55
<b>Results</b>	56
<b>Discussion</b>	63

**Figures & Legends -----73**

**Chapter III Abundant and dynamic expression of G protein-coupled P2Y  
receptor in mammalian development**

**Abstract-----91**

**Introduction-----93**

**Materials and Methods-----96**

*RT-PCR analysis-----96*

*Tissue preparation-----97*

*DAB Immunohistochemistry and Immunofluorescence double labeling*

*-----97*

*Photomicroscopy-----98*

**Results-----99**

**Discussion-----107**

**Figures & Legends-----115**

**Chapter IV Expression of P2X purinoceptors during rat brain development  
and their inhibitory role on motor axon outgrowth in neural  
tube explant cultures**

<b>Abstract</b>	131
<b>Introduction</b>	134
<b>Materials and Methods</b>	137
<i>RT-PCR analysis</i>	137
<i>Tissue processing and immunohistochemistry</i>	137
<i>Photomicroscopy</i>	138
<i>Neural tube explant culture</i>	138
<i>Immunostaining of collagen gels and quantitation of axon outgrowth</i>	139
<b>Results</b>	141
<b>Discussion</b>	146
<b>Figures &amp; Legends</b>	152

## **Chapter V Pharmacological and molecular characterization of functional P2 receptors in rat embryonic cardiomyocytes**

<b>Abstract</b>	164
<b>Introduction</b>	166
<b>Materials and Methods</b>	169
<i>Cell Culture and Ca<sup>2+</sup> mobilization analysis</i>	169
<i>Double labeling immunocytochemistry</i>	170

<i>RT-PCR analysis</i> -----	171
------------------------------	-----

<b>Results</b> -----	172
----------------------	-----

<b>Discussion</b> -----	175
-------------------------	-----

<b>Figures &amp; Legends</b> -----	180
------------------------------------	-----

## **Chapter VI Expression of ATP-gated P2X<sub>7</sub> receptor in the developing rat pancreas**

<b>Abstract</b> -----	192
-----------------------	-----

<b>Introduction</b> -----	193
---------------------------	-----

<b>Materials and Methods</b> -----	196
------------------------------------	-----

Tissue preparation-----	196
-------------------------	-----

<i>Immunofluorescence double labeling</i> -----	196
---	-----

<b>Results</b> -----	197
----------------------	-----

<b>Discussion</b> -----	199
-------------------------	-----

<b>Figures &amp; Legends</b> -----	202
------------------------------------	-----

## **Chapter VII General discussion and conclusion**

<b>VII.1 Introduction</b> -----	208
---------------------------------	-----

<b>VII.2 P2 receptors in ectoderm-derived tissues</b> -----	209
---	-----

Nervous system-----	208
<b>VII.3 P2 receptors in mesoderm-derived tissues-----</b>	<b>216</b>
VII.3a Somites and skeletal muscles-----	216
VII.3b Heart-----	218
<b>VII.4 P2 receptors in ectoderm-derived tissues-----</b>	<b>220</b>
Pancreas-----	220
<b>VII.5 Concluding Remarks-----</b>	<b>222</b>
<b>References-----</b>	<b>223</b>
<b>Appendix-----</b>	<b>254</b>

# I. General Introduction

## I.1 Brief historical perspective on purinergic signaling

### *I.1.a ATP as an extracellular signaling molecule*

Adenosine triphosphate (ATP), a molecule which belongs to the purine family, was first identified in muscle cells independently by Fiske and Subbarow and by Lohmann in 1929 (see Schlenk, 1987; Maruyama, 1991). The chemical structure of ATP is made of a nitrogenous base (adenine), a sugar (ribose) and a chain of three ionized groups (phosphates) bound to the ribose (see Bodin and Burnstock, 2001a). In the field of biochemistry, the most important value of ATP lies on its phosphate groups, which can undergo hydrolytic release in aqueous solution with large negative free energy changes. Therefore ATP was thought of largely as a store of free energy in the cell soon after its discovery, and even till now. Hydrolysis of ATP is used to drive innumerable biochemical reactions, including many that are not phosphorylations. It is a source of energy for cell motility, muscle contraction, and the specific transport of substances across membranes (Mathews and van Holde, 1990). ATP was generated during anaerobic glycolysis in the cytoplasm, within the citric cycle and predominantly during oxidative phosphorylation in the mitochondria (Kalckar, 1969). Hydrolysis of ATP can proceed in either of two ways. Either the terminal phosphate can be cleaved off to produce adenosine diphosphate (ADP) and phosphate ( $P_i$ ), or cleavage may occur at the second phosphodiester bond to yield adenosine monophosphate

(AMP) and pyrophosphate (PP<sub>i</sub>). The former reaction is the more common one in vivo, but the free energy yield is about the same for both. As a result, ATP soon appeared as the most fundamental of all biomolecules and the universal source of readily available chemical energy for all living cells. It has been estimated that ATP participates in more chemical reactions than any other compound on the earth's surface, except water (Burnstock, 1996).

Because of this essential intracellular role, there was a considerable resistance to the concept that ATP could exert any extracellular physiological action, the main argument being that cells would not release a bio-molecule so fundamental to life, a line of thought which was reinforced by the fact that a molecule the size and charge of ATP could not cross the plasma membrane by simple diffusion (Glynn, 1968; Chaudry, 1982). Very soon after the discovery of ATP, however, it became apparent that purine nucleotides were able to exert profound extracellular effects on different organs and tissues.

In the same year of ATP discovery, Drury and Szent-Györgyi (1929) reported the first time that extracellular purines were responsible for a negative chronotropic effect on the heart, a dilatation of coronary vessels and an inhibition of the spontaneous activity of the intestinal smooth muscle, though the crude tissue extracts used contained mostly AMP (see Vassort, 2001). In 1959, Holton showed that ATP was released to the rabbit ear artery

during antidromic stimulation of sensory nerve, resulting in vasodilatation. Hughes and Vane (1967, see Burnstock, 1979) also noted that the responses of the rabbit portal vein to ATP resembled the inhibitory responses to the nonadrenergic, noncholinergic (NANC) intramural nerve stimulation. The NANC nerves, which were characterized by the responses upon the stimulation in the presence of adrenergic and cholinergic neuron blocking agents (or in the absence of adrenergic and cholinergic stimulation), were first defined in 1963 (Burnstock et al, 1963, 1964; Martinson and Muren 1963), although atropine-resistant responses of the urinary bladder were described as far back as 1895 by Langley and Anderson (see Burnstock, 1986). Before ATP was identified to be the actual transmitter for NANC stimulation, other biochemicals were explored as possible candidates, e.g. catecholamines, 5-hydroxytryptamine, cyclic adenosine monophosphate (cAMP), histamine, prostaglandins, amino acids such as glycine and  $\gamma$ -aminobutyric acid (GABA), and polypeptides bradykinin and substance P. However, these substances were rejected by most researchers on the grounds that they were either inactive or did not mimic the nerve-mediated response, or that their action was by stimulation of nerves and not by direct action on smooth muscle (Burnstock et al., 1970). Evidence that ATP was synthesized, stored and released from NANC nerves supplying the intestinal smooth muscle, together with considerable additional evidence available, led Burnstock to propose that ATP was a primary neurotransmitter in NANC nerves in the gut and bladder and thus put forward the *purinergic*



nerve hypothesis (Burnstock, 1972). In the following years, the purinergic signaling was described in many other tissues and systems (see Burnstock, 1979, 1997).

### ***1.1.b Source and mechanisms of ATP release***

Considering that ATP functions as an extracellular signaling molecule, it must have a source of release. Both neuronal and non-neuronal cells have been shown to release ATP. A pilot study for neuronal ATP release has shown that ATP was released from the nerve endings upon antidromic stimulation of the sensory nerve (Holton, 1959). However, it was not until Burnstock (1972) proposed the purinergic hypothesis that ATP became a clear candidate for a neurotransmitter. Burnstock (1976) challenged the principle that nerve cells released one transmitter; his group had shown that ATP might be released from sympathetic nerves, together with noradrenaline in taenia coli (Su et al., 1971), and much supporting evidence has accumulated since then (see Burnstock, 1990, 1999a). Moreover, ATP was shown early on to act as a cotransmitter with acetylcholine in the bladder (Burnstock et al., 1978) and with noradrenaline in the cat nictitating membrane (Langer and Pinto, 1976), vas deferens (Vizi and Burnstock, 1988; Westfall et al., 1978), the rat tail artery (Sneddon and Burnstock, 1984) and the aorta (Sedaa et al., 1990).

There have been an increasing number of studies describing ATP release from

non-neuronal cells. The first hint of ATP release from non-neuronal cells was shown in the circulation of the occluded human forearm in response to effort (Forrester and Lind, 1969). Direct proof came from the investigation on isolated cells present in the vascular system such as platelets (Detwiler and Feinman, 1973), red blood cells (Bergfeld and Forrester, 1989), mononuclear cells (Maugeri et al., 1990), endothelial cells and smooth muscle cells (Pearson and Gordon, 1979; Bodin et al., 1991), which all release ATP mostly upon mechanical stimulation. Other cell types shown to release ATP, including distended uroepithelial cells (Ferguson et al., 1997), pancreatic  $\beta$  cells (Hazama et al., 1998), astrocytes (Contrina et al., 1998), glial cells (Queiroz et al., 1999), Sertoli cells (Lalevée et al., 1999) and chondrocytes (Graff et al., 2000). ATP can be released from non-neuronal cells by a large variety of stimuli, including, among others, hypoxia, acidosis, osmotic shock, receptor stimulation, fluid shear stress and mechanical stimulation (Detwiler and Feinman, 1973; Bergfeld and Forrester, 1989; Bodin and Burnstock, 1996). Recent findings identify transport proteins belonging to the ATP-binding cassette (ABC) family that transport ATP or at least stimulate the activity of a separate ATP channel protein (Schwiebert, 1999). The most common ABC proteins are the cystic fibrosis transmembrane conductance (CFTR), P-glycoprotein and the sulfonylurea receptor (SUR) (see Bodin and Burnstock, 2001a).

## **I.2 Purinergic receptors**

### ***1.2.a Classification of purinoceptors***

Extracellular purines and pyrimidines mediate diverse physiological activities by acting on cell surface receptors termed purinergic receptors or purinoceptors (see Abbracchio and Burnstock, 1998). There are two main families of purine receptors, adenosine or P1 receptors, and P2 receptors, recognizing primarily ATP, ADP, UTP and UDP (Burnstock, 1978). Adenosine or P1 receptors have been further subdivided, according to convergent molecular, biochemical, and pharmacological evidence into four subtypes,  $A_1$ ,  $A_{2A}$ ,  $A_{2B}$ , and  $A_3$ , all of which couple to G-proteins (see Ralevic and Burnstock, 1998). Similarly, P2 receptors, based on differences in molecular structure and signal transduction mechanisms were divided into two families: the ligand-gated ion channels (P2X receptors) and G protein-coupled receptors (P2Y receptors) (Abbracchio and Burnstock, 1994). To date, seven P2X receptors subtypes and eight P2Y receptors have been cloned (Burnstock, 2003). Individual subtypes of P2X and P2Y receptors will be discussed separately, with emphasis on the extent of homology between members within the family, tissue distributions (in rat, unless specified) and pharmacological characteristics of individual receptors.

### ***1.2.b P2X receptors***

P2X receptors are ligand-gated ion channels opened by micromolar extracellular ATP. The receptors mediate rapid (within 10 ms) and selective permeability to cations ( $Na^+$ ,  $K^+$ ,

Ca<sup>2+</sup>). To date, seven P2X receptor subunits (P2X<sub>1-7</sub>) currently known are encoded by different genes. Each subunit has a topology that is fundamentally different from that of other known ligand-operated channels. P2X receptors are made of proteins, with 379-595 amino acids, inserted in the membrane to form a pore comprising two hydrophobic transmembrane domains with a large extracellular hydrophilic loop. The NH<sub>2</sub> and COOH termini are presumed to be cytoplasmic. The actual P2X receptors are formed from either homomeric or heteromultimeric association of the subunits. The putative extracellular loop of cloned P2X<sub>1-7</sub> has 10 conserved cysteine and 14 conserved glycine residues as well as 2 to 6 potential N-linked glycosylation sites. Most of the conserved regions are in the extracellular loop, with the transmembrane domains being less well-conserved. Taken together both the extracellular loop and the transmembrane domains, the proteins are from 40 to 55% pairwise identical. The P2X<sub>4</sub> sequence is most closely related to more of the other forms, and the P2X<sub>7</sub> sequence is least like the others; these observations are true whichever species are considered (see North, 2002). The disulfide bridges present in the extracellular loop are believed to form the structural constraints needed to couple the ATP-binding site to the ion pore. As mentioned above, all the P2X receptor subunits have consensus sequences for N-linked glycosylation (Asn-X-Ser/Thr). Receptors in which any two of the three sites are glycosylated appear at the cell surface and are fully functional, whereas those in which only one site is glycosylated give barely detectable currents in response to ATP, and channels

with no sites glycosylated give no current (see North, 2002).

The recombinant receptors formed from homomeric association of subunits, when expressed in *Xenopus* oocytes or in mammalian cells have been functionally characterized and show distinct pharmacological profiles (see Ralevic and Burnstock, 1998). Almost all known ionotropic receptors exist as hetero-oligomers (Barnard, 1992). More importantly, the functional and pharmacological characteristics of the receptors are directly determined by the subunit composition, with different subunit combinations yielding different phenotypes (Barnard et al., 1998). Functional studies of native receptors, together with patterns of subunit gene expression, suggest heteromultimeric assembly among members of the P2X receptors (Cook et al., 1997; Lewis et al., 1995). Studies by coimmunoprecipitation have also determined which pairs of subunits are potentially able to coassemble, as not all combinations are possible (**Table 1**) (Torres et al., 1999). Briefly, with the exception of P2X<sub>6</sub>, all the other P2X receptor subunits formed homo-oligomeric complexes. When co-assembly between pairs of subunits is examined, all are able to form hetero-oligomeric assemblies with the exception of P2X<sub>7</sub> receptor. P2X<sub>5</sub> receptor is the only receptor subunit that is able to form hetero-oligomeric complexes with all the members within the family.

*I.2.b.i P2X<sub>1</sub> receptor*

Using a cDNA library generated from rat vas deferens, the first cDNA encoding the P2X<sub>1</sub> receptor was isolated by direct expression in *Xenopus* oocytes. (Valera et al., 1994). The recombinant receptor, having a single open reading frame encoding 399 amino acids, is activated by agonists with the order of potency as 2MeSATP  $\geq$  ATP >  $\alpha\beta$ -meATP  $\gg$  ADP and UTP, and inward currents evoked by these compounds are reversibly blocked by general P2 receptor antagonists like suramin and pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) (Valera et al., 1994). Sustained application of agonist to P2X<sub>1</sub> receptors results in rapid channel opening (few milliseconds), fast desensitization (300 ms) and receptor internalization (1-3 min). The receptors reappear at the cell surface soon after agonist application is terminated (see North, 2002).

P2X<sub>1</sub> receptor mRNA is expressed in urinary bladder, smooth muscle layers of small arteries and arterioles, and vas deferens, with lower levels in lung and spleen (Valera et al., 1994; Collo et al., 1996). The P2X<sub>1</sub> receptor seems to be the most significant P2X receptor subtype in vascular smooth muscle, which was revealed by the similar electrophysiological profiles and pharmacological properties observed in smooth muscle (Bean, 1992). Therefore, it is believed that the vascular smooth muscle P2X receptor is a P2X<sub>1</sub> receptor homomer (see Ralevic and Burnstock, 1998). In addition, the P2X<sub>1</sub> receptor is also

expressed in myocardium (Hou et al., 1999) and nervous tissues including dorsal root ganglia, trigeminal ganglia, celiac ganglia, spinal cord, and rat brain (Valera et al., 1994, Kidd et al., 1995, Collo et al., 1996; Xiang et al., 1998, Kukley et al., 2001).

### *1.2.b.ii P2X<sub>2</sub> receptor*

The P2X<sub>2</sub> receptor was first cloned from rat pheochromocytoma PC12 cells (Brake et al., 1994). The homology between P2X<sub>2</sub> receptor (472 amino acids) and other members of the family is shown in **Table 2**. ATP, ATP- $\gamma$ S and 2MeSATP are approximately equipotent for P2X<sub>2</sub> receptor at eliciting non-selective inward cation currents, whereas  $\alpha\beta$ -meATP and  $\beta,\gamma$ -meATP are inactive as agonists or antagonists (Brake et al., 1994). However, there are no agonists or antagonists currently known that are selective for P2X<sub>2</sub> receptors. Nevertheless, P2X<sub>2</sub> receptor has a special feature of its marked sensitivity to change in pH which makes it distinct from the other P2X subtypes, even from P2Y and P1 receptors (King et al., 1996). When expressed in the oocytes, the receptor shows a maximum response to ATP at pH 6.5. The P2X<sub>2</sub> receptor undergoes little or no desensitization. It also differs from the P2X<sub>1</sub> receptor in that it is less permeable to Ca<sup>2+</sup> and shows much higher sensitivity to inhibition by extracellular Ca<sup>2+</sup> (Evans et al., 1996). Apart from Ca, other divalent cations cause a fast block of the single P2X<sub>2</sub> channels with the order of potency as Mn > Mg > Ca > Ba, which is the order of ionic radii. This suggests that the divalent ions are binding

to a charged site within the channel (Ding and Sachs, 1999; 2000). The divalent ions can also inactivate the channel with the order of effectiveness as  $\text{Ca} > \text{Mg} > \text{Ba} > \text{Mn}$  (Ding and Sachs, 2000).

P2X<sub>2</sub> receptor mRNA is distributed in bladder, brain, spinal cord, superior cervical ganglia, adrenal medulla, intestine and vas deferens, with highest levels found in the pituitary gland and vas deferens (Brake et al., 1994). Recently, expression was also reported in retina (Greenwood et al., 1997), cochlea (Housley et al., 1999), vascular smooth muscle (Nori et al., 1998), thymus (Glass et al., 2000), osteoclasts (Hoebertz et al., 2000), sympathetic ganglia (Schadlich et al., 2001) and skeletal muscle fiber (Ryten et al., 2001). Distinct but restricted patterns of distribution have been described in rat brain (see Nörenberg and Illes, 2000).

A splice variant of a P2X<sub>2</sub> receptor has been isolated from rat cerebellum (Brändle et al., 1997; Simon et al., 1997). The receptor protein (called P2X<sub>2b</sub>) has a 69 amino acid deletion of the carboxyl-terminal, shows a similar distribution in the rat central and peripheral nervous system as the original P2X<sub>2</sub> receptor, and forms homomeric receptor mediating inward currents to ATP. Although they are equipotent to agonists, P2X<sub>2b</sub> showed significantly lower antagonist sensitivity and a faster rate of desensitization compared to P2X<sub>2</sub> receptor.



*1.2.b.iii P2X<sub>3</sub> receptor*

The P2X<sub>3</sub> receptor subunit cDNAs were cloned from rat dorsal root ganglion (Chen et al., 1995; Lewis et al., 1995) and was predicted to be 397 amino acids, with the amino acid sequence exhibiting different degree of identity with other members of the family (**Table 2**). P2X<sub>3</sub> receptor shows similar profiles with P2X<sub>1</sub> receptor upon agonist activation. It is rapidly activated by agonists with a potency order of 2MeSATP >> ATP > αβ-meATP > ATP-γS >> ADP >> UTP ~ β,γ-meATP, and undergoes rapid desensitization with slow recovery in high ATP concentration (in less than 100ms). These shared characteristics makes the two homomeric receptors distinct from the other homomeric forms. The antagonists suramin, PPADS, and TNP-ATP do not readily distinguish between P2X<sub>1</sub> and P2X<sub>3</sub> receptors, but NF023 is approximately 20 times less effective at P2X<sub>3</sub> than P2X<sub>1</sub> receptors. The P2X<sub>3</sub> receptor is remarkably insensitive to block by extracellular calcium (Virginio et al., 1998). In contrast, increasing the extracellular Ca<sup>2+</sup> concentration can greatly accelerate the recovery from desensitization (Cook and McCleskey, 1997; Cook et al., 1998).

The P2X<sub>3</sub> receptor has a very restricted tissue distribution in the nervous system. It is expressed only by a subset of sensory neurons (trigeminal, nodose, and dorsal root ganglia), most of them are capsaicin-sensitive neurons involved in nociception (Chen et al., 1995;

Lewis et al., 1995; Vulchanova et al., 1998; Xiang et al., 1998). Accordingly, P2X<sub>3</sub> protein or its mRNA was found in cell bodies of sensory neurons, and in their central termination fields (dorsal horn of the spinal cord, nucleus of the solitary tract), as well as in their peripheral endings, e.g. in taste buds and the spiral ganglion of the inner ear. However, P2X<sub>3</sub> was also found in other areas such as supraoptic nucleus and sympathetic ganglia (see Nörenberg and Illes, 2000), retina (Wheeler-Schilling et al., 2001) and endothelial cells (Glass and Burnstock, 2001).

However, in other areas, such as certain sensory neurons in the central and peripheral nervous system and sympathetic ganglion cells, the action of ATP is mimicked by  $\alpha\beta$ -meATP, but slow desensitization. This type of response is later confirmed to be generated by heteromeric P2X<sub>2/3</sub> receptor (Lewis et al., 1995; Radford et al., 1997; Torres et al., 1999). The heteromer shares some properties with homomeric P2X<sub>2</sub> receptor: it is potentiated by low pH, and shows low desensitization. On the other hand, the heteromeric P2X<sub>2/3</sub> receptor is activated by  $\alpha\beta$ -meATP, and blocked by TNP-ATP as well as PPADS and suramin, all of which are the properties of P2X<sub>3</sub> homomer.

#### *1.2.b.iv P2X<sub>4</sub> receptor*

The cDNAs for the rat P2X<sub>4</sub> receptor has been cloned from rat hippocampus (Bo et al.,

1995) and subsequently from rat brain (Séguéla et al., 1996; Soto et al., 1996), superior cervical ganglia (Buell et al., 1996) as well as pancreatic islet cells (Wang et al., 1996). The amino acid identity between P2X<sub>4</sub> receptor (388 amino acids) and other members of the family is shown in **Table 2**. The P2X<sub>4</sub> receptor is activated by ATP and partially by 2-MeSATP, and  $\alpha\beta$ -meATP is either weak or inactive, whereas ADP, UTP and  $\beta\gamma$ -meATP are inactive. Expression of P2X<sub>4</sub> receptor gives an ATP-activated cation-selective channel that has a significantly high Ca<sup>2+</sup> permeability, and whose agonist sensitivity is increased by Zn<sup>2+</sup> without altering maximal response (Soto et al., 1996). Desensitization at P2X<sub>4</sub> receptors is intermediate between that observed at P2X<sub>1</sub> and P2X<sub>2</sub> receptor (Séguéla et al., 1996).

The rat P2X<sub>4</sub> receptor, but not its human homologue, is unusual in its low sensitivity to blockade by the widely used ATP antagonists, suramin, Reactive blue2 and PPADS and indeed, responses to ATP are even potentiated (Bo et al., 1995). A lysine residue present in the P2X<sub>1</sub> and P2X<sub>2</sub> receptors, but absent in the P2X<sub>4</sub> receptor, is believed to be critical for the binding of antagonists but not agonists (Buell et al., 1996).

P2X<sub>4</sub> receptor expression is widely distributed in the brain and other tissues such as spinal cord, sensory ganglia, superior cervical ganglion, lung, bronchial epithelium, thymus, bladder, acinar cells of the salivary gland, adrenal gland, testis and vas deferens (Bo et al.,

1995; Buell et al., 1996; Collo et al., 1996; Séguéla et al., 1996). Recent studies have shown that P2X<sub>4</sub> receptor also expressed in vascular smooth muscle (Nori et al., 1998), inner ear tissues (Brändle et al., 1999), pancreas (Hede et al., 1999), osteoclasts (Hoebertz et al., 2000), endothelial cells and follicular cells in thyroid (Glass and Burnstock, 2001) and retina (Brändle et al., 1998; Wheeler-Schilling et al., 2000; Wheeler-Schilling et al., 2001).

#### *1.2.b.v P2X<sub>5</sub> receptor*

The P2X<sub>5</sub> receptor cDNA was first isolated from cDNA libraries constructed from rat celiac ganglion and heart (Collo et al., 1996; Garcia-Guzman et al., 1996). The extent of amino acid identity between the 417 amino acid-P2X<sub>5</sub> receptor protein and the members within the family is shown in **Table 2**. Rapid inward currents are activated by ATP > 2MeSATP > ADP. The most striking feature of the current elicited by ATP in cells expressing the rat P2X<sub>5</sub> receptor is their small amplitude, compared with the currents observed with P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, or P2X<sub>4</sub> receptors expressed under similar conditions. However, P2X<sub>5</sub> receptor shared some similar features with P2X<sub>2</sub> receptors: they show little desensitization, are not activated by  $\alpha\beta$ -meATP, and are blocked by suramin and PPADS at concentrations similar to those effective at P2X<sub>2</sub> receptors (Collo et al., 1996; Garcia-Guzman et al., 1996).

P2X<sub>5</sub> receptor shows a very restricted expression pattern in the brain, where the expression was only found in the mesencephalic trigeminal nucleus and pineal gland (Collo et al., 1996). In the peripheral nervous system, expression was also detected in the ventral horn of the cervical spinal cord (Collo et al., 1996), sensory ganglia (Xiang et al., 1998, 1999), sympathetic neurons (Schadlich et al., 2001), retinal ganglion cells and (Wheeler-Schilling et al., 2001). Other tissues expressing P2X<sub>5</sub> receptor are stratified squamous epithelia of the skin (Gröschel-Stewart et al., 1999a), duodenal goblet cells (Gröschel-Stewart et al., 1999b), developing skeletal muscle (Ryten et al., 2001), vascular smooth muscle cells and the follicular cells in the thyroid (Glass and Burnstock, 2001).

Recent papers have reported the existence of heteromeric P2X<sub>1/5</sub> receptors with unique features (Torres et al., 1998; Haines et al., 1999; Surprenant et al., 2000). The heteromeric receptor is more sensitive to ATP than those with homomeric receptors. Although the P2X<sub>1/5</sub> receptor is less sensitive to  $\alpha\beta$ -meATP than the homomeric P2X<sub>1</sub> receptor, the heteromer shows a sustained current evoked by  $\alpha\beta$ -meATP, which is not seen for either of the homomers when expressed separately. The currents generated by the heteromeric receptor are considerably larger than those seen with P2X<sub>5</sub> subunits expressed alone, and the current is inhibited by either an increase or a decrease of the extracellular pH. Furthermore, P2X<sub>1/5</sub> heteromer is much less permeable to Ca<sup>2+</sup> than the P2X<sub>1</sub> homomer.

*1.2.b.vi P2X<sub>6</sub> receptor*

The cDNA for P2X<sub>6</sub> receptor was isolated from a rat superior cervical ganglion cDNA library (Collo et al., 1996). The predicted receptor protein has 379 amino acids and the sequence shows homology with other P2X receptors (**Table 2**). Currents evoked by ATP in P2X<sub>6</sub> receptor-expressing cells resembled those seen for the P2X<sub>2</sub> receptor. Rapid currents are mediated by ATP > 2MeSATP > ADP with little desensitization, whereas  $\alpha\beta$ -meATP has no effect. Currents are only partially inhibited by antagonist such as suramin or PPADS. Although the currents in cells expressing P2X<sub>6</sub> receptor were large, they were observed in only a small fraction of cells examined.

The mRNA transcript of P2X<sub>6</sub> receptor is heavily expressed in the CNS, with heaviest staining in cerebellar Purkinje cells and ependyma. The mRNA is also present in the spinal cord, trigeminal, dorsal root and celiac ganglia. In non-neuronal tissues, P2X<sub>6</sub> receptor mRNA is prominent in gland cells of the uterus, granulose cells of the ovary, and bronchial epithelia (Collo et al., 1996). Immunoreactivity of the P2X<sub>6</sub> receptor protein has been shown in superior cervical and celiac ganglia (Xiang et al., 1998), thymic epithelial cells (Glass et al., 2000), vascular smooth muscle (Glass and Burnstock, 2001) and developing skeletal muscle (Ryten et al., 2001).

Coimmunoprecipitation studies have shown that P2X<sub>6</sub> receptor has a very low tendency to form homomeric ion channel due to failure of self co-precipitation (Torres et al., 1999). Instead, accumulated evidence has suggested the presence of two P2X<sub>6</sub>-possessing heteromeric ion channels, the P2X<sub>2/6</sub> and P2X<sub>4/6</sub> heteromeric receptors. Cells expressing the P2X<sub>2/6</sub> receptors have subtly different responses to ATP than those expressing P2X<sub>2</sub> receptors only (King et al., 2000), with the most convincing one being the biphasic inhibition of the current by suramin at pH 6.5; one component has the high sensitivity of homomeric P2X<sub>2</sub> receptor whereas the other is less sensitive. For the P2X<sub>4/6</sub> heteromers, the currents elicited by ATP are larger in cells transfected with P2X<sub>4</sub> and P2X<sub>6</sub> receptor mRNA than those transfected with P2X<sub>4</sub> only (Le et al., 1998).

#### *1.2.b.vii P2X<sub>7</sub> receptor*

The P2X<sub>7</sub> receptor of 595 amino acids cloned from rat macrophages and brain (Surprenant et al., 1996) is the cytolytic P<sub>2Z</sub> receptor previously described in mast cells, macrophages, fibroblasts, lymphocytes, erythrocytes and erythroleukemia cells. The recombinant receptor has an agonist potency order of BzATP >> ATP >> 2MeSATP > ATP- $\gamma$ S > ADP, whereas  $\alpha\beta$ -meATP and  $\beta\gamma$ -meATP are ineffective. The P2X<sub>7</sub> receptor, though insensitive to suramin and PPADS, is inhibited by divalent cations, KN62 and

oxidized ATP (see Ralevic and Burnstock, 1998). The unique feature of P2X<sub>7</sub> receptors is that under normal physiological conditions, the receptors are selectively permeable to small cations only, whereas in the continued presence of ATP and when divalent cation levels are low, the ion channels can convert to a pore, permeable to both molecules and ions. The currents evoked do not readily desensitize. Instead, longer applications of either BzATP or ATP result in increased permeability to larger organic cations, and the currents take longer to decline after each application. Prolonged stimulations may also result in cell swelling, vacuolization, and cell death by necrosis or apoptosis (Dubyak and el-Moatassim, 1993). P2X<sub>7</sub> receptor is structurally similar to other P2X receptors except having a significantly longer intracellular C-terminal (240 amino acids) than the other members of the P2X receptor family, of which the last 177 amino acids are crucial for non-selective pore formation (Surprenant, 1996, Smart et al., 2003). Another interesting feature is that after a brief exposure to ATP, the effectiveness of ADP and AMP is increased, suggesting that a brief initial exposure to ATP caused a long lasting change in the receptor, which subsequently alters its ability to differentiate ATP from ADP and AMP (Chakfe et al., 2002). According to Torres et al (1999), P2X<sub>7</sub> receptors do not co-immunoprecipitate with other members of the family.

P2X<sub>7</sub> mRNA and protein are distributed in immune cells (Collo et al., 1997), parotid



acinar cells (Tenneti et al., 1998), retina (Brändle et al., 1998), rat duodenal enterocytes and goblet cells and stratified squamous epithelium (Gröschel-Stewart et al., 1999a; 1999b), pancreas (Hede et al., 1999), kidney (Harada et al., 2000), vascular smooth muscle cells and endothelial cells (Glass and Burnstock, 2001), brain (Deuchars et al., 2002; Sperlágh et al., 2002) and cochlea (Nikolic et al., 2003).

### ***1.2.c P2Y receptors***

P2Y receptors are purine and pyrimidine nucleotide receptors that are coupled to G proteins. Although the purinergic receptors were originally cloned for receptors that are activated by purine nucleotides such as ATP and ADP, receptors for pyrimidines that are activated specifically by uridine nucleotides (UTP and UDP) were first proposed by Seifert and Schultz (1989). For the current 8 mammalian P2Y receptors cloned, 5 of them (P2Y<sub>1,2,4,6,12</sub>) have their orthologs cloned in rats. The rat P2Y receptors are 328 to 374 amino acid proteins. The typical P2Y receptor protein, like other G protein-coupled receptors, consists of 7 predicted hydrophobic transmembrane domains. However, the P2Y receptor family differs from other known families of G protein-coupled receptors by a high diversity in the amino acid sequences of its different members within the same species, despite a much higher homology found between a particular receptor subtype in different species (see Von Kügelgen and Wetter, 2000). The amino acid similarity of P2Y receptor sequences is

summarized in **Table 3**. Some highly conserved amino acids residues encode for the transmembrane regions 3, 5, 6 and 7 have been suggested to contribute to the agonists binding (Van Rhee et al., 1995).

The signaling pathway of P2Y<sub>1,2,4,6</sub> receptors is coupling to phospholipase C, leading to formation of inositol 1,4,5-triphosphate (IP<sub>3</sub>) and mobilization of Ca<sup>2+</sup> from intracellular stores (see Von Kügelgen and Wetter, 2000). Increase in IP<sub>3</sub> and intracellular Ca<sup>2+</sup> can stimulate a variety of pathways including protein kinase C (PKC), phospholipase A<sub>2</sub> and nitric oxide synthase which subsequently can activate other pathways such as phospholipase D and mitogen-activated protein kinase (MAPK). Coupling to adenylate cyclase by P2Y<sub>11-14</sub> receptors has also been described (see Ralevic and Burnstock, 1998). The response time of P2Y receptors is longer than that of the P2X receptors because it involves second-messenger systems.

### *1.2.c.i P2Y<sub>1</sub> receptor*

The P2Y<sub>1</sub> receptor was originally cloned from late embryonic chick brain (Webb et al., 1993) and the orthologs were then detected in several mammalian species. The P2Y<sub>1</sub> receptors cloned from different mammalian species are all of 373 amino acids. In all species, the receptor is selective for adenine nucleotides, and especially, nucleotide

diphosphate. However, the receptors present in different species show different agonists with different order of potency. In rat tissue, the recombinant receptor (in rat) is activated by agonists with a potency order of 2MeSADP > ADP > 2MeSATP > ATP, whereas  $\alpha\beta$ -meATP and UTP are inactive (Tokuyama et al., 1995; Vöhringer et al., 2000; see also Sak and Webb, 2002). The most potent antagonist for P2Y<sub>1</sub> receptor is MRS2179 (see Von Kügelgen and Wetter, 2000). The signal transduction pathway of recombinant P2Y<sub>1</sub> receptor is the activation of phospholipase C, which involves the G protein G<sub>q/11</sub> characterized by its insensitivity to pertussis toxin.

P2Y<sub>1</sub> receptor is expressed in spleen, lung, liver, kidney, (Tokuyama et al., 1995), heart (Webb et al., 1996), lens fiber cells (Merriman-Smith et al., 1998), astrocytes (Fam et al., 2000), brain (Morán-Jiménez and Matute, 2000), hepatocytes (Dixon et al., 2000), skeletal muscle (Choi et al., 2001) and osteoclasts (Hoebertz et al., 2001).

### *1.2.b.ii P2Y<sub>2</sub> receptor*

The first cloned P2Y<sub>2</sub> receptor was isolated from mouse neuroblastoma cells (Lustig et al., 1993) and subsequently in rat alveolar type II cells (Rice et al., 1995). The P2Y<sub>2</sub> receptor (374 amino acids) is activated by ATP and UTP with approximately equal potency and is insensitive or is only weakly activated by ADP, UDP and other nucleoside

diphosphates, 2MeSATP and  $\alpha\beta$ meATP (see Sak and Webb, 2002). There are no selective antagonists for P2Y<sub>2</sub> receptors, though it is antagonized by suramin and PPADS. P2Y<sub>2</sub> receptor can couple via both G<sub>i/o</sub> and G<sub>q/11</sub> proteins to mediate phospholipids breakdown and phosphoinositides as well as Ca<sup>2+</sup> mobilization via PLC $\beta$ , an effect which may accordingly be pertussis toxin-sensitive, -partially sensitive, or -insensitive (See Dubyak and el-Moatassim, 1993). For a given signaling pathway, a variety of downstream signaling molecules was reported and seems to be partially dependent on the cell type in which the P2Y<sub>2</sub> receptor is expressed (see Ralevic and Burnstock, 1998).

P2Y<sub>2</sub> receptor expression is widely distributed, and some of the physiological significance of P2Y<sub>2</sub> receptor expression has been reported. P2Y<sub>2</sub> receptor present on the endothelium stimulates the synthesis and release of prostacyclin and nitric oxide, leading to vasodilatation. On the other hand, P2Y<sub>2</sub> receptors on neutrophils stimulate degranulation and consequently induce aggregation. UTP stimulates mucin secretion from goblet cells, increased surfactant released from type II alveolar cells, and increase the beat frequency of cilia in isolated normal and cystic fibrosis epithelial cells (Kellerman, 2002).

### *1.2.c.iii P2Y<sub>4</sub> receptor*

The P2Y<sub>4</sub> receptor was first cloned from human placenta (Communi et al., 1996) and

then from rat heart (Bogdanov et al., 1998b). The cDNA cloned from rat heart gives rise to a predicted protein of 361 amino acids. Although the human P2Y<sub>4</sub> receptor is highly selective for uracil nucleotide over adenine nucleotide, the rat counterpart is activated equipotently by the full agonists ATP and UTP, whereas the partial agonists such as 2MeSATP, ADP and ATP- $\gamma$ S are also equipotent. (Bogdanov et al., 1998b). The receptor causes rapid Ca<sup>2+</sup> mobilization upon agonist stimulation (Webb et al., 1998). The P2Y<sub>4</sub> receptor is insensitive to UDP stimulation (see Sak and Webb, 2002). The receptor is reversibly antagonized by Reactive blue 2 but not by either PPADS or suramin, which helps differentiated it from the P2Y<sub>2</sub> receptor.

The rat P2Y<sub>4</sub> receptor shows a restricted expression pattern. The receptor transcript has been detected in the heart (Bogdanov et al., 1998b), neonatal brain, skeletal muscle and spleen, and adult vas deferens and spinal cord (Webb et al., 1998), pancreas (Hede et al., 1999), cochlear tissues (Teixeira et al., 2000), kidney (Bailey et al., 2000) and bile duct epithelia (Dranoff et al., 2001).

#### *1.2.c.iv P2Y<sub>6</sub> receptor*

This uridine nucleotide-specific receptor has been cloned from rat aortic smooth muscle (Chang et al., 1995). The rat P2Y<sub>6</sub> receptor consists of 328 amino acids, the shortest

sequence among the family. The receptor is activated most potently by UDP, which is approximately 100-fold more potent than UTP, whereas ATP, ADP or 2MeSATP are almost inactive (Nicholas et al., 1996). The P2Y<sub>6</sub> receptor is blocked by Reactive blue 2 and suramin. The response is pertussis toxin insensitive, indicating the involvement of G<sub>q/11</sub> proteins in stimulation of PLC and in the formation of IP<sub>3</sub> (Chang et al., 1995).

The P2Y<sub>6</sub> mRNA is found abundantly in various tissues including lung, stomach, intestine, spleen, mesentery and aorta (Chang et al., 1995), heart (Webb et al., 1996), cochlear tissues (Teixeira et al., 2000) and kidney (Bailey et al., 2001). The more widespread distribution of the P2Y<sub>6</sub> receptor, compared with the P2Y<sub>4</sub> receptor, suggests that this receptor is more likely to account for endogenous uridine nucleotide-specific responses.

#### *1.2.c.v P2Y<sub>11</sub> receptor*

The P2Y<sub>11</sub> receptor was cloned from human placenta (Communi et al., 1997). The predicted protein possesses 371 amino acids. The receptor coupled to the stimulation of both the phosphoinositide and the adenylyl cyclase pathways. The P2Y<sub>11</sub> receptor is the only P2Y receptor selective for ATP because it is stimulated by agonists with a rank order of potency of ATP > 2MeSATP > ATP- $\gamma$ S >> ADP, with UTP and UDP inactive (Communi et al., 1997). The P2Y<sub>11</sub> receptor is antagonized by suramin and partially by Reactive blue 2, but

not by PPADS (Communi et al., 1999). Quantitative RT-PCR study has shown that P2Y<sub>11</sub> receptor is strongly expressed in the brain lymphocytes and spleen (Moore et al., 2001).

#### *1.2.c.vi P2Y<sub>12</sub> receptor*

The human and rat P2Y<sub>12</sub> receptors were both cloned from platelets cDNA library and presented in the same report (Hollopeter et al., 2001). The rat P2Y<sub>12</sub> receptor is a 343-amino acid protein which is activated by agonists in the order of potency as 2MeSATP > 2MeSADP > ADP >> ATP (Simon et al., 2002). It has to be noted that 2MeSATP acts as a very potent agonist in recombinant P2Y<sub>12</sub> receptor, whereas it appears weaker in cells expressing endogenous P2Y<sub>12</sub> receptor, or even act as antagonists in platelet cells (Simon et al., 2002). The response is antagonized by Reactive blue 2 and suramin, but not by PPADS or MRS2179, which is selective for P2Y<sub>1</sub> receptor (Kulick and von Kügelgen, 2002). The receptor couples to pertussis toxin-sensitive G-proteins (G<sub>i/o</sub>) and inhibits adenylyl cyclase upon agonist stimulation (Kulick and von Kügelgen, 2002; Simon et al., 2002). In addition, the receptor coupled to G<sub>i/o</sub> also interacts with the inward rectifier K<sup>+</sup> channel and the voltage gated Ca<sup>2+</sup> channel, suggesting that it involves another transduction pathway independent of second messengers and downstream P2Y signaling (Simon et al., 2002). Expression of P2Y<sub>12</sub> receptor is so far detected in neuronal cells (Unterberger et al., 2002), glioma cells (Czajkowski et al., 2002), endothelial cells (Simon et al., 2002) and platelets (Hollopeter et

al., 2001).

#### *1.2.c.vii P2Y<sub>13</sub> receptor*

An orphan G-protein coupled receptor (SP174) was cloned from a human neutrophil cDNA library and, together with the preexisting mouse ortholog, designated as P2Y<sub>13</sub> receptors (Zhang et al., 2002). The receptor contains a 1002-base open reading frame encoding 333 amino acid residues, which shows highest homology with P2Y<sub>12</sub> receptor (45%) and the UDP-glucose receptor (later confirmed to be P2Y<sub>14</sub> receptor) (43%) (Zhang et al., 2002). The receptor is activated by agonists with a decreasing order of potency of 2MeSADP = 2MeSATP > ADP > ATP. The receptor couples to Gi proteins and adenylyl cyclase pathway.

The mRNA dot blot experiment shows that strong expression is detected in spleen, pancreas, brain and liver (Zhang et al., 2002).

#### *1.2.c.viii P2Y<sub>14</sub> receptor*

An orphan G-protein coupled receptor that specifically responds to UDP-glucose and related sugar-nucleotides (Nomura et al., 1994; Chambers et al., 2000) was recently confirmed to be a human P2Y<sub>14</sub> receptor (Abbracchio et al., 2003). This receptor is



originally cloned from human myeloid cells and designated an orphan receptor (Nomura et al., 1994). Sequence comparisons reveal that it is structurally related to the known members of the human P2Y receptor family (Chambers et al., 2000), with 18-45% overall identity mainly distributed in the transmembrane domains. A G-protein coupled receptor cloned from ventral tegmentum in rat shows 80% amino acid identity and a fully conserved amino acid motif in the sixth and the seventh transmembrane domains with P2Y<sub>14</sub> receptor, suggesting that it is the rodent ortholog for P2Y<sub>14</sub> receptors.

The recombinant P2Y<sub>14</sub> receptor is responsive to the agonists such as UDP glucose, UDP-galactose, UDP –glucuronic acid and UDP-N-acetylglucosamine, whereas ATP, ADP, UTP or UDP do not activate the receptor. Pertussis toxin completely abolishes agonist responses, indicating the receptor to be coupled to G<sub>i/o</sub> protein (Wittenberger et al., 2001). The rat P2Y<sub>14</sub> receptor shows highest expression in cells of haemopoietic origin and clear expression in the brain (Charlton et al., 1997).

### **I.3 Purinergic signaling during embryonic development**

#### ***I.3.a Brief introduction on mammalian embryonic development***

##### ***I.3.a.i From zygote to bilaminar germ disc***

Embryonic development starts from the moment when an oocyte is fertilized by a sperm.

The chromosomes of the oocyte and sperm enclosed within the female and male pronuclei respectively fuse with each other to produce a single diploid zygote (see Larsen, 1998). Within a short period of time after fusion of the pronuclei, the zygote undergoes a series of mitotic cell divisions along the journey from the oviduct to the uterus to form a round shaped morula, consisting of around 32 cells enclosed in an acellular layer called zona pellucida. The centrally placed cells (embryoblasts) will form the inner cell mass that gives rise to most of the embryo proper, whereas the cells at the periphery (trophoblasts) are the primary source for the membranes of the placenta. Hydrostatic pressure develops within the morula due to continued fluid entry, resulting in the development of a large cavity within the morula and the embryo is now called blastocyst. When the morula reaches the uterus, the blastocyst hatches from the clear zona pellucida and eventually implants tightly to the uterine wall. Meanwhile, the embryoblast splits into an external columnar cell layer called epiblast and an internal cuboidal cell layer called hypoblast. The two layers together make up the bilaminar germ disc.

### *1.3.a.ii Gastrulation*

The bilaminar germ disc is later converted into a trilaminar germ disc by a process of gastrulation whereby epiblast cells migrate towards and through a region, called the primitive streak, to form the so-called mesoderm (see Larsen, 1998). The primitive streak develops

when a groove (primitive groove) appears along the longitudinal midline of the germ disc and then elongates to occupy about half the length of the embryo. A deeper depression called primitive node develops at the presumptive cranial end of the groove. With the formation of mesoderm, the hypoblast is replaced with a new cell layer derived from epiblast called endoderm, while the epiblast itself is transformed into the ectoderm. Thus the mesoderm separates the overlying ectoderm from the subjacent endoderm. The most important achievement of gastrulation is that it establishes the basic vertebrate body plan: the anteroposterior and the dorsoventral axes, for the developing embryo.

### *1.3.a.iii Somite formation and development of urogenital system and limb*

The mesoderm that forms in the midline gives rise to a transient structure called notochord. The mesoderm adjacent to the notochord forms the paraxial mesoderm, which soon undergoes segmentation to form somitomes and then to somites. These somites will give rise to the myotomes, sclerotomes and dermatomes that form skeletal muscle, vertebrae and skin, respectively. The intermediate mesoderm forms just lateral to the paraxial mesoderm will later give rise to the urinary system. Three sequential urinary systems develop from the intermediate mesoderm, i.e. i) cervical nephrotomes, which are never functional; ii) a thoracolumbar mesonephric system, which functions briefly during embryonic life; iii) a sacral metanephric system, which ascends to the lumbar region forming

the definitive kidney (see Larsen, 1998). The metanephric system is developed by reciprocal interaction between the ureteric buds that branch from the mesonephric ducts and the metanephric blastema, both of which are derived from intermediate mesoderm (see Larsen, 1998; Vainio and Lin, 2002), resulting in the formation of nephrons differentiated within the metanephric blastema, and the collecting systems formed by bifurcation of the ureteric buds. The most lateral mesoderm, the lateral plate mesoderm, contributes to the formation of the body wall and to somatic and visceral peritoneum (see Larsen, 1998).

Migration of the primordial germ cells to the posterior body wall results in induction of the genital ridges just medial to the mesonephros on each side of the midline. Cells from the mesonephros and the coelomic epithelium invade the mesenchyme in the region of the presumptive gonads to form the primitive sex cords that surround the germ cells. Interaction between the mesonephric and paramesonephric ducts and the primitive sex cords results in the formation of gonads (see Larsen, 1998).

At the stage when the cranial neural tube closure is almost complete, somites induce proliferation of the lateral plate mesoderm in the presumptive limb region to form outgrowths called limb buds, which are covered by surface ectoderm. The limb buds differentiate along three interrelated axes: the proximodistal, the craniocaudal and the dorsoventral axes. The

lateral plate mesoderm also gives rise to the bones, tendons, ligaments and vasculature of the limbs, while the somites migrate to the limb bud and contribute to the muscular component of the limbs. Development of the forelimb buds occurs prior to that of the hindlimb buds (see Larsen, 1998).

#### *1.3.a.iv Neurulation and neural crest migration and differentiation*

The axial mesoderm, including notochord, induces thickening of the overlying ectoderm to form a bilateral thickened epithelium, the neural plate. The neural plate appears first at the cranial end of the embryo and differentiates craniocaudally. The neural plate is broad cranially and tapered caudally. Completion of gastrulation is followed by another very important process called neurulation. Neurulation commences as the neural plate begins to fold on either side and come into contact and, eventually, fuse with each other to form a hollow tube along the embryo (see McLachlan, 1994). Neurulation does not take place simultaneously along the whole length of the forming tube: it begins in the region between the developing hindbrain and upper neck and then extends cranially and caudally. Closure of the cranial neural tube occurs prior to that of the caudal neural tube. Before neurulation, several expansions occur in discrete regions of the cranial neural plate. Soon after neurulation, the expansions undergo further enlargement and flexing to form the brain vesicles that give rise to the future brain, with the caudal neural tube forming the future

spinal cord.

Neural crest cells are a special population of cells that arises along the lateral margins of the neural folds (see Larsen, 1998). During neurulation, these cells detach from the neural plate and migrate ventro-laterally to many locations in the body, where they differentiate into a remarkable variety of structures, e.g. in the peripheral nervous system, the neural crest cells differentiated into glia cells and ganglia including dorsal root, sympathetic chain, enteric, preaortic and some cranial ganglia (trigeminal, facio-acoustic, glossopharyngeal and vagal). Other neural crest derivatives include arachnoid and pia mater, dermal bones of skull, pharyngeal arch cartilages, connective tissue surrounding papillary and ciliary muscle in the eyes, odontoblasts and melanocytes, adrenal medulla, truncoconal septum, dermis and hypodermis of face and neck.

#### *1.3.a.v Development of cardiovascular system*

The heart is the first organ to function in the embryo. It is originated from a group of mesoderm-derived angioblasts that, subject to induction by the endoderm, differentiated into flattened endothelial cells that join together to form a pair of vascular elements called the endocardial tubes locating cranial and lateral to the neural plate early before neurulation. During embryonic folding, the tubes are brought into the thoracic region, where they meet

along the midline and fuse to form a single primitive heart tube. A series of constrictions and expansions forms along the primitive heart tube that contributes to the various heart chambers (see Larsen, 1998). The heart tube formed soon undergoes looping, which helps bringing the primitive atria and ventricles in their adult positions. Trabeculation takes place in the looped heart, which is believed to be important for myocardial growth (see Sedmera et al., 2000). Remodeling also occurs in the looped heart to establish the proper connection for systemic and pulmonary circulation, followed by septation of the heart and valve formation.

#### *1.3.a.vi Development of respiratory and gastrointestinal system*

In early stages, the embryo is a flat, ovoid disc. Due to differential growth of various embryonic structures, the flattened disc is converted into a 3-dimensional embryo (see Larsen, 1998). The endoderm of the trilaminar embryo is destined to give rise to the lining of the respiratory and gastrointestinal tract. Embryo folding also converts the superior and inferior portions of the endoderm into blind-ended tube that gives rise to a cranial blind-ended foregut, a midgut that opens into the yolk sac, and a caudal blind-ended hindgut. The lungs emerged from the outpouching of the endodermal foregut as lung bud. The lung bud begins to grow ventrocaudally through the mesenchyme surrounding the foregut. Soon after, the lung bud bifurcates into right and left primary bronchial buds. The primary bronchial buds

undergo continue branching morphogenesis, followed by mesenchymal thinning, epithelial differentiation and surfactant protein expression (see McMurtry, 2002).

Gut development involves invagination of endoderm and the subsequent growth and differentiation of the subjacent splanchnic mesenchyme (mesodermal). Thus, the gut is composed of an outer mesodermal-derived smooth muscle and an inner endodermal-derived luminal lining flanking the most anterior (mouth) and most posterior (anus) ectodermal-derived epithelium (see Roberts, 2000). The foregut itself will form the thoracic and abdominal esophagus, stomach, and about half the duodenum; the midgut will form half the duodenum, the jejunum and ileum, ascending colon, and two-thirds of the transverse colon. The hindgut will form one-third of the transverse colon, the descending and sigmoid colons, and rectum. Meanwhile, endodermal bud sprouts from the inferior end of the foregut and develops into liver, gallbladder and pancreas, whereas the nearby spleen is formed by mesodermal condensation (see Larsen, 1998).

### ***1.3.b Purinergic signaling during embryonic development***

An embryo requires different cell activities such as cell proliferation, differentiation, migration and degeneration that work in orchestra to ensure proper embryonic development. It therefore requires specific signals given by specific signaling molecules at specific time



points. Various signal transduction pathways then cross-talk with each other to provide positional information and induce cell fate specification. Many signaling molecules are well known to regulate various developmental processes in embryos. Examples of those signaling molecules include Sonic hedgehog (Shh), fibroblast growth factors (FGF), bone morphogenic proteins (BMP), Notch and Delta, retinoic acid and Wnt family signaling pathway.

Accumulated evidence suggests that extracellular nucleosides and nucleotides may exert profound effects during embryonic development in different species (see Burnstock, 2001). In early zebrafish embryo, an ionotropic P2X<sub>3</sub> receptor is expressed in the trigeminal primordial and the spinal sensory Rohon-Beard cells and in the putative posterior lateral line ganglion (Norton et al., 2000). Studies on *Xenopus* cell culture have shown that extracellular ATP potentiates acetylcholine (ACh) responses at developing neuromuscular synapses during early phase of synaptogenesis (Fu and Poo, 1991; Fu, 1994; Fu and Huang, 1994). In addition, endogenously released ATP acting in concert with various protein kinases, is involved in the maintenance and/or development of the quantum size of synaptic vesicles at embryonic neuromuscular synapses (Fu et al., 1997). A novel P2Y purinoceptor (X1P2Y or P2Y<sub>8</sub>) was expressed in the neural plate of *Xenopus* embryos from stages 13 to 18 and again at stage 28 when secondary neurulation occurs in the tail bud (Bogdanov et al.,

1997). However, expression ceased after neural tube closure, suggesting that this receptor may be important during early neurogenesis.

ATP, but not pyrophosphate, AMP, ADP or GTP, has been shown to induce precocious evagination of the embryonic chick thyroid, an event which has been hypothesized to be involved in the formation of the thyroid gland from the thyroid primordium (Hilfer et al., 1977). A transmitter-like action of ATP on patched membranes of myoblasts and myotubes cultured from 12-day-old chick embryos was reported (Kolb and Wakelam, 1983). ATP has a potent depolarizing activity on myotubes derived from pectoral muscle cultured from 11-day-old chick embryos (Hume and Hönig 1986). At embryonic day 6 of chick embryo, ATP elicits vigorous contractions in all the muscles tested, but by embryonic day 17 none of the muscles contract in responses to ATP. However, denervation of muscles in newly hatched chicks leads to the reappearance of sensitivity to ATP, suggesting that the expression of ATP receptors is regulated by motor neurons (Wells et al., 1995). Meyer et al (1999b) have shown that expression of two purinoceptors (P2X<sub>5</sub> and P2X<sub>6</sub> receptors) was detected in developing skeletal muscle of chick embryos. These receptors were first expressed at early stages of skeletal muscle development, whereas expression disappeared immediately before myotube formation i.e. fusion of myoblasts to form myotubes. In the embryonic chick neural retina, ATP or UTP induced an increase in intracellular Ca<sup>2+</sup> and the response is

blocked by suramin and Reactive blue 2, which suggests that the intracellular  $\text{Ca}^{2+}$  rise is mediated by  $\text{P2Y}_2$  or  $\text{P2Y}_4$  receptors. Interestingly, such increase is dramatically reduced just before synaptogenesis, indicating a very specific temporal effect of extracellular nucleotides (Sugioka et al., 1996). During the first 10 days of embryonic development,  $\text{P2Y}_1$  receptor is expressed in a developmentally regulated manner in the limb buds, mesonephros, brain, somites and facial primordia of the chick embryos (Meyer et al., 1999a). It is also specifically expressed in the undifferentiated limb mesenchyme in chick embryo, and the expression was lost when the tissue differentiated. Application of ATP or ADP, the potent agonists for  $\text{P2Y}_1$  receptor, inhibits cartilage formation in micromass culture (Meyer et al., 2001). It was therefore suggested that ATP acting on  $\text{P2Y}_1$  receptor is involved in the differentiation of limb mesenchymal cells, more specifically in regulating cartilage formation, during embryonic development.

In rat embryos of embryonic day 16, expression of  $\text{P2X}_3$  receptor is detected in the distinct regions of the brainstem such as mesencephalic trigeminal nucleus, superior and inferior olives, intermediate reticular zone, the spinal trigeminal tract and the prepositus hypoglossal nucleus. The expression, however, is downregulated in the postnatal brain. The  $\text{P2X}_3$  receptor in the adult animal has been shown to be involved in sensory functioning. The expression in non-sensory related regions in the embryonic brain and subsequent

downregulation as development progresses suggests a role to play during mammalian neurogenesis. Dynamic expression of different P2X receptors (P2X<sub>5</sub>, P2X<sub>6</sub> and P2X<sub>2</sub> receptors) was reported in rat developing skeletal muscle (Ryten et al., 2001) in which P2X<sub>5</sub> and P2X<sub>6</sub> receptors were expressed transiently in the embryonic skeletal muscle, consistent with the results of Meyer et al (1999b). While P2X<sub>6</sub> and P2X<sub>2</sub> receptor expression was widespread along the myotubes, P2X<sub>5</sub> receptor was restricted to regions of muscle close to the myotendinous junctions. The same authors also reported that addition of ATP into rat skeletal muscle satellite cell culture isolated from rat skeletal muscle inhibits cell proliferation, together with an upregulation of markers of muscle cell differentiation (myogenin, p21 and myosin heavy chain) and an increase in the rate of myotube formation. UTP, in contrast, induces an increase in satellite cell proliferation. Addition of ATP also enhances phosphorylation of MAPKs, particularly p38 (Ryten et al., 2002). Inhibition of p38 activity reverses the ATP-induced suppression of cell proliferation. All the findings mentioned above suggest that extracellular nucleotides, by acting via P2 receptors, are likely to play roles during embryonic development.

#### **I.4 Objective of studies**

Although it appears that extracellular nucleotides are candidates of signal transduction molecules involved in embryonic development, many of the studies were performed in

non-mammalian species. In addition, early studies on purinergic signaling in embryos were performed prior to receptor cloning, and systematic analysis on expression patterns of purinergic receptors during embryogenesis is lacking. Thus, the present study is mainly focused on the expression patterns of P2 purinoceptors, both P2X and P2Y receptors, during mammalian (rat) embryogenesis. Studies of the expression patterns of purinoceptors in mammalian embryos are crucial to our understanding on the specific roles of extracellular nucleotides in the embryonic development. Particular interest will be given to those receptors that show dynamic expression patterns during embryonic development. The correlation between the spatio-temporal expression of both purinoceptor mRNA transcripts and the receptor proteins and the occurrence of different developmental process will also be examined. Furthermore, with the clues obtained from the expression studies, functional studies will also be carried out to investigate the possible functions of particular purinoceptors during the development of rat embryos.

Table 1 Summary of the potential ability of co-assembly between P2X receptor subunits

	<b>P2X<sub>1</sub></b>	<b>P2X<sub>2</sub></b>	<b>P2X<sub>3</sub></b>	<b>P2X<sub>4</sub></b>	<b>P2X<sub>5</sub></b>	<b>P2X<sub>6</sub></b>	<b>P2X<sub>7</sub></b>
<b>P2X<sub>1</sub></b>	+	+	+	-	+	+	-
<b>P2X<sub>2</sub></b>		+	+	-	+	+	-
<b>P2X<sub>3</sub></b>			+	-	+	-	-
<b>P2X<sub>4</sub></b>				+	+	+	-
<b>P2X<sub>5</sub></b>					+	+	-
<b>P2X<sub>6</sub></b>						-	-
<b>P2X<sub>7</sub></b>							+

HEK 293 cells transfected with P2X receptor subunits tagged with either FLAG (DYKDDDDK) or the HA (YPYDVPDYA) epitopes into the carboxyl termini were undergone immunoprecipitation. “+”, subunits immunoprecipitated with antibody to one epitope could be detected with an antibody to the second epitope. (Data from Torres et al., 1999).

Table 2 Amino acid identity of P2X receptor subunits

	<b>P2X<sub>1</sub></b>	<b>P2X<sub>2</sub></b>	<b>P2X<sub>3</sub></b>	<b>P2X<sub>4</sub></b>	<b>P2X<sub>5</sub></b>	<b>P2X<sub>6</sub></b>	<b>P2X<sub>7</sub></b>
<b>P2X<sub>1</sub></b>	100 (100)	40.5 (40.6)	46.4 (47.9)	50.6 (50.3)	45.5 (44.7)	46.8 (46.2)	44.9 (45.1)
<b>P2X<sub>2</sub></b>		100 (100)	51.5 (51.1)	50.5 (50.5)	46.9 (46.9)	42.7 (42.7)	41.0 (41.0)
<b>P2X<sub>3</sub></b>			100 (100)	49.2 (48.6)	47.0 (49.3)	41.4 (43.2)	43.1 (44.7)
<b>P2X<sub>4</sub></b>				100 (100)	53.5 (55.4)	47.3 (47.6)	49.8 (48.6)
<b>P2X<sub>5</sub></b>					100 (100)	49.2 (48.5)	42.0 (42.0)
<b>P2X<sub>6</sub></b>						100 (100)	39.2 (41.0)
<b>P2X<sub>7</sub></b>							100 (100)

The identities between amino acid sequences at the transmembrane regions and large extracellular loop of the rat P2X receptor subunits were expressed in percentage.

The percentages in parenthesis represent the identities between human P2X receptor subunits.

Table 3 Amino acid identity of P2Y receptors

	<b>P2Y<sub>1</sub></b>	<b>P2Y<sub>2</sub></b>	<b>P2Y<sub>4</sub></b>	<b>P2Y<sub>6</sub></b>	<b>P2Y<sub>11</sub></b>	<b>P2Y<sub>12</sub></b>
<b>P2Y<sub>1</sub></b>	100 (100)	32 (31)	33 (34)	33 (33)	(26)	20 (19)
<b>P2Y<sub>2</sub></b>		100 (100)	48 (51)	39 (37)	(25)	22 (20)
<b>P2Y<sub>4</sub></b>			100 (100)	41 (38)	(23)	23 (21)
<b>P2Y<sub>6</sub></b>				100 (100)	(23)	19 (23)
<b>P2Y<sub>11</sub></b>					(100)	(15)
<b>P2Y<sub>12</sub></b>						100 (100)

The identities between amino acid sequences of the rat P2Y receptor subtypes were expressed in percentage. The percentages in parenthesis represent the identities between human P2Y receptor subtypes. Note that rat P2Y<sub>11</sub> receptor has not yet been cloned.



## **Chapter II      Localization of P2X<sub>3</sub> receptors and coexpression with P2X<sub>2</sub> receptors during rat embryonic neurogenesis**

### **ABSTRACT**

It is well known that extracellular ATP mediates rapid excitatory signaling by means of the ionotropic P2X receptors. One of its subunits, the P2X<sub>3</sub> receptor, is well documented to be associated with sensory innervation in adult animals. It is speculated that the P2X<sub>3</sub> receptor may have already been present in the early sensory system. The aim of this study was to investigate the distribution of the P2X<sub>3</sub> receptor during neurogenesis by using immunohistochemistry on rat embryos from embryonic day (E) 9.5-18.5. The P2X<sub>3</sub> receptor was first identified in the hindbrain neural tube and the sensory ganglia in E11-11.5 embryos. At E14.5, the optic tract and retina, nucleus tractus solitarius, mesencephalic trigeminal nucleus, and sensory nerves in both respiratory and digestive tract showed positive staining. The facial nucleus, the prepositus hypoglossal nucleus, and the sympathetic ganglia also showed P2X<sub>3</sub> immunoreactivity, even though these are not sensory associated. P2X<sub>3</sub> immunoreactivity was detected in the vestibular nucleus, the nerves in mesentery, bladder, and kidney in E16.5 and in nerves in vibrissae in E18.5. P2X<sub>3</sub> immunoreactivity in the facial

nucleus, spinal trigeminal tract, the mesencephalic trigeminal nucleus, and the vestibular nucleus were undetectable in postnatal day 16 rat brainstem. The P2X<sub>3</sub> receptor was coexpressed with the P2X<sub>2</sub> receptor in nucleus tractus solitarius, dorsal root ganglion, nodose ganglion, and the taste bud in E16.5 embryo, which was 5 days later than the first appearance of the native P2X<sub>3</sub> receptor. In summary, we present a detailed expression pattern of the P2X<sub>3</sub> receptor during neurogenesis and report that P2X<sub>3</sub> immunoreactivity is down-regulated in early postnatal brainstems.

## INTRODUCTION

Purine compounds such as adenosine 5'-triphosphate (ATP) play important roles in energy metabolism, synthesis of nucleic acids, and regulation of enzymes in living organisms. Nevertheless, the functions of these compounds are not restricted to intracellular actions but also to extracellular signaling. In recent years, the biological functions of extracellular ATP as a neurotransmitter and a neuromodulator have been studied intensively (Burnstock, 1997; Abbracchio and Burnstock, 1998). Extracellular ATP evokes responses by means of two families of P2 receptors, namely P2X and P2Y purinoceptors (Kennedy and Burnstock, 1985; Abbracchio and Burnstock, 1994). The P2X receptors consist of ligand-gated ion channels, which mediate rapid and selective permeability to certain types of cations (Na<sup>+</sup>, K<sup>+</sup>, Ca<sup>2+</sup>) (Bean, 1992; Dubyak and El Moatassim, 1993; North, 1996). To date, seven subunits of P2X receptors have been cloned (P2X<sub>1-7</sub>) from different tissues (reviewed by Ralevic and Burnstock, 1998). P2Y receptors are purine and pyrimidine nucleotide receptors that are coupled to G proteins, with eight established subtypes in mammals recently proposed (Abbracchio et al., 2003).

The distribution of the seven cloned P2X receptors in the central nervous system (CNS) has been well studied in adult rat (Kidd et al., 1995; Collo et al., 1996, 1997; Soto et al., 1996; Kanjhan et al., 1999; Yao et al., 2001). Among the P2X receptor subunits, P2X<sub>3</sub> is well known to show strong expression in sensory neurons (Vulchanova et al., 1997; Llewellyn-Smith and Burnstock, 1998; Xiang et al., 1998). Xiang et al. (1998) demonstrated that the P2X<sub>3</sub> receptor is highly expressed in trigeminal, nodose, and dorsal root ganglia compared with other P2X receptors studied. Studies of coexpressed P2X<sub>2</sub>/P2X<sub>3</sub> receptors and native P2X receptors in sensory neurons indicate heteropolymerization of P2X<sub>2</sub> and P2X<sub>3</sub> receptors (Lewis et al., 1995; Vulchanova et al., 1997; Virginio et al., 1998). Homomeric P2X<sub>3</sub> receptor is expressed in the capsaicin-sensitive, small dorsal root ganglion neurons, whereas the heteromeric P2X<sub>2/3</sub> receptor is expressed in the capsaicin-insensitive, medium neurons (Ueno et al., 1999). These results all suggest the involvement of purinergic signaling in sensory function by means of the action of the P2X<sub>3</sub> receptor. This has been reinforced in knockout experiments in which P2X<sub>3</sub>-deficient mice exhibited a marked urinary bladder hyporeflexia and showed a reduction in pain sensation (Cockayne et al., 2000). However, Xiang et al. (1998) have demonstrated the expression of P2X<sub>3</sub> receptor protein in scattered neurons in superior cervical and coeliac ganglia. In addition, Glass and Burnstock (2001) have also reported P2X<sub>3</sub> receptor expression in thyroid follicular and endothelial cells, suggesting that the P2X<sub>3</sub> receptor may have other roles in addition to sensory functioning.

There is growing evidence to suggest that purinergic signaling is involved in early embryonic development. Purinoceptors were shown to be one of the first functionally active membrane receptors in chick embryo cells during gastrulation, in which, by means of purinoceptors, ATP induced rapid accumulation of inositol phosphate and Ca<sup>2+</sup> mobilization in a similar way and to the same extent as acetylcholine (Laasberg, 1990). Recent reports also implicate ATP as a key regulator of the development of various organs and systems in frog and chick as well as in mammalian embryos (reviewed by Burnstock, 1996, Burnstock, 2001). Responses to ATP have been described in chick ciliary neurons acutely dissociated from day 14 embryonic ciliary ganglia (Abe et al., 1995). In many cases, responses to extracellular ATP have been shown to vary, depending upon the stage of embryonic development. For example, ATP elicits vigorous muscle contraction at embryonic day 6 (E6), but by E17, no effect of ATP on muscle contraction is observed (Wells et al., 1995). Meyer et al. (1999) demonstrated that two P2X receptor subunits, P2X<sub>5</sub> and P2X<sub>6</sub>, were first expressed at early stages of chick skeletal muscle development and expression disappeared immediately before fusion of myoblasts to form myotubes. These data strongly suggest that P2X receptors play a role in embryonic development. However, although the involvement of P2X receptors has been shown in early development of chick embryo (Meyer et al., 1999a,b), there is little information regarding the expression and function of the P2X receptors in mammalian embryos. One study

by Ryten et al. (2001) demonstrated the sequential expression of P2X<sub>5</sub>, P2X<sub>6</sub>, and P2X<sub>2</sub> receptor subtypes in developing rat skeletal muscles, whereas Kidd et al. (1998) reported P2X<sub>3</sub> receptor expression in various nuclei such as spinal trigeminal tract, mesencephalic trigeminal nucleus, and solitary nucleus in late embryonic rat brain; this expression was down-regulated in young adult brain. This finding clearly demonstrates the presence of the P2X<sub>3</sub> receptor in the sensory system of the prenatal central nervous system. For the peripheral nervous system, the sensory ganglia such as the trigeminal ganglia and dorsal root ganglia have their primordial tissues present as early as in E10 and in E11 in the rat embryo, respectively (Kaufman and Bard, 1999; Kaufman, 1992). However, it is not currently known whether P2X<sub>3</sub> receptors are already expressed during early neurogenesis of the sensory system and, if present, whether P2X<sub>3</sub> receptor subtypes are expressed as homomeric receptors or coexpress with other P2X receptor subtypes (especially P2X<sub>2</sub> receptors).

It is not currently known whether P2X<sub>3</sub> receptors (either homomeric or heteromeric forms) are expressed during early neurogenesis. Thus, in the present study, we investigated the distribution of P2X<sub>3</sub> receptors during the development of the nervous system in the rat embryo. Expression of P2X<sub>3</sub> receptor protein in the neonatal rat brain was examined to show whether there is a down-regulation of P2X<sub>3</sub> receptor protein expression after birth. Coexpression of

P2X<sub>2</sub> and P2X<sub>3</sub> by double labeling was also examined to investigate whether P2X<sub>2</sub> and P2X<sub>3</sub> receptor coexpression is a common phenomenon during early neurogenesis.

## MATERIALS AND METHODS

### *Tissue preparation*

The embryonic expression of P2X<sub>3</sub> receptor protein was studied in Sprague-Dawley rat embryos of E9.5-18.5 by using immunohistochemical techniques. Postnatal rat brain on postnatal day (P) 1 and P16 were chosen for examination. The day of identification of the presence of a vaginal plug was designated as day zero (E0). Pregnant Sprague-Dawley rats were killed by asphyxiation with a rising concentration of CO<sub>2</sub> (between 0% and 100%), and death was confirmed by cervical dislocation according to Home Office (UK) regulations covering schedule 1 procedures. Embryos from prenatal day 9.5-18.5 were collected and fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (PB; pH 7.2) at 4°C overnight. Embryos were then washed in 0.1 M phosphate buffered saline (PBS, pH 7.2) and dehydrated by using 10% sucrose, 20% sucrose, and finally 30% sucrose. Thereafter, the embryos were immersed in OCT-embedding medium and frozen in precooled isopropanol (-70°C) for cryosectioning. Whole embryos were serially cryosectioned (12µm) and mounted on gelatin-coated slides and dried at room temperature. Every section cut was analyzed for immunoreactivity. Neonatal rat brains were dissected after cervical dislocation, and the brains were fixed and processed as



described above. Frozen sections (15µm) sections were cut and mounted. One in every ten sections was analyzed for immunoreactivity.

### *Immunohistochemistry*

Immunohistochemistry for P2X receptors was performed by using rabbit polyclonal antibodies against a unique peptide sequence of P2X<sub>2</sub> and P2X<sub>3</sub> receptor subtypes provided by Roche Bioscience, Palo Alto, CA (Oglesby et al., 1999). The immunogens used for production of polyclonal P2X<sub>3</sub> antibody were synthetic peptides corresponding to the carboxyl terminal of the cloned rat P2X<sub>2</sub> and P2X<sub>3</sub> receptors, covalently linked to keyhole limpet hemocyanin. The peptide sequences of the P2X<sub>2</sub> and P2X<sub>3</sub> receptors are of amino acid sequence 458-472 (QQDSTSTDPKGLAQL) and 383-397 (VEKQSTDSGAYSIGH), respectively. The polyclonal antibodies were raised by multiple, monthly injections of New Zealand rabbits with the corresponding peptides (prepared by Research Genetics, Huntsville, AL). The specificity of the antisera was verified by immunoblotting with membrane preparation from CHO K1 cells expressing the cloned P2X<sub>2</sub> and P2X<sub>3</sub> receptors (Oglesby et al., 1999). As previously reported by Oglesby et al. (1999), the antisera recognized only one protein of the expected size in the heterologous expression systems and were shown to be receptor-subtype-specific.

For immunostaining of cryosections, the standard avidin-biotin complex (ABC) technique was used. Sections were post-fixed with 4% paraformaldehyde for 2 minutes at room temperature. Endogenous peroxidase was blocked by 0.5% H<sub>2</sub>O<sub>2</sub> and 50% methanol (methanol:PBS, 1:1) for 20 minutes. The P2X<sub>3</sub> primary antibody was used at a concentration of 1:200 prepared in 10% normal horse serum (NHS) containing 0.2% Triton X-100. For P2X<sub>2</sub> immunohistochemistry, the primary antibody was used at a dilution of 1:200 prepared in 10% NHS only. Subsequently, the sections were incubated with biotinylated donkey anti-rabbit IgG (Jackson ImmunoResearch Lab, West Grove, PA) at a dilution of 1:500 in PBS containing 1% NHS for 1 hour. The sections were then incubated in ExtrAvidin peroxidase diluted 1:1000 in PBS for 30 minutes at room temperature. For color reactivity, a solution containing 0.05% 3,3'-diaminobenzidine (DAB), 0.04% nickel ammonium sulfate, 0.2% β-D-glucose, 0.004% ammonium nitrate, and 1.2 U/ml glucose oxidase in 0.1 M PB (pH 7.2) was applied. Sections were washed three times with 0.1 M PBS after each of the above steps (except for serum preincubation). Slides were mounted with Eukitt (BDH Laboratory, UK) and examined with light microscopy. The control experiments were carried out with the primary antibodies preadsorbed with the peptides for immunizing the rabbits or the primary antibody replaced with the normal horse serum.

### *Immunofluorescence double labeling*

In colocalization studies investigating the coexpression of P2X<sub>2</sub> and P2X<sub>3</sub> receptors, P2X<sub>2</sub> receptor immunoreactivity was enhanced with tyramide amplification, which allows high sensitivity and low background specificity (Renaissance, TSA indirect, NEN, USA). Tyramide amplification was performed after the primary antibody, specific for the P2X<sub>2</sub> receptor (1:800), was coupled to biotinylated donkey anti-rabbit IgG and ExtrAvidin peroxidase as described above. The immunoreactivity was detected with Streptavidin-fluorescein isothiocyanate (FITC) (Amersham, UK). Polyclonal rabbit antibody against P2X<sub>3</sub> receptor subtype (1:150) was applied as a second primary antibody and detected with Cy3-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Lab, West Grove, PA). To prevent the generation of artifacts due to nonspecific labeling after tyramide amplification, double labeling was also performed by using anti-P2X<sub>3</sub> receptor antibody as the first primary antibody and the anti-P2X<sub>2</sub> receptor antibody as the second primary antibody, to confirm the expression pattern.

To demonstrate the colocalization of the P2X<sub>2</sub> receptor with embryonic heart muscle, the P2X<sub>2</sub> receptor antibody (1:800) was used as the first primary antibody, enhanced with tyramide amplification and detected with Streptavidin-FITC as described above. Mouse monoclonal antibody against  $\alpha$ -smooth muscle actin (1:400; Sigma, UK) was applied as the second primary

antibody and the immunoreactivity was then detected with rhodamine (TRITC)-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Lab, West Grove, PA).

### *Photomicroscopy*

Images of DAB immunohistochemical staining and immunofluorescence labeling were taken with the Leica DC 200 digital camera (Leica, Switzerland) attached to a Zeiss Axioplan microscope (Zeiss, Germany). Images were imported into a graphics package (Adobe Photoshop 5.0, USA). The two-channel readings for green and red fluorescence were merged by using Adobe-Photoshop 5.0.

### *Data analysis*

Analysis was performed and scored and was confirmed by an independent observer in a blind manner. Scores for P2X<sub>3</sub> immunohistochemical staining were made by using a subjective, graded scale varying from -, undetectable staining; +, weak staining but distinguishable from background, or scattered cells with moderate intensity staining; ++, moderate intensity staining in over 50% of cells; +++, very intense immunoreactivity in over 50% of cells.

## RESULTS

### *P2X<sub>3</sub> immunoreactivity in the rat embryonic nervous system*

Immunohistochemistry was performed to investigate the pattern of P2X<sub>3</sub> receptor protein expression during rat embryonic development. By using the standard ABC method with nickel and DAB as chromogens, black staining indicated positive immunoreactivity. In this study, rat embryos of E9.5-18.5 were chosen to investigate P2X<sub>3</sub> immunoreactivity and the results are summarized in Table 1.

No detectable P2X<sub>3</sub> immunoreactivity was observed in E9.5-E10.5 embryos. Weak P2X<sub>3</sub> immunolabeling was first identified in the trigeminal preganglia, facioacoustic ganglion complex, glossopharyngeal-vagal ganglion complex, and the ventrolateral region of the hindbrain neural tube in E11-11.5 rat embryos (data not shown). At E12.5, stronger P2X<sub>3</sub> staining intensity was found in the same embryonic tissues as E11.5 rat embryos (Fig. 1). For the trigeminal preganglion in E11-11.5 rat embryos, P2X<sub>3</sub> was found in the neurons and fibers only, which were separated from the neural tube. In E12.5 rat embryos, when the spinal trigeminal tract has begun to appear between the trigeminal ganglion and the neural tube, the spinal trigeminal tract was stained with P2X<sub>3</sub> antibody (Fig. 1). In addition, the dorsal root

ganglia and the vagal trunk also started expressing P2X<sub>3</sub> receptors in E12.5 rat embryos (Fig. 1). Unlike the E11.5 embryo, where P2X<sub>3</sub> receptors were expressed in only a few neurons and fibers in the neural tube, extensive neurons and fibers in the ventrolateral region of the neural tube showed stronger P2X<sub>3</sub> immunoreactivity in E12.5 embryos (Fig. 1). Although the expression was strong in the hindbrain neural tube, weak expression was also found in the spinal neural tube. However, expression of P2X<sub>3</sub> protein was not found in the forebrain neural tube.

For E14.5 rat embryos, more embryonic organs showed P2X<sub>3</sub> neural immunoreactivity (Fig. 2). The central nervous system (CNS), which differentiates from neural tube, was shown to have P2X<sub>3</sub> immunoreactivity at this stage. The P2X<sub>3</sub> receptor was expressed in the mesencephalic trigeminal nucleus, spinal trigeminal tract, nucleus tractus solitarius, and the spinal cord. In the pontine region, P2X<sub>3</sub> receptor expression was strong in the facial nerves, and both the settled and migrating facial neurons of the facial nucleus. The prepositus hypoglossal nucleus, however, showed very weak P2X<sub>3</sub> receptor staining. In the spinal cord, the P2X<sub>3</sub> receptor was expressed in the ventral region of the spinal cord (Fig. 2). The optic nerve and retina (neural layer) showed very weak P2X<sub>3</sub> immunoreactivity (data not shown). In the peripheral nervous system, trigeminal and dorsal root ganglia (which were more

differentiated than in previous stages) showed strong P2X<sub>3</sub> receptor expression. Vestibulocochlear ganglia, which are derived from the facioacoustic ganglion complex, also expressed P2X<sub>3</sub> receptor protein. In addition to the cell bodies of the ganglia showing P2X<sub>3</sub> expression, nerve fibers in the ganglion (e.g., trigeminal nerve, facial nerve, vestibular nerve, glossopharyngeal nerve, spinal nerve, vagal trunk, and sympathetic trunk) also expressed P2X<sub>3</sub> protein (data not shown). The innervation of visceral organs such as lung, esophagus and stomach (Fig. 2), and the nerves in tongue and pharynx were P2X<sub>3</sub> receptor-positive.

In E16.5 rat embryos, vestibular nucleus in the medulla started to show weak P2X<sub>3</sub> receptor staining (data not shown). Peripheral nerves such as the mesenteric nerves (especially those surrounding blood vessels), nerves in the bladder and intestine did not show P2X<sub>3</sub> receptor expression until E16.5. However, P2X<sub>3</sub> immunoreactivity was not detected in the ventral spinal cord in E16.5 embryos. Unlike the sensory ganglia (e.g., trigeminal ganglion, dorsal root ganglia, and nodose ganglia) that showed strong P2X<sub>3</sub> immunoreactivity, only scattered ganglionic cells in superior cervical ganglion and the sympathetic ganglion were stained weakly with P2X<sub>3</sub> receptor antibody in E18.5 embryos (Fig. 3). The sympathetic trunk, however, showed relatively stronger P2X<sub>3</sub> receptor expression (Fig. 3). In the CNS, P2X<sub>3</sub> immunoreactivity was strong in the dorsal spinal cord (Fig. 4) and the mesencephalic

trigeminal nucleus (Fig. 5). P2X<sub>3</sub> receptor expression was also found along the whole optic tract running from the neural layer of the retina through the optic chiasm to the lateral geniculate of the diencephalon. However, the lateral geniculate nucleus in the diencephalon appeared to have no P2X<sub>3</sub> immunoreactivity. In the retina, high magnification revealed that P2X<sub>3</sub> expression was restricted to the retinal ganglion cells in the inner neural layer of the retina and was not seen in the outer pigmental layer (Fig. 4). The prepositus hypoglossal nucleus in the medulla still expressed weak P2X<sub>3</sub> receptor protein. Strong P2X<sub>3</sub> immunoreactivity was observed in the peripheral nerves supplying the tongue, mesentery, and vibrissae (Fig. 4). There was no immunostaining observed in any of the following regions: forebrain (olfactory bulb, cerebral cortex, caudate putamen, amygdala, internal capsule), diencephalon (thalamus, hypothalamus), cerebellum and brainstem (superior and inferior colliculus, superior and inferior olive, vagal motor nucleus, dorsal motor nucleus of vagus, trigeminal motor nucleus, cuneate nucleus, gracile nucleus). There was no visible staining in control experiments where the P2X<sub>3</sub> antibody was replaced with NHS (data not shown) or preadsorbed with peptide (Fig. 4).

#### *P2X<sub>3</sub> receptor immunoreactivity in neonatal rat brain*



In P1 rat brain, P2X<sub>3</sub> receptor expression was localized to a subpopulation of the mesencephalic trigeminal nucleus. At this developmental stage, weaker P2X<sub>3</sub> receptor expression was seen in spinal trigeminal tract, spinal trigeminal nucleus, facial nucleus and facial nerve, vestibular nucleus, nucleus tractus solitarius, and in the prepositus hypoglossal nucleus when compared with expression in embryonic brain (Fig. 5). In P16 rat brain, no P2X<sub>3</sub> receptor immunoreactivity was detected in the mesencephalic trigeminal nucleus, spinal trigeminal tract, facial nerves, and facial nucleus or the vestibular nucleus. Only the nucleus tractus solitarius and the hypoglossal nucleus remained P2X<sub>3</sub> immunopositive at this time point (data not shown).

#### *Expression of P2X<sub>2</sub> and P2X<sub>2/3</sub> receptor protein*

P2X<sub>2</sub> receptor expression was first identified in the E11-11.5 rat embryo. Immunostaining was observed in the notochord at the level of the spinal neural tube and the myocytes of the heart. The expression of the P2X<sub>2</sub> receptor in notochord persisted in E12.5 embryo (Fig. 6). However, P2X<sub>3</sub> receptor protein was not detected in the notochord or the heart at this stage (Fig. 6). In the heart, cardiomyocytes stained strongly with P2X<sub>2</sub> receptor antibody.  $\alpha$ -smooth muscle actin, which is known to be strongly expressed during early development of cardiac muscle (Woodcock-Mitchell et al., 1988; Sawtell and Lessard, 1989), was used as a marker for

early stage cardiac muscle. Double-labeling experiments showed that P2X<sub>2</sub> was coexpressed with  $\alpha$ -smooth muscle actin in both E11.5 and E12.5 heart, including the truncus arteriosus, right and left atria, ventricle, and bulbus cordis (Fig. 7). The smooth muscle layer of the dorsal aorta was continuous with the embryonic heart. Together with the heart muscles, the smooth muscle layer at these stages also expressed  $\alpha$ -smooth muscle actin. However, the aortic muscle layer did not show any P2X<sub>2</sub> immunoreactivity (Fig. 7). In E11.5 and 12.5 rat embryos, no detectable P2X<sub>2</sub> immunoreactivity was seen in the neural tubes. In the central nervous system, very weak P2X<sub>2</sub> immunoreactivity was first identified in the nucleus tractus solitarius and the spinal nerves emerging from the dorsal root ganglia of E14.5 embryo. However, the dorsal root ganglia did not show any P2X<sub>2</sub> immunoreactivity. At E16.5, the smooth muscle of the dorsal aorta, trachea and bronchi, esophagus, stomach, intestine, and bladder clearly stained positive with the P2X<sub>2</sub> receptor antibody. In addition, the nodose ganglia and the vagal trunk showed weak and moderate P2X<sub>2</sub> immunoreactivity (Fig. 6), respectively. The peripheral nerves supplying the tongue also showed P2X<sub>2</sub> immunoreactivity. The nucleus tractus solitarius and the nodose ganglia in E18.5 embryos showed obvious P2X<sub>2</sub> receptor expression (Fig. 6). Most of the skeletal muscles in E18.5 embryos were found to be P2X<sub>2</sub> receptor positive (data not shown). In all the P2X<sub>3</sub>-immunopositive neural tissue examined, the P2X<sub>2</sub> receptor was expressed in the nucleus tractus solitarius and spinal nerves from E14.5 and the nodose ganglion, the vagal trunk, and the peripheral nerves supplying the tongue from E16.5.

However, at E14.5, the staining was very weak even after tyramide amplification. Thus, coexpression of P2X<sub>2</sub> and P2X<sub>3</sub> receptors could only be detected clearly at E16.5. Double labeling experiments (Fig. 7) showed that in the nodose ganglia, only a subpopulation of neurons showed P2X<sub>2/3</sub> colocalization. After tyramide amplification, the dorsal root ganglia showed P2X<sub>2</sub> immunoreactivity; however, high magnification revealed the staining to be localized in the spinal nerves. Only few neurons in the dorsal root ganglia showed P2X<sub>2</sub> receptor staining, and this was coexpressed with P2X<sub>3</sub> receptor protein. A high degree of P2X<sub>2</sub> and P2X<sub>3</sub> coexpression was detected in the peripheral nerves ending in tongue. The strongest staining of both P2X<sub>2</sub> and P2X<sub>3</sub> immunoreactivity was found in the median circumvallate papilla. Quantitatively, however, P2X<sub>2</sub>-positive nerves in the tongue were more frequently identified than P2X<sub>3</sub>-positive nerves. Apart from taste buds in tongue, the nucleus tractus solitarius in E16.5 showed a high degree of P2X<sub>2</sub> and P2X<sub>3</sub> colocalization (Fig. 7).

Preliminary studies in our laboratory have shown that, except for P2X<sub>3</sub>, all the other P2X receptors, including P2X<sub>2</sub>, were absent in neural tubes and the sensory ganglia from E11 to E12.5 embryos. They were first detected in the embryonic brain and spinal cord in E14 embryos (unpublished data). In addition, of all the P2X receptors examined, only P2X<sub>2</sub> receptor subtypes were found in the heart and the notochord at this stage.

## DISCUSSION

P2X receptors are ligand-gated ion channels activated by extracellular ATP that mediate rapid cation permeability and fast excitatory neurotransmission in both the central and peripheral nervous systems (reviewed by Ralevic and Burnstock, 1998). One of the P2X receptor subunits, P2X<sub>3</sub>, was cloned from rat dorsal root ganglia (Chen et al., 1995; Lewis et al., 1995) and is known to be largely restricted to a subset of sensory neurons (trigeminal, nodose, and dorsal root ganglia). In early reports, P2X<sub>3</sub> was not detected in sympathetic, enteric, and CNS neurons (Chen et al., 1995; Collo et al., 1996), although the presence of the P2X<sub>3</sub> receptors has been demonstrated in superior cervical and celiac ganglia (Xiang et al., 1998; Zhong et al., 2000) and nucleus tractus solitarius (Vulchanova et al., 1997; Llewellyn-Smith and Burnstock, 1998; Yao et al., 2000). In this study, we present the detailed expression pattern of the P2X<sub>3</sub> receptor at different stages of rat embryonic development. In addition, the coexpression of P2X<sub>2</sub> and P2X<sub>3</sub> receptors was also examined to investigate whether P2X<sub>2/3</sub> receptor heteromerization is an early event during embryo development. The results obtained have shown that the P2X<sub>3</sub> receptor is the dominant receptor subtype among the P2X receptor family in the early embryonic nervous system and that P2X<sub>3</sub> receptor expression is

down-regulated in the neonatal rat brain. P2X<sub>2/3</sub> expression appeared late in development compared with the individual receptor subtypes.

During E11-11.5, when gastrulation is complete and the neural tube has closed, gangliogenesis occurs (Kaufman and Bard, 1999). At this stage, the trigeminal ganglion and facioacoustic ganglion complex is formed and the glossopharyngeal-vagal preganglion is developing. At this time, P2X<sub>3</sub> protein first appears during rat embryonic development and is localized in the developing trigeminal preganglia, facioacoustic ganglion complex, and glossopharyngeal-vagal ganglion complex. At E12.5, the spinal trigeminal tract, which acts as a connection between the peripheral nervous system and CNS in the trigeminal system, showed strong P2X<sub>3</sub> immunoreactivity. P2X<sub>3</sub> receptors were also found in the vagal trunk and dorsal root ganglia at this stage.

The ganglia mentioned above are either wholly or partially derived from neural crest cells (Le Douarin and Kalcheim, 1999). These ganglia are also involved in sensory function. It is not known whether expression of the P2X<sub>3</sub> receptor has any association with neural crest development or whether it is only associated with sensory function. From E14.5 onward, the mesencephalic trigeminal nucleus, the nucleus tractus solitarius and the prepositus hypoglossal

nucleus in the CNS showed P2X<sub>3</sub> immunoreactivity. Although the mesencephalic trigeminal nucleus belongs to the CNS, it is not derived from the neural tube. Instead, studies on the heterospecific grafting between quail and chick embryos have shown that the mesencephalic trigeminal nucleus is actually derived from neural crest cells in which the precursor cells of the nucleus migrate from the crest toward the ventricular surface of the neuroepithelium (Narayanan and Narayanan, 1978). This finding further increases the association between the neural crest cells and P2X<sub>3</sub> receptor expression. P2X<sub>3</sub> receptors are constantly expressed in the above ganglia throughout prenatal development (from E11.5 to E18.5), and most of the ganglia still express P2X<sub>3</sub> receptor even in adulthood (Xiang et al., 1998, 1999), so they would appear to be involved in development, maturation, and normal sensory functioning of the ganglia. P2X<sub>3</sub> receptors were expressed not only in sensory ganglia but also in the superior cervical ganglia and sympathetic ganglia, although the immunostaining appeared scattered and weak. Xiang et al. (1998) showed scattered ganglionic cells expressing P2X<sub>3</sub> receptor protein in the superior cervical ganglia, which is consistent with the present study and suggests that the pattern of P2X<sub>3</sub> immunoreactivity in the superior cervical ganglion persists from the embryonic stage to adulthood.

P2X<sub>3</sub> receptor expression was not only detected in the sensory and sympathetic ganglia but also in the neural tube, which gives rise to the CNS. The results from this study showed that, in early stage embryos, intense P2X<sub>3</sub> receptor expression was observed in the anterior part of the hindbrain neural tube (ventral neural tube) and that the intensity of P2X<sub>3</sub> immunoreactivity decreased with increasing distance along the spinal cord. The anterior hindbrain neural tube gives rise to the metencephalon, which consists of a dorsal region that develops into the cerebellum and a ventral region that will form the pons. The posterior hindbrain neural tube forms the myelencephalon which gives rise to the medulla oblongata. Our results show that P2X<sub>3</sub> receptors are expressed in the ventral part of the prospective metencephalon and myelencephalon, thus, defining the P2X<sub>3</sub> immunopositivity in the pons and medulla in the late stage embryos. Later during development, P2X<sub>3</sub> receptor protein was expressed in brainstem nuclei such as mesencephalic trigeminal nucleus, nucleus tractus solitarius, and prepositus hypoglossal nucleus. These results are in agreement with a study demonstrating P2X<sub>3</sub> immunoreactivity in E16 rat embryos reported by Kidd et al. (1998), except that we did not identify P2X<sub>3</sub> receptor expression in the superior and inferior olives. P2X<sub>3</sub> receptors were also expressed in the neural layer of the retina and the optic tract that extends all the way to the lateral geniculate in the diencephalon. The P2X<sub>3</sub> receptor expression in the retina appeared to be present even in the adult (Brändle et al., 1998). Our results show that P2X<sub>3</sub> immunoreactivity was present in the ventral spinal cord at E12.5-E14.5. However, P2X<sub>3</sub>

receptor expression was not observed in the ventral spinal cord at E16.5. Instead, strong P2X<sub>3</sub> immunoreactivity was localized in the dorsal spinal cord. Surprisingly, P2X<sub>3</sub> receptors were present in the facial motor nucleus, which is known to be involved in motor function. Our results show that both the ventral spinal cord and facial motor nucleus are down-regulated during prenatal and postnatal development, respectively. Such changes in expression pattern together with the P2X<sub>3</sub> receptor expression in the sympathetic nervous system suggests that the P2X<sub>3</sub> receptor has a role other than a sensory function during early development of the nervous system. Although intense P2X<sub>3</sub> receptor protein expression was detected in the rat embryonic brain and spinal cord, previous studies have shown reduced expression of the P2X<sub>3</sub> receptor in the adult rat brain (Kidd et al., 1998). The nucleus tractus solitarius and the spinal cord have been described in the adult rat CNS (Vulchanova et al., 1997; Kidd et al., 1998; Llewellyn-Smith and Burnstock, 1998). In addition, a recent report also described strong P2X<sub>3</sub> receptor immunoreactivity in nucleus tractus solitarius, and medial and lateral parabrachial nucleus by using antibodies recognizing the extracellular domain of the P2X<sub>3</sub> receptor protein (Yao et al., 2000). In the present study, we show that P2X<sub>3</sub> immunoreactivity in the spinal trigeminal tract, facial nucleus, mesencephalic trigeminal nucleus, and vestibular nucleus is absent in P16 rat brain. Together, the results suggest that the expression of the P2X<sub>3</sub> receptor is developmentally regulated and the transient expression of P2X<sub>3</sub> in these tissues may indicate a role in neurogenesis.



In addition to the CNS, P2X<sub>3</sub> immunoreactivity is also found in nerve fibers innervating the developing visceral organs, including tongue, vibrissae, lung, bladder, stomach, and intestine. Chen et al. (1995) claimed that the P2X<sub>3</sub> receptor was absent from the lung, bladder, stomach, intestine by using Northern analysis, a technique that is not sensitive for detecting low levels of mRNA expression. Cockayne et al. (2000) have shown recently that P2X<sub>3</sub> knockout mice suffered from urinary bladder hyporeflexia, demonstrating the importance of P2X<sub>3</sub> receptors in somatic and visceral sensory function.

In the present study, we show that during organogenesis (i.e., E11-E12.5), P2X<sub>3</sub> and P2X<sub>2</sub> receptors are differentially expressed in embryonic tissues, whereas the P2X<sub>3</sub> receptor is expressed in both the central and peripheral nervous system, the P2X<sub>2</sub> receptor is mainly expressed in the cardiac muscle and notochord at the level of the spinal neural tube. The notochord, a mesodermally derived structure, is well known for its inductive effect on neural tube patterning (Roelink et al., 1994) in both invertebrates and vertebrates. It is not yet known whether ATP has any effect on spinal cord patterning by means of the P2X<sub>2</sub> receptor. Therefore, it would be of interest to investigate in future studies whether there is any interaction between the ATP effects on the neural tube by means of P2X<sub>3</sub> and that on the

notochord by means of P2X<sub>2</sub>. The findings from the present study indicate that P2X<sub>3</sub> and P2X<sub>2</sub> are expressed as homomeric receptors. During embryonic development, P2X<sub>3</sub> receptor protein expression is restricted to the nervous system, whereas P2X<sub>2</sub> receptor protein is also expressed in developing muscle tissues. The P2X<sub>2</sub> receptor is expressed in cardiac muscle, visceral smooth muscle, and in skeletal muscle. A recent study from our laboratory has shown the expression of P2X<sub>2</sub> in rat skeletal muscle in the late embryonic stages (Ryten et al., 2001). In this study, although P2X<sub>3</sub> and P2X<sub>2</sub> homomeric receptors were individually expressed as early as in E11.5, the coexpression of the two receptor subtypes could only be detected clearly at E16.5, which was 5 days later than the first appearance of individual receptor expression. Despite the strong expression of P2X<sub>3</sub> receptor found in dorsal root ganglion, only scattered neurons showed P2X<sub>2</sub> immunoreactivity in the dorsal root ganglion, which previously has been shown to express heteromeric P2X<sub>2/3</sub> receptor expression (Lewis et al., 1995; Ueno et al., 1999). The nodose ganglion, which is also known to express P2X<sub>2/3</sub> receptors, also showed P2X<sub>2</sub> and P2X<sub>3</sub> coexpression in a subpopulation of neurons at E16.5. These data are in agreement with previous functional studies from our laboratory that showed P2X<sub>2/3</sub> heteromers are expressed in a subpopulation of nodose ganglia (Lewis et al., 1995; Dunn et al., 2000). Functional studies in the P2X<sub>3</sub> knockout animal have shown that it is mainly the P2X<sub>3</sub> receptor that responds to ATP in the dorsal root ganglion, whereas the P2X<sub>2</sub> and P2X<sub>2/3</sub> receptors appear more important in the nodose ganglion (Cockayne et al., 2000). In the present study, the

distribution in the P2X<sub>2</sub> and P2X<sub>3</sub> receptors in the dorsal root ganglion and the nodose ganglion seem to be consistent with the functional studies mentioned above. Previous reports have shown that the P2X<sub>2</sub> receptor is expressed in the retinal ganglion cells in rat (Greenwood et al., 1997). In contrast, our study shows that P2X<sub>3</sub> receptor protein is only detected in the retinal ganglion cells from E14.5 onward; furthermore, P2X<sub>2</sub> receptor expression was not detected in the retina at any of the prenatal stages examined (data not shown).

The results obtained may indicate that the role of the P2X<sub>3</sub> receptor as a sensory-involving molecule in the retina may be replaced, at least in part, by P2X<sub>2</sub> receptor expression during postnatal development. Both the taste buds in the tongue in the peripheral nervous system and the nucleus tractus solitarius in the central nervous system showed a high degree of P2X<sub>2</sub> and P2X<sub>3</sub> coexpression. In tongue, the median circumvallate papilla showed strong P2X<sub>3</sub> and P2X<sub>2</sub> immunoreactivity which is in agreement with the results demonstrated by Bo et al. (1999). Therefore, it is not surprising that the nucleus tractus solitarius also showed a high degree of P2X<sub>2</sub> and P2X<sub>3</sub> coexpression, as the sensory fibers that receive input from the taste cells run in cranial nerves VII, IX, and IX and enter the solitary tract in the medulla. Despite the fact that dorsal root ganglion, nodose ganglion, taste buds, and nucleus tractus solitarius have sensory functions in the peripheral and central nervous systems, different degrees of P2X<sub>3</sub> and P2X<sub>2</sub>

receptor expression in different sensory neurons and nerves account for the different responses reported in functional studies (reviewed by Nörenberg and Illes, 2000). Preliminary immunohistochemical studies in our laboratory have shown that the P2X<sub>3</sub> receptor protein is the only receptor subtype among the P2X receptor family present in the early central and peripheral nervous system before E14.5. These data suggest that the homomeric P2X<sub>3</sub> is the dominant P2X receptor during early neurogenesis, despite the fact that P2X<sub>2</sub> and P2X<sub>4</sub> are the dominant receptor subtypes in the adult central nervous system (reviewed by Nörenberg and Illes). In addition, our data also indicate that the P2X<sub>3</sub> receptor is expressed as a homomeric receptor rather than the heteromeric P2X<sub>2/3</sub> form in early stage embryos.

In summary, we have shown a detailed expression pattern of P2X<sub>3</sub> in both central and peripheral nervous systems at different stages of rat embryonic development. Strong association was observed between P2X<sub>3</sub> expression and neural crest derivatives. The P2X<sub>3</sub> receptors appear to have a major role in sensory function in the early stage embryos but these receptors may also be involved in somatic and autonomic motor systems. P2X<sub>3</sub> and P2X<sub>2</sub> receptors are expressed separately during organogenesis and the P2X<sub>2</sub> and P2X<sub>3</sub> receptor coexpression appeared later in development than the individual native P2X receptors. Absence of other P2X receptor expression in the nervous system of the early stage embryos indicates

that P2X<sub>3</sub> may be the only receptor subtype involved in fast excitatory signaling mediated by ATP during embryonic neurogenesis. The precise function of purinergic signaling by means of the P2X<sub>3</sub> receptor in the embryo still remains to be elucidated. However, the transient expression of P2X<sub>3</sub> receptor protein reported here clearly suggests a role in the development of the nervous system in the mammalian embryo. The involvement of other P2X and P2Y receptor subtypes in early mammalian embryogenesis remains to be explored.

The work of this chapter has been published in:

Cheung KK and Burnstock G. (2001). Localization of P2X<sub>3</sub> receptors and coexpression with P2X<sub>2</sub> receptors during rat embryonic neurogenesis. *J Comp Neurol.* **443**:368-382.

## FIGURES & LEGENDS

**TABLE 1.** Localization of P2X<sub>3</sub> receptor immunoreactivity at different stages during rat embryonic development

Embryonic PNS	E9.5-10.5	E11-11.5	E12.5	E14.5	E16.5	E18.5
Trigeminal (V) ganglia and its nerve	-	+	++	+++	+++	+++
Facial (VII) ganglia and its nerve	-	+	++	+++	+++	+++
Vestibulocochlear (VIII) ganglia and its nerve	-	+	++	+++	+++	+++
Glossopharyngeal (IX) ganglia and its nerve	-	+	+++	+++	+++	+++
Dorsal root ganglia and its nerve	-	-	+	+++	+++	+++
Vagal (X) ganglia and vagal trunk	-	-	+++	+++	+++	+++
Sympathetic trunk	-	-	-	+	++	++
Sympathetic ganglia	-	-	-	+	+	+
Nerves supplying the internal organs						
Stomach and intestine	-	-	-	++	++	+++
Lung and trachea	na	-	-	++	++	+++
Tongue and pharynx	na	na	na	++	+++	+++
Mesentery	na	na	na	-	+++	+++
Kidney	na	na	na	-	+	+
Bladder	na	na	na	-	++	++

Nerves in mesentery	-	-	-	-	++	+++
Nerves around vibrissae	na	na	na	-	-	++
<b>Embryonic CNS</b>						
Forebrain neural tube	-	-	-	na	na	na
Olfactory bulb	na	na	na	-	-	-
Cerebral cortex	na	na	na	-	-	-
Caudate putamen	na	na	na	-	-	-
Amygdala	na	na	na	-	-	-
Internal capsule	na	na	na	-	-	-
Hippocampus	na	na	na	-	-	-
Thalamus	na	na	na	-	-	-
Hypothalamus	na	na	na	-	-	-
Optic (II) tract	na	na	na	+	++	+++
Retina	na	na	-	+	++	+++
Superior and inferior colliculus	na	na	na	-	-	-
Mesencephalic trigeminal nucleus of the fifth nerve	na	na	na	++	++	+++
Locus coeruleus	na	na	na	-	-	-
Hindbrain neural tube	-	+	++	na	na	na
Spinal cord	-	-	+	++	+++	+++
Spinal trigeminal tract	na	na	++	+++	+++	+++
Trigeminal motor nucleus	na	na	na	-	-	-
Superior and Inferior olive	na	na	na	-	-	-
Nucleus tractus solitarius	na	na	na	+++	+++	+++
Facial nucleus	na	na	na	+++	+++	+++
Cerebellum	na	na	na	-	-	-

---

Vagal motor nucleus	na	na	na	-	-	-
Prepositus hypoglossal nucleus	na	na	na	+	+	++
Vestibular spinal nucleus	na	na	na	-	+	++
Dorsal motor nucleus of vagus	na	na	na	-	-	-
Cuneate nucleus	na	na	na	-	-	-
Gracile nucleus	na	na	na	-	-	-


The degree of P2X<sub>3</sub> immunoreactivity: +, just detectable; ++, moderate; +++, strong;

-, undetectable; na, not applicable











**Figure 1** P2X<sub>3</sub> immunoreactivity in embryonic day (E) 12.5 rat embryos. **A-C:** Transverse sections at the first (A), second (B), and third (C) branchial arch levels showing P2X<sub>3</sub> immunoreactivity (arrow) in the trigeminal ganglion, facioacoustic ganglion complex, and glossopharyngeal ganglion, respectively. Note the expression of P2X<sub>3</sub> in the primitive spinal trigeminal tract between the trigeminal ganglion and the neural tube (Nt). **D:** Transverse section at the caudal part of the embryo showing P2X<sub>3</sub> expression (arrow) in the dorsal root ganglia on both sides of the neural tube. Insert figures show enlargements of the areas indicated by arrows in the corresponding figures. **E:** Transverse section at the hindbrain neural tube showing P2X<sub>3</sub>-positive neurons (arrows in the insert) and nerve fibers in the ventrolateral region of the neural tube. **F:** Transverse section at the pericardio-peritoneal canal (Pc) showing P2X<sub>3</sub> expression in the vagal trunk (arrows) on both sides of the esophagus (Opg). Note also that P2X<sub>3</sub> receptor expression in the hindbrain neural tube shown in both B and E was much stronger than the spinal neural tube shown in C and D. Scale bar = 200µm in D (applies to A-D), 50µm in inset of D (applies to insets in A-D), 50µm in inset of E, 200µm in E,F.

**Fig 1**



**Figure 2** P2X<sub>3</sub> immunoreactivity in embryonic day (E) 14.5 rat embryo. **A:** coronal section at the midbrain level showing P2X<sub>3</sub> expression in the mesencephalic trigeminal nucleus. **B:** Coronal section at the pontine level showing strong P2X<sub>3</sub> expression in the spinal trigeminal tract (Sp5t) and the longitudinal running trigeminal nerve (5n). **C,D:** Coronal section at the pontine level showing the genu of the facial nerve (g7n) and the facial nucleus (7N) stained strongly with P2X<sub>3</sub> receptor antibody. **E:** Coronal section at the medulla level showing the P2X<sub>3</sub> stained nucleus tractus solitarius. **F:** Transverse section showing P2X<sub>3</sub> receptor expression in the ventral spinal cord. **G,H:** Spinal nerves (Spn), and nerves found in lung (L) (G) and stomach (Sm) (H) at this stage showing P2X<sub>3</sub> immunoreactivity. Scale bar in H = 25µm in A, 50µm in B,E,F, 100µm in C,D,G,H.









**Fig 2**



**Figure 3** P2X<sub>3</sub> immunoreactivity in neural crest-derived ganglia of the embryonic day (E) 18.5 rat embryo. **A-D:** The P2X<sub>3</sub> receptor is strongly expressed in trigeminal ganglion (**A**), dorsal root ganglion (**C**), vestibulocochlear ganglion (**E**) and nodose ganglion (**F**). Note the peripheral staining of P2X<sub>3</sub> immunoreactivity in the ganglionic neurons. (**B**) and (**D**) H&E staining showing the cellular structures of the trigeminal (**B**) and dorsal root ganglia (**D**) (2-3 sections from the corresponding P2X<sub>3</sub> immunostained sections). **G:** Scattered ganglionic cells (arrows) in superior cervical sympathetic ganglion also express P2X<sub>3</sub> protein. **H:** Strong P2X<sub>3</sub> receptor expression was detected in the nerve fibres of the sympathetic trunk (syk). Only scattered neurons in the sympathetic ganglion showed weak P2X<sub>3</sub> immunoreactivity. Note also the uneven localization of the P2X<sub>3</sub> immunoreactivity on the surface of the neuronal membrane.


Scale bar = 100µm in H (applies to A-H).

**Fig 3**



**Figure 4** P2X<sub>3</sub> immunoreactivity in embryonic day (E) 18.5 rat embryo. **A:** Transverse section showing P2X<sub>3</sub> immunoreactivity in the dorsal spinal cord in the lumbar region. **B:** High-magnification image showing the retinal ganglion cells in the neural retina (Ret) expressing P2X<sub>3</sub> receptor protein. No P2X<sub>3</sub> immunoreactivity was found in the pigmental layer of the retina. **C:** Coronal section showing very weak P2X<sub>3</sub> receptor expression (arrows) in the prepositus hypoglossal nucleus ventrolateral to the fourth ventricle. **D:** Transverse section showing strong P2X<sub>3</sub> expressing in the taste bud of the tongue (Tog). **E:** Transverse section showing the mesentery (Mes) of the gut. P2X<sub>3</sub> immunoreactivity was found in the nerves surrounding the blood vessels (Bv) in the mesentery. **F:** Transverse section showing the vibrissae (Vb). P2X<sub>3</sub>-positive nerve fibers (arrows) are found innervating the hair follicle of the vibrissae. **G:** Transverse section showing P2X<sub>3</sub> receptor expression in the nerves surrounding the esophagus (Opg); the nearby vagal trunk (Vk) also showed strong P2X<sub>3</sub> immunoreactivity. **H:** Adjacent section of G incubated with P2X<sub>3</sub> receptor preadsorbed with the preimmune peptide did not show any P2X<sub>3</sub> receptor staining. Scale bar in A = 200μm, scale bar in H = 200μm in C,D,F, 100μm in E,G,H, 50μm in B.







**Fig 4**






**Figure 5** P2X<sub>3</sub> immunoreactivity in late embryonic and neonatal rat brainstem. **A,C,E:** P2X<sub>3</sub> receptor expression in the mesencephalic trigeminal nucleus in embryonic day (E) 18.5, postnatal day (P) 1, and P16 rat brainstem, respectively. Note that only a subpopulation of the neurons in the mesencephalic trigeminal nucleus showed positive immunostaining in P1 brainstem (C). No P2X<sub>3</sub> immunoreactivity was detected in P16 brainstem (E). The spinal trigeminal tract, the nucleus tractus solitarius, the vestibular nucleus, and the prepositus hypoglossal nucleus in P1 brainstem clearly expressed P2X<sub>3</sub> receptor (**B,D**). **F:** In P16 medulla, P2X<sub>3</sub> receptor in the spinal trigeminal tract was not detected. Scale bars = 100µm in E (applies to A,C,E), 500µm in D (applies to B,D), 200µm in F.

**Fig 5**




**Figure 6** P2X<sub>2</sub> immunoreactivity at different stages of rat embryo development. **A:** Transverse section in the spinal neural tube (Nt) in embryonic day (E) 12.5 embryos showing P2X<sub>2</sub> receptor expression in the notochord. **B:** Adjacent section of A stained with P2X<sub>3</sub> receptor antibody. P2X<sub>3</sub> receptor protein was absent in the notochord. **C:** Transverse section at the heart level showing P2X<sub>2</sub> receptor expression in the E12.5 heart, including the left and right atria (LA and RA), bulbus cordis (B), and the primitive ventricle (V). **D:** Transverse section showing the esophagus in E16.5 rat embryo. The P2X<sub>2</sub> receptor was localized in the smooth muscle of the esophagus. **E:** Sagittal section showing the trunk region of the E16.5 embryo. The P2X<sub>2</sub> immunoreactivity was found in the vagal trunk (Vk) at the periphery of the esophagus (Opg). **F,G:** The nucleus tractus solitarius in E16.5 showed P2X<sub>2</sub> immunoreactivity (F) and the preadsorption control in the adjacent section did not show any P2X<sub>2</sub> receptor staining (G). 4V, fourth ventricle. **H,I:** P2X<sub>2</sub> immunoreactivity was found in the nodose ganglion (H) and the nucleus tractus solitarius (I) in E18.5 rat embryo. Scale bar = 500µm in C. Scale bar in I = 200µm in E, 100µm in H, 50µm in A,B,D,F,G.

**Fig 6**



**Figure 7** Immunofluorescence double labeling for the P2X<sub>2</sub> receptor and  $\alpha$ -smooth muscle actin (A-C), and for P2X<sub>2</sub> and P2X<sub>3</sub> receptors (D-O) in rat embryos. **A:** In embryonic day (E) 12.5 heart, the cardiac muscles in the heart and the smooth muscle in the dorsal aorta (arrows) showed  $\alpha$ -smooth muscle actin expression (red). **B:** On the same section immunostained with P2X<sub>2</sub>, the heart also showed P2X<sub>2</sub> receptor expression (green). However, no P2X<sub>2</sub> immunoreactivity was found in the dorsal aorta, indicated by arrows. **C:** Double-labeling images showed the colocalization of the P2X<sub>2</sub> receptor and  $\alpha$ -smooth muscle actin in the cardiac muscle but not the dorsal aorta (arrows). **D-F:** P2X<sub>3</sub> (D) and P2X<sub>2</sub> (E) immunoreactivities in nucleus tractus solitarius in E16.5 embryos. Most of the cells in the nucleus tractus solitarius showed P2X<sub>3</sub> and P2X<sub>2</sub> coexpression (F), although the staining intensity of P2X<sub>3</sub> is much stronger than P2X<sub>2</sub> (even after tyramide amplification). **G-I:** P2X<sub>3</sub> and P2X<sub>2</sub> immunoreactivities in nodose ganglion in E16.5 embryos. Most of the neurons in nodose ganglion showed P2X<sub>3</sub> receptor expression (G), whereas only scattered P2X<sub>2</sub> receptor expression was detected (H). **I:** Double-labeling revealed a subpopulation of nodose ganglion showing P2X<sub>2</sub> and P2X<sub>3</sub> receptor coexpression (arrows). Although P2X<sub>2</sub> immunoreactivity was not as strong as that of P2X<sub>3</sub>, scattered neurons did show P2X<sub>2</sub> receptor protein only, instead of P2X<sub>2</sub> and P2X<sub>3</sub> heteromers. **J-L:** P2X<sub>3</sub> and P2X<sub>2</sub> immunoreactivities in the E16.5 dorsal root ganglion. Neurons in the dorsal root ganglion showed strong P2X<sub>3</sub> receptor expression (J). Only very few neurons in the dorsal root ganglion showed P2X<sub>2</sub> immunoreactivity (K), and

Fig 7



they coexpressed with P2X<sub>3</sub> receptors indicated by arrows (L). K: The P2X<sub>2</sub> receptor, appeared to be mainly expressed in spinal nerves instead of the neurons. Note that the stronger P2X<sub>2</sub> receptor expression in the spinal nerves compared with P2X<sub>3</sub> receptor was due to tyramide amplification. For 3,3'-diaminobenzidine immunostaining, P2X<sub>3</sub> receptor protein showed stronger expression than that of the P2X<sub>2</sub> receptor (data not shown). M-O: P2X<sub>3</sub> and P2X<sub>2</sub> immunoreactivities in the taste bud in E16.5 embryo. P2X<sub>3</sub> and P2X<sub>2</sub> receptors were coexpressed in the taste bud in the tongue (O). The nearby peripheral nerves showed P2X<sub>2</sub> and P2X<sub>3</sub> coexpression, although some of the nerves also showed P2X<sub>2</sub> receptor expression only. Scale bar = 100µm C (applies to A-C). Scale bar in O = 100µm in G-I,M-O, 50µm in D-F,J-L.

# **Chapter III      Abundant and dynamic expression of G protein-coupled    P2Y    receptors    in mammalian development**

## **ABSTRACT**

Extracellular ATP mediates diverse biological effects by activating two families of receptors, the P2X and P2Y receptors. There is growing evidence to show that activation of G protein-coupled P2Y receptors can produce trophic effects in many cell types. Yet the expression and function of the P2Y receptors in development has rarely been studied, and has never been investigated in mammalian development. This study used the reverse transcriptase-polymerase chain reaction and immunohistochemistry to demonstrate the abundant and dynamic expression of P2Y receptors in rat development. These receptors were expressed in a wide range of embryonic structures, notably somites, skeletal muscle, the central and peripheral nervous system, the heart, lung and liver. All the P2Y receptors studied were expressed as early as E11, when most embryonic organs were far from being functional and still in the process of being formed. P2Y receptor proteins were strongly expressed in temporary, developmental structures that do not have a correlate in the adult animal, including the somites (P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub>) and the floor plate of the neural tube (P2Y<sub>1</sub>). P2Y receptors were also dynamically expressed,



with receptor mRNA and protein being both up- and down-regulated at different developmental stages. The down-regulation of the P2Y<sub>1</sub>, 2 and 4 receptor proteins in skeletal muscle and heart, and the disappearance of the P2Y<sub>4</sub> receptor from the brainstem and ventral white matter of the spinal cord postnatally, demonstrated that many P2Y receptors were likely to be involved in functions specific to embryonic life. Thus, these findings strongly suggest that P2Y receptors play an important role in the development of many tissues, and pioneer further studies into the role of purinergic signaling in development.

## INTRODUCTION

Extracellular nucleotides evoke responses by activation of two families of purinoceptors, namely the P2X and P2Y receptors (Abbracchio and Burnstock, 1994). Whereas P2X receptors are ligand-gated ion channels, P2Y receptors are G protein-coupled receptors. Eight P2Y receptor subtypes have been cloned to date in mammals (P2Y<sub>1,2,4,6,11,12,13,14</sub>) (Abbracchio et al., 2003). These receptors couple predominantly to phospholipase C activation, leading to the formation of inositol phosphate and mobilization of intracellular Ca<sup>2+</sup> (Ralevic and Burnstock, 1998; Vassort, 2001). In addition to increased intracellular Ca<sup>2+</sup>, a variety of signal transduction pathways, involving protein kinase C, phospholipase A2 and the mitogen-activated protein kinases, mediate the effects of P2Y receptors. Thus, activation of the P2Y receptors can cause long-term, trophic effects on cell activity (Neary et al., 1996; Abbracchio and Burnstock, 1998, Burnstock, 2002a).

P2Y receptors have been implicated in the regulation of cell proliferation and differentiation. Activation of P2Y receptors on a variety of cell types, including astrocytes and vascular smooth muscle cells, results in cell proliferation (Burnstock, 2002b; Neary et al., 1998; 1999; Neary, 2000). In contrast, activation of the P2Y<sub>11</sub> receptor has been strongly implicated in neutrophil differentiation (Jiang et al., 1997; Conigrave et al., 1998; Communi et al., 2000). Although these

findings strongly suggest a role for purinergic signaling in development, there have been few studies focusing on the expression and function of P2Y receptors in embryonic and postnatal development.

The *Xenopus* P2Y receptor, the XIP2Y (also called P2Y<sub>8</sub>), was shown in the neural plate during neurulation, but not detected after neural tube closure (Bogdanov et al., 1997), suggesting a role for this receptor in the process of neurulation. More recently, expression of P2Y<sub>1</sub> receptor (cP2Y<sub>1</sub>) mRNA and protein has been demonstrated during chick embryonic development (Meyer et al., 1999a; Choi et al., 2001). Meyer et al. (1999a) reported strong expression of cP2Y<sub>1</sub> receptor mRNA in undifferentiated limb mesenchyme cells, but expression was lost as the cells differentiated. The same group also demonstrated that ATP acting by means of cP2Y<sub>1</sub>, significantly inhibited cartilage formation in micromass cultures (Meyer et al., 2001).

These studies are limited to the P2Y<sub>1</sub> and P2Y<sub>8</sub> receptors. Other P2Y receptor subtypes have rarely been studied in development, and none have ever been studied in mammalian *in vivo* development. In this chapter we used the reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry to investigate the expression of four P2Y receptors, P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub>, in rat embryonic and postnatal development. Expression of all the P2Y receptors cloned in rat to date was studied by RT-PCR. In addition, by using specific antibodies

that have only recently become commercially available, the localization of P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptor proteins was investigated. Thus, it has been possible to demonstrate for the first time, the abundant and dynamic expression of P2Y receptors in mammalian development.

## MATERIALS AND METHODS

### *RT-PCR analysis*

Total RNA was extracted from fresh embryonic tissues at E11, E12, E14 and E18 by using SV Total RNA Isolation system (Promega, Madison, WI). Reverse transcription and cDNA amplification for all the P2Y receptors was carried out with a thermal cycler (Hybaid, UK) in a two-step protocol using Ready-To-Go RT-PCR Beads (Amersham Pharmacia Biotech, Buckinghamshire, UK). Every sample was further treated with Amplification Grade DNase I (Sigma, UK) to remove any residual DNA present that could generate false positive results. Briefly, 1 µg of total RNA was reverse transcribed using the pd(T)<sub>12-18</sub> as the first-strand primer at 42°C for 30 min and the enzyme was denatured at 95°C for 5 min. The sequence specific primers (Life Technologies, Bethesda, MD) for P2Y receptors (Bailey et al., 2000; 2001; see **Appendix**) were then added to the reaction mixtures and the PCR cycling parameters were 95°C for 30 s, 58°C for 1 min (58°C for P2Y<sub>1</sub>, 60°C for P2Y<sub>2</sub> and P2Y<sub>6</sub>, 64°C for P2Y<sub>4</sub>), 72°C for 1.5 min for 35 cycles (40 cycles for P2Y<sub>4</sub>), followed by a further stage of 10-min extension at 72°C. The resulting PCR products were resolved in a 2% agarose gel containing ethidium bromide and observed under ultraviolet illumination.

RT-PCR results for all tissues were confirmed by repetition with at least three separate RNA samples, prepared from embryonic tissues obtained from separate rat litters. Furthermore, a minimum of three RT-PCR experiments were performed for each P2Y receptor on each individual embryonic tissue. Control experiments were conducted by denaturing the reverse transcriptase (95°C for 15 min) before the RT-PCR reaction. These experiments demonstrated that, on denaturation of the reverse transcriptase, no P2 receptor mRNA could be detected. Thus, we were able to verify that the results obtained were due to the presence of P2 receptor mRNA in a sample and not as a result of genomic DNA contamination.

#### *Tissue preparation*

Please refer to the section of **Materials and Methods** on Chapter II. Tibialis anterior muscles from both 3-week- and 2-month-old animals were collected and freshly embedded in Tissue-Tek. Frozen sections (12µm) were cut in a cryostat and mounted.

#### *DAB Immunohistochemistry and Immunofluorescence double labeling*

Please refer to the section of **Materials and Methods** on Chapter II for immunohistochemistry (using DAB as chromogen). For double labeling using antibodies raised from different species, the primary antibodies were applied to the tissue sections at the

same time for overnight incubation at room temperature. After washing with PBS, secondary antibodies were applied to the tissue sections at the same time for 1 hour incubation at room temperature. The sections were washed and mounted with glycerol:PBS (9:1). For double labeling using antibodies raised from same species (e.g. rabbit), the first primary antibody was applied to the tissue sections for overnight incubation at room temperature. After washing and secondary antibody incubation, sections were washed and the second primary antibody was then applied to the same tissue sections for overnight incubation at room temperature. After washing with PBS, second secondary antibodies were applied to the tissue sections for 1 hour incubation at room temperature. The sections were washed and mounted with glycerol:PBS (9:1). The primary antibodies used were rabbit anti-P2Y<sub>1,2,4</sub> (diluted 1:200 for P2Y<sub>1</sub> and P2Y<sub>2</sub>; 1:100 for P2Y<sub>4</sub>; Alomone, Israel; see **Appendix**), rabbit anti-PGP9.5 (UltraClone Ltd., UK), mouse anti- $\alpha$ -smooth muscle actin (1:400, Sigma) and mouse anti-MF20 (1:100, Developmental Studies Hybridoma Bank). For labeling of acetylcholine receptors, sections were incubated with Texas Red-conjugated  $\alpha$ -bungarotoxin (1:800, Sigma). The secondary antibodies used were either fluorescein Isothiocyanate-conjugated or Cy3-conjugated (Jackson Immunoresearch Laboratories, Inc., WestGrove, PA).

### *Photomicroscopy*

Please refer to the section of **Materials and Methods** on Chapter II.

## RESULTS

### *RT-PCR for P2Y receptors*

By using RT-PCR, the developmental expression profiles for P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> were studied in rat embryos (**Fig. 1, Table 1, 2**). All the P2Y receptor subtypes examined were detected as early as embryonic day 11 (E11), and mRNA transcripts were present throughout development (E12-E18). From E11 onward, clear bands were observed for P2Y<sub>1</sub> and P2Y<sub>4</sub> mRNA transcripts (**Fig 1**). P2Y<sub>2</sub> receptor expression was very weak at E11 but became progressively stronger with development. Although P2Y<sub>6</sub> receptor expression was present as early as E11, expression was only barely detectable and strong expression was observed only at E18.

To determine more precisely the location of P2Y receptor expression, brain, heart, liver, lung and muscle were taken from both E14 and E18 embryos for RT-PCR analysis (**Fig. 1, Table 2**). All embryonic tissues examined expressed at least one P2Y receptor subtype. However, different embryonic organs demonstrated different P2Y receptor profiles. For example, at E14 only P2Y<sub>4</sub> receptor mRNA was detected in the brain, whereas P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> were expressed in lung, and all the P2Y receptors tested (P2Y<sub>1, 2, 4, 6</sub>) were expressed in heart.



Furthermore, the expression of P2Y receptor mRNA was up- and down-regulated during the course of embryonic development. In the brain, no P2Y<sub>1</sub> was detected at E14, but at E18, RT-PCR demonstrated strong expression. Similarly in muscle, P2Y<sub>6</sub> expression only began at E18. In contrast, whereas P2Y<sub>4</sub> was expressed in the lung at E14, no P2Y<sub>4</sub> transcripts were detected at E18.

*Immunohistochemistry demonstrated expression of P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptor protein in somites*

P2Y receptor immunoreactivity was first detected in embryos at E11. At this stage P2Y<sub>1</sub> and P2Y<sub>4</sub> receptor proteins were detected in the somites. Whereas the P2Y<sub>4</sub> receptor was detected in the dermomyotome, P2Y<sub>1</sub> receptor expression appeared to be restricted to the myotome (**Fig. 2 A, C and D**). The P2Y<sub>2</sub> receptor was also expressed in the somites at E12 (**Fig. 3 A**), a day later than the expression of P2Y<sub>1</sub> and P2Y<sub>4</sub>. By using MF20 as a marker for the myogenic cells of the myotome (**Fig. 3 B**), the expression of all the P2Y receptors was demonstrated specifically in this area of the somite. As in the case of P2Y<sub>1</sub> and P2Y<sub>4</sub>, double-labeling for P2Y<sub>2</sub> and MF20 showed co-localization of these proteins in the myotome as opposed to the sclerotome (**Fig. 3 C**).

Immunohistochemistry demonstrated expression of P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptor protein in skeletal muscle

Consistent with the expression of P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> in the myotome, the primary skeletal muscle fibers were also immunopositive for these P2Y receptors (Fig. 2 B, E and F). However, in the case of the P2Y<sub>1</sub> and P2Y<sub>2</sub> receptors, expression was not maintained. By E18, no P2Y<sub>1</sub> or P2Y<sub>2</sub> immunoreactivity was detected in skeletal muscle fibers (Fig. 2 G). In contrast, at this stage strong P2Y<sub>4</sub> receptor expression was found in all skeletal muscle masses (Fig. 2 H).

Examination of postnatal skeletal muscles (3-week and 2-month old rats) demonstrated the down-regulation of P2Y<sub>4</sub> receptor expression. Immunoreactivity for P2Y<sub>4</sub> was detected only in the peripheral muscle fibers. P2Y<sub>1</sub> and P2Y<sub>2</sub> receptor expression was detected in cells in between muscle fibers. The smooth muscle layer of blood vessels showed strong P2Y<sub>1</sub> receptor staining (Fig 3 D), as identified by double labeling with smooth muscle actin (data not shown). The P2Y<sub>2</sub> receptor was expressed in scattered cells adjacent to the skeletal muscle fibers (Fig 3 E). Although the identity of the cells was not confirmed, this expression pattern would suggest that these cells were skeletal muscle satellite cells. None of the P2Y receptors showed any immunoreactivity at the neuromuscular junction (identified by staining with Texas Red-labeled  $\alpha$ -bungarotoxin) in either the prenatal or postnatal skeletal muscle examined (Fig 3 D-F).

*Immunohistochemistry demonstrated expression of only P2Y<sub>1</sub> and P2Y<sub>4</sub> receptor protein in the brain*

Consistent with RT-PCR results, which demonstrated the expression of P2Y<sub>4</sub> receptor mRNA alone at E14, only P2Y<sub>4</sub> receptor protein was detected in embryonic brain at this age (**Fig. 4 A- F**). Receptor expression was demonstrated in the olfactory system, diencephalons, amygdala and brainstem. In the olfactory system, P2Y<sub>4</sub> receptor staining was detected in the olfactory nerve and lateral olfactory tract (**Fig. 4 A and B**). In the diencephalons, expression was restricted to the anterior hypothalamus, dorsal geniculate nucleus and lateral hypothalamic area (**Fig. 4 C and D**). In the amygdala, only the cortical amygdaloid nucleus showed P2Y<sub>4</sub> receptor expression (**Fig. 4 D**). P2Y<sub>4</sub> receptor expression in the brainstem was widespread. The midbrain, pons and medulla all showed P2Y<sub>4</sub> receptor immunoreactivity (**Fig. 4 E and F**). The cerebral cortex, the basal ganglia, the hippocampus and the cerebellum did not show any P2Y<sub>4</sub> receptor staining at E14.

Expression of P2Y<sub>4</sub> receptor protein was not maintained in all parts of the brain postnatally. In the neonatal brain (postnatal day 1, P1), P2Y<sub>4</sub> receptor expression disappeared from the midbrain, isthmus and medulla. However, receptor protein was still detected in the olfactory system, the amygdala, the diencephalons and the pons. In addition, areas such as the septum and the neuroepithelium (adjacent to the ventricles), which had previously not showed any staining

for P2Y<sub>4</sub> became immunopositive for this receptor (**Fig. 4 G and H**). Consistent with the up-regulation of P2Y<sub>1</sub> receptor mRNA in late embryonic development, P2Y<sub>1</sub> receptor protein was also detected in the P1 brain. Receptor expression was restricted to the cerebral peduncle (**Fig. 4 I**). As would be predicted from RT-PCR no P2Y<sub>2</sub> receptor protein was expressed at any stage examined.

*Immunohistochemistry demonstrated expression of P2Y receptor protein in the spinal cord and peripheral nervous*

P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptor proteins were all expressed in the neural tube and peripheral nervous system from E12. At this stage, P2Y<sub>1</sub> receptor protein was detected in the floor plate of the spinal neural tube (**Fig. 5 A**). Subsequently, expression was detected in the ventral commissure of both E14 and E18 spinal cord (**Fig. 5 B**). P2Y<sub>1</sub> receptor protein was also detected weakly in the gray matter, but not the white matter at E18 (**Fig. 5 B**). The P2Y<sub>2</sub> receptor was first detected in the spinal motor nerves in E12 embryos (**Fig. 5 C**). At E14, P2Y<sub>2</sub> receptor protein was expressed heavily in the white matter of the intermediate and ventral horns, and the dorsal column of the spinal cord (**Fig. 5 D**). The gray matter showed clear but relatively weaker P2Y<sub>2</sub> immunoreactivity. This pattern of expression was maintained in late embryonic development (**Fig. 5 E**). At E18, the presence of P2Y<sub>2</sub> receptor expression in the dorsal root ganglia was also clearly apparent (**Fig. 5 E**). P2Y<sub>4</sub> immunoreactivity was first weakly detected

in the ventral horn of the spinal neural tube at E12. Staining for P2Y<sub>4</sub> in the ventral horns increased in strength at E14. Both the spinal motor neurons and the white matter showed immunoreactivity for this receptor (**Fig. 3 G**). However, double labeling with the neural marker PGP9.5 showed that P2Y<sub>4</sub> was not expressed in any of the peripheral nerves (**Fig. 3 J-L**). In the E18 spinal cord, P2Y<sub>4</sub> expression disappeared from the ventral white matter and was only weakly expressed in the gray matter and dorsal root ganglia (**Fig. 5 F**).

*Immunohistochemistry demonstrated expression of P2Y receptor proteins in the embryonic cardiovascular system, liver, lung and lens*

P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptor proteins were strongly expressed in the cardiovascular system, liver, lungs and lens. The P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors were first weakly expressed in the heart at E11 and expression became stronger at E12 (**Fig. 6 A and B**). Immunostaining was localized to both the primitive atria and ventricles at this stage. By E14, the P2Y receptors (P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub>) were detected only in the atria and the inner trabecular layer of the ventricles (**Fig. 6 C**). The outer myocardial layer and the interventricular septum showed either weak or no expression. At E18, P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptor expression was restricted to the atria and the inner trabecular layer of the ventricles. No P2Y receptor proteins were detected in the myocardium and interventricular septum (**Fig. 6 D**). In the case of all three P2Y receptors detected, P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub>, expression appeared to be restricted to the myocardium, with no

immunostaining present in the endocardium. This was confirmed by double-labeling experiments, performed for P2Y<sub>1,2,4</sub> and muscle myosin/ von Willebrand factor (a marker for endothelial cells), which showed that expression of the P2Y receptors was localized to the myocardial and not the endocardial cells (data not shown).

In the case of P2Y<sub>1</sub>, receptor protein was also detected in the blood vessels from E12 onwards (**Fig. 6 E and F**). Colocalization experiments, performed for P2Y<sub>1</sub> and smooth muscle actin/ von Willebrand factor (a marker for endothelial cells), confirmed that expression of the P2Y<sub>1</sub> receptor was localized to the smooth muscle cells of the dorsal aorta and not the endothelial cells (data not shown).

P2Y receptor expression in the liver began at E14 (**Fig. 7 A**). At this stage only the P2Y<sub>1</sub> receptor was expressed. By E18, P2Y<sub>2</sub> receptor expression could also be detected. Whereas the P2Y<sub>1</sub> receptor showed distinct staining in scattered cells (**Fig. 7 B**), very weak P2Y<sub>2</sub> receptor expression was detected in the general embryonic liver parenchyma (data not shown). The P2Y<sub>4</sub> receptor was not detected in the liver in any of the stages examined.

In the lung, the smooth muscle layer beneath the bronchial epithelium showed P2Y<sub>1</sub>

receptor immunoreactivity weakly in E14 and clearly in E18 embryos (**Fig. 7 C**). The P2Y<sub>2</sub> receptor was not expressed in the lung until E18. Some, but not all, of the epithelial cells of the bronchus within the fetal lung showed P2Y<sub>2</sub> immunoreactivity (**Fig. 7 D**). P2Y<sub>4</sub> receptor expression was absent from the lung (**Fig 7 E**).

The P2Y<sub>1</sub> receptor was strongly expressed in the primary lens fibers at E14 (**Fig. 7 F**). Although these fibers differentiate from the epithelial cells in the anterior part of the lens (between the lens capsule and the elongating primary lens fibers), the epithelial cells showed no P2Y<sub>1</sub> receptor immunostaining. Immunoreactivity for the P2Y<sub>1</sub> receptor was maintained in the lens fibers postnatally (**Fig. 7 G**). At this stage, the P2Y<sub>4</sub> receptor was also expressed in the lens fibers but was absent from lens epithelial cells (**Fig. 7 H**). No P2Y<sub>2</sub> receptor expression was detected in the lens at any stage examined.

## DISCUSSION

Despite that P2Y receptors have been shown to regulate cell proliferation and differentiation, key processes in tissue formation, few studies have investigated the expression and function of P2Y receptors in embryonic development. Before this study, the expression of the P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptors had never been investigated in development and none of the P2Y receptors had ever been studied in mammalian development. Using RT-PCR and immunohistochemistry, it was possible to demonstrate the abundant and dynamic expression of the P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptors in many tissues and organs, including skeletal muscle, heart, brain, spinal cord, liver, lung and lens, in rat embryonic and postnatal development. The pattern and timing of receptor expression strongly suggested a role for these receptors in development.

All the P2Y receptors studied were expressed as early as E11, when most embryonic organs far from being functional, were still in the process of being formed. Furthermore, P2Y receptor proteins were strongly expressed in transient, developmental structures, including the somites (P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub>) and the floor plate of the neural tube (P2Y<sub>1</sub>). While both these structures play an essential role in embryonic development, the floor plate in patterning the ventral neural tube and the somites in the formation of mesodermal tissues, neither are retained. P2Y receptors were also dynamically expressed, with receptor mRNA and protein being both up- and



down-regulated. The down-regulation of the P2Y<sub>1</sub>, 2 and 4 receptor proteins in skeletal muscle and heart, and the disappearance of the P2Y<sub>4</sub> receptor from the brainstem and ventral white matter of the spinal cord postnatally demonstrated that many P2Y receptors were developmentally regulated and were involved in functions specific to embryonic life. Thus these findings strongly suggest that whereas there are many well-recognized functions for P2Y receptors in mature, adult tissues, P2Y receptors may also play a role in tissue formation and development.

#### *Skeletal muscle*

The transient expression of the P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors in skeletal muscle strongly suggests a role for these receptors in the formation and differentiation of skeletal muscle. The onset of P2Y<sub>1</sub> and P2Y<sub>4</sub> receptor expression (E11) was similar to that of MyoD and Myf5, the two myogenic transcription factors responsible for defining the muscle precursor cells (myoblasts) (Buckingham, 2001). The expression of both receptors was ultimately confined to the myotome, as opposed the dermatome that will form the dermis of the skin. It is still difficult to determine whether the expression of P2Y<sub>1</sub> and P2Y<sub>4</sub> receptors was required for myogenic specification, or the expression follow the specification, unless the P2Y receptor expression has been positioned in the signaling pathway of myogenesis. The P2Y<sub>2</sub> receptor was expressed a day later (E12) in the myotome. P2Y receptor expression in muscle was not maintained. Staining for the P2Y<sub>1</sub> and P2Y<sub>2</sub> receptors disappeared by E18 and P2Y<sub>4</sub> receptor

expression was down-regulated postnatally. These findings suggested that while the P2Y receptors were unlikely to be involved in myogenic specification, these receptors could regulate subsequent processes in muscle formation including the proliferation of myoblasts, migration or fusion to form primary and secondary myotubes (Buckingham, 2001). In fact, a recent study by Ryten et al. (2002) demonstrates that myoblast proliferation *in vitro* can be potentiated by application of UTP, an agonist at both P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors. P2Y receptors have also been implicated in the migration of several cell types, including vascular smooth muscle cells and human dendritic cells (Idzko et al., 2002; Pillois et al., 2002).

The pattern of P2Y receptor expression in skeletal muscle also suggested a role specifically for the P2Y<sub>4</sub> receptor in myotube maturation and differentiation. P2Y<sub>4</sub> receptor expression was maintained during postnatal development of muscle fibers, which included muscle fiber hypertrophy and maturation of the neuromuscular junction. Since these processes are largely dependent on changes in intracellular Ca<sup>2+</sup> concentration and P2Y receptor activation will result in the mobilization of intracellular calcium, this receptor has the potential to be involved in any of these processes (Olson and Williams, 2000a; 2000b; Sanes and Lichtman, 2001). However, because neither the P2Y<sub>4</sub> receptor, nor for that matter the P2Y<sub>1</sub> and P2Y<sub>2</sub> receptors, were found to be expressed specifically at the neuromuscular junction, it is more likely that P2Y<sub>4</sub> receptor activation plays a role in muscle fiber hypertrophy or fiber-type determination. Although these

findings do not entirely agree with a recent study by Choi et al. (2001), they are consistent with the work of Meyer et al. (1999a). Choi et al. (2001) have demonstrated the up-regulation of the P2Y<sub>1</sub> receptor during the course of embryonic muscle development in chick and expression of P2Y<sub>1</sub> receptor protein at the adult neuromuscular junctions in chick and rat, whilst our findings and those of Meyer et al. (1999a) suggest that this receptor is down-regulated in development and is not expressed at the neuromuscular junction.

### *Heart*

The dynamic expression of the P2Y receptors in embryonic heart also suggested a role for these receptors in the development of cardiac muscle. Immunoreactivity for the P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors was detected in both the primitive atria and ventricles of the embryonic heart from E11, just before trabeculations first become evident along the inner myocardial layers (E11.5) (Sedmera et al., 2000). At E14, when trabeculations develop and become compressed within the ventricular wall, P2Y receptor expression was restricted to the trabeculated layers of the atria and ventricles, no immunoreactivity being found in the compact layer of the ventricular myocardium. Consistent with previous reports, P2Y receptors were down-regulated with further development (Webb et al., 1996).

Because formation of the trabeculated layer of the heart and its fusion with the compact layer is vital to heart development, the expression of the P2Y receptors in the trabeculated layer

specifically, is likely to be of functional significance. In fact, trabeculations are so vital to cardiac morphogenesis that the absence of these structures in neuregulin null mice results in embryonic death at E11 (the tubular heart stage) (Gassmann et al., 1995; Lee et al., 1995). Thus, the pattern and timing of P2Y receptor expression in the heart might suggest a role for these receptors in the differentiation of the trabeculated layer and the formation of the ventricular myocardium.

### *Nervous system*

Expression of the P2Y receptor proteins, and particularly the P2Y<sub>4</sub> receptor, was prominent in the embryonic nervous system. Among all the P2Y receptors examined, the P2Y<sub>4</sub> receptor was the first to be expressed in the embryonic brain at E14 on the basis of both RT-PCR and immunohistochemistry. Instead of a general or weak expression throughout the whole brain, the receptor expression was intense and localized. At E14, P2Y<sub>4</sub> immunoreactivity was detected in the telencephalon (olfactory system, pallidum and amygdala), diencephalons (lateral hypothalamic area and dorsal geniculate nucleus) and brainstem (midbrain, pons and medulla). After birth, additional regions of the brain, such as the septum and the neuroepithelium adjacent to the ventricles showed P2Y<sub>4</sub> receptor expression, and P2Y<sub>1</sub> receptor staining was detected in the cerebral peduncle. However, of greatest developmental significance was the disappearance of P2Y<sub>4</sub> immunoreactivity from the brainstem after birth. Thus, the P2Y<sub>4</sub> receptor appeared to be

the dominant P2Y receptor present early in the brain. The early expression of P2Y<sub>4</sub> receptor in specific brain regions and its subsequent down-regulation in some areas, suggested that this receptor has role to play in prenatal brain development, particularly within the brainstem.

The spinal cord showed immunoreactivity for the P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors. Expression of all these receptors was related either directly or indirectly to motor neuron development. The P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors were expressed in the ventral horns of the embryonic spinal cord, in the case of the P2Y<sub>4</sub> receptor only transiently (E14-E18). Both P2Y<sub>2</sub> and P2Y<sub>4</sub> receptor expression was mainly localized to the white matter of the ventral horns, although the spinal motor neurons also showed weak expression. P2Y<sub>1</sub> expression was localized to the floor plate of the spinal neural tube and subsequently the ventral commissure of the spinal cord, the former an important structure in the differentiation of the ventral neural tube. The floor plate expresses a powerful signaling molecule, Sonic hedgehog (Shh), which specifies the identities of motor neurons and interneurons in a concentration-dependent manner (Dodd et al., 1998). Thus the expression of the P2Y<sub>1</sub> receptor in floor plate, and the P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors in the ventral horns, suggests that purinergic signaling could regulate motor neuron development at multiple sites.

It seems likely that not all P2Y receptor expression had a role in embryonic development,

but rather some receptor expression was related to adult function. The lack of dynamic or transient P2Y receptor expression in the embryonic and fetal liver suggested that P2Y receptors were not involved in liver formation. As in adult hepatocytes (Dixon et al., 2000), experiments conducted on embryonic liver demonstrated the expression of P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptor mRNA transcripts and immunoreactivity for P2Y<sub>1</sub> and, to a lesser extent, the P2Y<sub>2</sub> receptor. Expression of the P2Y<sub>1</sub> and P2Y<sub>4</sub> receptors in the lens fibers is also unlikely to be involved in lens development. The P2Y<sub>1</sub> receptor is strongly expressed in both the adult (Merriman-Smith et al., 1998) and embryonic lens, but the P2Y<sub>4</sub> receptor was only expressed postnatally. Nonetheless this study does demonstrate for the first time the expression of the P2Y<sub>4</sub> receptor in lens fibers, and expression of this receptor could account for the reports of responses of adult lens cells to ATP (Churchill and Louis, 1997; Collison and Duncan, 2001). Similarly, expression of the P2Y<sub>1</sub> and P2Y<sub>2</sub> receptors in the fetal lung is unlikely to be related to lung development. In the fetal (E18) lung, the P2Y<sub>2</sub> receptor was expressed in the epithelial cells of the bronchi. Adult lung epithelial cells also express this receptor and can respond to the P2Y<sub>2</sub> receptor agonist UTP, with an increase in transepithelial chloride secretion and mucus secretion (Rice and Singleton, 1987; Rice et al., 1995; Burnstock, 2002b). The P2Y<sub>1</sub> receptor, which is known to be expressed on many types of smooth muscle cells, was also expressed in the smooth muscle layer of the bronchi. Thus, although P2Y receptors are undoubtedly essential for proper lung function, it is very unlikely that embryonic P2Y receptor expression is related to

organogenesis of the lung.

The question of the source(s) of ATP involved in activating these P2 receptors should next be raised. Many cell types are known to release ATP in response to mechanical disturbance (Burnstock, 1999b; Bodin and Burnstock, 2001a,b) and because there is much cellular movement during embryogenesis, several cell types might be releasing ATP. In addition, the presence of apoptotic cells in several developing tissues might represent another source of ATP.

In summary, we have demonstrated for the first time the early and dynamic expression of the P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptors during rat embryonic development. Although not all P2Y receptor expression is likely to be related to embryonic development, these findings suggest the involvement of purinergic signaling in skeletal muscle, heart and central nervous system development. Thus, purinergic signaling is likely to be an important signaling system in embryonic development and in particular organogenesis.

The work of this chapter has been published in:

Cheung KK, Ryten M and Burnstock G. (2003). Abundant and dynamic expression of G protein-coupled P2Y receptors in mammalian development. *Dev Dyn.* (in press)

## FIGURES & LEGENDS

**Figure 1** RT-PCR analysis to investigate the expression of P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptor transcripts during rat development from embryonic day 11 (E11) to E18. Total RNA from whole embryos (E11, E12, E14 and E18) or isolated embryonic organs (brain, heart, liver, lung and muscle) was extracted and subsequently used for RT-PCR experiments.





**Table 1** Summary of the expression of P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptor mRNA at different developmental ages (E11, E12, E14 and E18). Key: (+) indicates clear positive bands, (-) indicated absence of expression and (+/-) indicates barely detectable bands.

**Table 2** Summary of the expression of P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptor mRNA in brain, heart, liver, lung and skeletal muscle taken from E14 and E18 embryos. Key: (+) indicates clear positive bands, (-) indicated absence of expression and (+/-) indicates barely detectable bands.

**Table 1**









	<b>E11</b>	<b>E12</b>	<b>E14</b>	<b>E18</b>
<b>P2Y<sub>1</sub></b>	+	+	+	+
<b>P2Y<sub>2</sub></b>	+/-	+	+	+
<b>P2Y<sub>4</sub></b>	+	+	+	+
<b>P2Y<sub>6</sub></b>	+/-	+/-	+/-	+

**Table 2**

	<b>Brain</b>		<b>Heart</b>		<b>Liver</b>		<b>Lung</b>		<b>Muscle</b>	
	<b>E14</b>	<b>E18</b>	<b>E14</b>	<b>E18</b>	<b>E14</b>	<b>E18</b>	<b>E14</b>	<b>E18</b>	<b>E14</b>	<b>E18</b>
<b>P2Y<sub>1</sub></b>	-	+	+	+	+	+	+	+	+	+
<b>P2Y<sub>2</sub></b>	-	-	+	+	+	+	+	+	+	+
<b>P2Y<sub>4</sub></b>	+	+	+	+	+	+/-	+	-	+	+
<b>P2Y<sub>6</sub></b>	-	-	+	+	+	+	-	+/-	-	+


**Figure 2:** Immunoreactivity for P2Y receptors in somites and developing skeletal muscle. **A,** Transverse section with haematoxylin and eosin staining showing the morphology of E11 somites (sm). **B,** Transverse section showing haematoxylin and eosin staining of an E14 embryo at the mid-liver level. The rectangular insert shows an area of developing skeletal muscle. **C,** Transverse section taken at the level of the embryonic heart at high magnification showing limited P2Y<sub>1</sub> receptor expression in E11 somites (sm). In order to aid orientation the ventral (v) and dorsal (d) aspects are marked. P2Y<sub>1</sub> receptor expression was detected in the myotome. **D,** Transverse section taken at the caudal region at high magnification showing widespread P2Y<sub>4</sub> receptor expression in E11 somites (sm). P2Y<sub>4</sub> receptor expression was detected in the dermomyotome. **E,** Higher magnification (of the rectangular insert shown in B) demonstrating P2Y<sub>1</sub> receptor expression in the developing skeletal muscle (skm). **F,** Higher magnification (of the rectangular insert shown in B) demonstrating P2Y<sub>4</sub> receptor expression in the developing skeletal muscle (skm). **G, H,** Transverse sections of E18 embryo showing the intercostal muscle between ribs (rb). The P2Y<sub>1</sub> receptor was not detected in the skeletal muscle fibers (**G**), whereas strong P2Y<sub>4</sub> receptor immunoreactivity (**H**) was detected in the intercostal muscle. Scale bar = 50µm (**C, D**), 200µm (**A, E-H**) and 750µm (**B**).

**Fig 2**



**Figure 3:** Immunofluorescence of P2Y receptors during skeletal muscle development and in the embryonic spinal cord. **A**, Transverse section showing P2Y<sub>2</sub> receptor immunoreactivity (green) in E12 myotomes (my). **B**, The same section also showed immunoreactivity for MF20 (red), a marker of the differentiated myogenic cells. **C**, Double labeling showing that the P2Y<sub>2</sub> receptor and MF20 were co-expressed in the myotome (yellow). **D-F**, Double labeling experiments for P2Y receptors (green) and acetylcholine receptors (red) on the tibialis anterior muscle of 3-week old animal. **D**, P2Y<sub>1</sub> receptor immunoreactivity was localized at the smooth muscle layer of the blood vessel (bv) between the skeletal muscle fibers. **E**, P2Y<sub>2</sub> receptor immunoreactivity was detected in scattered cells (arrowhead) located between skeletal muscle fibers. **F**, P2Y<sub>4</sub> receptor protein was detected on the membranes of the peripheral, but not the central muscle fibers. None of the P2Y receptors were detected at the neuromuscular junctions, as demonstrated by acetylcholine receptor expression (red). **G**, Transverse section showing P2Y<sub>4</sub> receptor immunoreactivity (green) in the spinal cord of an E14 embryo. Arrows showing the spinal nerves emerging from dorsal (dh) and ventral horns (vh). **H**, PGP9.5 immunoreactivity (red) on the same section (G). **I**, Double labeling showing the co-localization (yellow) of the P2Y<sub>4</sub> receptor and the PGP9.5 in the ventral spinal horn but not the dorsal spinal cord. **J**, Transverse section showing expression of the P2Y<sub>4</sub> receptor (green) in embryonic skeletal muscle (skm). **K**, PGP9.5 stains nerves (red) innervating the muscles in the same section. **L**, Double labeling experiment showing that P2Y<sub>4</sub> receptor protein was expressed in the muscles only but not in the

**Fig 3**




peripheral nerves innervating the muscles. Scale bar = 105 $\mu$ m (A-C), 50 $\mu$ m (D-F), 200 $\mu$ m (G-L).

**Figure 4:** P2Y receptor immunoreactivity in embryonic and neonatal rat brain. Coronal sections of an E14 embryonic brain are shown in an antero-posterior direction (A to F). A, B, P2Y<sub>4</sub> immunoreactivity was detected in the olfactory tubercle (A, ot) and the lateral olfactory tract (B, lot). C, D, In the diencephalon, P2Y<sub>4</sub> receptor protein was expressed in the anterior hypothalamus (C, ah), the dorsolateral geniculate nucleus (D, dgn) and the lateral hypothalamic area (D, lh). The cortical amygdaloid nucleus also stained for P2Y<sub>4</sub> (D, ca). E, F, In the brainstem, the P2Y<sub>4</sub> receptor expression was detected in the midbrain (E, mb), the pons (E, pn), the isthmus (F, is) and the medulla (F, md). G, H, Coronal sections of a neonatal rat brain showing P2Y<sub>4</sub> receptor immunoreactivity in the septum (G) and the neuroepithelium adjacent to the ventricles (H). I, Coronal section showing P2Y<sub>1</sub> receptor immunoreactivity in the cerebral peduncle. Scale bar = 500 $\mu$ m (A-F), 100 $\mu$ m (G) and 200 $\mu$ m (H-I).




**Fig 4**



**Figure 5:** Immunohistochemical expression of P2Y receptors in the embryonic nervous system.







**A,** Transverse section of E12 embryos (at the level just caudal to the hindbrain neural tube) showing P2Y<sub>1</sub> receptor immunoreactivity specifically located in the floor plate region (fp, arrow). **B,** Transverse section showing P2Y<sub>1</sub> receptor expression in the ventral commissure (arrowhead) of the E18 spinal cord. Note the very weak P2Y<sub>1</sub> immunoreactivity in the gray matter (gm). **C,** Transverse section of E12 embryos demonstrating P2Y<sub>2</sub> receptor expression in spinal nerves (arrows). **D,** In E14 spinal cord P2Y<sub>2</sub> receptor protein was heavily expressed in the white matter of the ventral horns (vh) and in the peripheral nerves. The gray matter and dorsal root ganglia (drg) also stained weakly for the P2Y<sub>2</sub> receptor. **E,** At E18, widespread P2Y<sub>2</sub> receptor expression was detected in the spinal cord, with very strong immunoreactivity in the white matter of the intermediate and ventral horns (arrows). Immunostaining for P2Y<sub>2</sub> was also detected in the dorsal root ganglia. **F,** The P2Y<sub>4</sub> receptor was expressed in the gray matter of the spinal cord at E18. Weak staining was also observed in the white matter and dorsal root ganglia at this stage. Scale bar = 50µm (A), 200µm (C), 450µm (B, E-F) and 750µm (D).

**Fig 5**











**Figure 6:** Immunoreactivity for the P2Y receptors in the embryonic cardiovascular system. **A,** Transverse section showing the expression of the P2Y<sub>2</sub> receptor in the developing heart at E12. **B,** Transverse section showing the expression of the P2Y<sub>4</sub> receptor in the developing heart at E12. **C, D,** Transverse sections showing P2Y<sub>4</sub> receptor immunoreactivity in the hearts of E14 (**C**) and E18 (**D**) embryos demonstrate that this receptor was specifically expressed in the trabeculated layer of the ventricles and atria of the developing hearts, but was absent from the interventricular septum (ivs). **E, F,** Transverse sections showing P2Y<sub>1</sub> receptor immunoreactivity in the smooth muscle layers of dorsal aorta at E12 (**E**) and E18 (**F**). Scale bar = 200µm (**A, B**), 450µm (**C**), 750µm (**D**), 50µm (**E**) and 200µm (**F**).

**Fig 6**



**Figure 7:** Immunoreactivity of P2Y receptors on embryonic liver, lung and lens. **A, B,** Transverse sections showing P2Y<sub>1</sub> receptor expression in E14 (**A**) and E18 (**B**) liver. The P2Y<sub>1</sub> receptor was expressed weakly in E14 (**A**) and clearly in E18 (**B**) liver. Scattered cells showed clear P2Y<sub>1</sub> receptor immunoreactivity in E18 liver. **C, D, E,** Transverse sections showing P2Y<sub>1</sub> (**C**), P2Y<sub>2</sub> (**D**) and P2Y<sub>4</sub> (**E**) receptor-stained E18 lung tissues. Note that the P2Y<sub>1</sub> receptor was expressed in the smooth muscle layer of the bronchi (arrows, **C**) and the P2Y<sub>2</sub> receptor expressed in the epithelial cells (arrows, **D**). The P2Y<sub>4</sub> receptor was not expressed in the lung (**E**). **F, G,** Transverse sections of the lens at E14 (**F**) and P1 (**G**) show that the P2Y<sub>1</sub> receptor was expressed in the elongating lens fiber cells (lf), but not the epithelial cells (ep) inside the anterior capsule of the developing lens. **H,** The P2Y<sub>4</sub> receptor was also expressed in the elongating lens fiber cells at P1 (lf). Scale bar = 200µm (**A-E**), 50µm (**F**), 100µm (**G**) and 50µm (**H**).

**Fig 7**



## **Chapter IV      Expression of P2X purinoceptors during rat brain development and their inhibitory role on motor axon outgrowth in neural tube explant cultures**

### **ABSTRACT**

Extracellular ATP is well known as a neurotransmitter and neuromodulator in adult central and peripheral nervous systems. ATP mediates rapid synaptic responses via ligand-gated P2X receptors. However, little is known about the involvement of ATP during the development of mammalian embryos. We studied the expression pattern of P2X receptor subtype mRNA and protein during prenatal rat brain development (from E10 to P1 brain) using RT-PCR and immunohistochemical methods. It was shown that the P2X<sub>3</sub> receptor was the first to be expressed in the neural tube at E11, followed by the P2X<sub>2</sub> and P2X<sub>7</sub> in the embryonic brain at E14, and later the P2X<sub>4</sub>, P2X<sub>5</sub> and P2X<sub>6</sub> receptors at P1. P2X<sub>7</sub> receptor was expressed in the lateral hypothalamus and isthmus in the E14 brain, and subsequently expressed throughout the brain as development proceeded. Expression of P2X<sub>4</sub> receptor was observed in the striatal subventricular zone, mesencephalic trigeminal nucleus, parabrachial nucleus, lateral deep cerebellar nucleus and cuneate nucleus, whereas P2X<sub>5</sub> receptor was detected in the striatal



subventricular zone, supraoptic nucleus and cuneate nucleus. P2X<sub>5</sub> immunoreactivity was also observed in cells scattered over the cortex and the diencephalon. P2X<sub>6</sub> receptor expression was detected weakly but widespread in the lateral hypothalamus. P2X<sub>1</sub> receptor expression was not observed in the brain at any of the stages examined. The sensory-related P2X<sub>3</sub> receptor was also expressed in a subpopulation of motor neurons and the outgrowing motor axons in the ventral neural tube of rat embryos at E11-12 and the expression was downregulated as development progressed, whereas the outgrowing axons emerged from somatomotor neurons did not express P2X<sub>3</sub> receptor. It was therefore speculated that ATP might be involved in motor axon outgrowth. Thus we then investigated the effect of ATP on motor axon outgrowth in collagen-embedded neural tube explant cultures. Motor neurons-containing neural tube explants at E12 were cultured for 4 days in a 3-dimensional collagen gel bathed with 100 $\mu$ M ATP or  $\alpha\beta$ -meATP (selective agonist for P2X<sub>1</sub>, P2X<sub>2/3</sub> and P2X<sub>3</sub> receptors). Both ATP- and  $\alpha\beta$ -meATP-treated neural tubes showed a significant reduction in neurite outgrowth compared with the control explants. The inhibitory effect could not be induced by UTP. In conclusion, all P2X receptor subtypes, except for P2X<sub>1</sub>, are strongly represented in the developing rat embryonic brain. The possibilities will be discussed that: ATP is involved in inhibition of motor axon outgrowth during early embryonic neurogenesis, most likely via the P2X<sub>3</sub> receptor; that P2X<sub>7</sub> receptors may be involved in programmed cell death during embryogenesis and; that P2X<sub>4</sub>, P2X<sub>5</sub> and P2X<sub>6</sub> receptors might

be involved in postnatal neurogenesis.

## INTRODUCTION

Extracellular ATP was first shown to be released from sensory nerves during antidromic stimulation in 1959 (Holton, 1959). However, it was not until Burnstock et al (1970) found evidence for the role of ATP as a neurotransmitter in nonadrenergic, noncholinergic (NANC) nerves supplying the gut and bladder that purinergic signaling was hypothesized (Burnstock, 1972). It is now well known that ATP mediates wide ranges of physiological activities by activating two types of receptors: ligand-gated P2X receptors and G protein-coupled P2Y receptors (Ralevic and Burnstock, 1998). To date, seven P2X receptor subunits (P2X<sub>1-7</sub>) (North, 2002) and eight P2Y receptors (P2Y<sub>1,2,4,6,11,12,13,14</sub>) have been cloned from mammals (Burnstock, 2003a; Abbracchio et al., 2003).

ATP is released from the peripheral and central neurons, where it can act on P2X receptors to elicit fast excitatory neurotransmission (Burnstock, 2003b). Of the seven cloned P2X receptor subunits, P2X<sub>2</sub>, P2X<sub>4</sub>, and P2X<sub>6</sub> receptor transcripts and proteins are widely distributed in adult rat brains (Nörenberg and Illes, 2000). P2X<sub>1</sub> receptor is localized in the adult cerebral cortex, striatum, hippocampus and cerebellum. P2X<sub>5</sub> shows restricted localization, where the mRNA transcript was only found in the mesencephalic trigeminal nucleus. P2X<sub>3</sub> is present in the sensory-related area such as nucleus tractus solitarius

(Nörenberg and Illes, 2000). P2X<sub>7</sub> has been reported recently in the hippocampus and medulla oblongata (Deuchars, 2001; Sperlágh et al., 2002). Functional analysis showed that ATP acts both as a fast neurotransmitter and as a neuromodulator regulating the release of classical neurotransmitters like glutamate and GABA (Labrakakis et al., 2000; D'Ambrosi et al., 2001; Sperlágh et al., 2002; see Burnstock, 2003b).

We have previously identified the P2X<sub>2</sub> and P2X<sub>3</sub> receptor expression in rat embryonic brain (Cheung and Burnstock, 2002). P2X<sub>2</sub> receptor is first expressed weakly in the nucleus tractus solitarius at embryonic day 14 (E14), whereas P2X<sub>3</sub> receptor is expressed even earlier in a subpopulation of the neurons and its extended axons in the ventral hindbrain neural tube as early as E11. At E12 the axons expressing P2X<sub>3</sub> receptor grew dorsally to leave the hindbrain via the large dorsal exit point to trigeminal ganglia, suggesting that the P2X<sub>3</sub> immunoreactive cells were branchiomotor (BM) or visceromotor (VM) neurons (Jacob et al., 2001). However, expression of P2X<sub>3</sub> receptor was downregulated during further development. According to the spatial and temporal information of P2X<sub>3</sub> receptor expression in the ventral neural tube, we proposed that the receptor has a role to play in axon outgrowth during hindbrain development.

In the present study, we use RT-PCR and immunohistochemistry to examine the expression pattern of all the seven P2X receptor subunits during embryonic rat brain development from

E14 to postnatal day 16 (P16). In addition, we have explored the role of ATP on axon outgrowth during embryonic neurogenesis by culturing hindbrain neural tube explants containing motor neurons in collagen gels in the presence of ATP and its derivative  $\alpha\beta$ -meATP, which is a stable and selective agonist for P2X<sub>3</sub> receptors (and P2X<sub>1</sub> receptors).

## MATERIALS AND METHODS

### *RT-PCR analysis*

Embryonic and neonatal Sprague-Dawley rat brain tissues of different ages were dissected and the meninges were removed. Total RNA was extracted from the whole brain tissues of four developmental ages (E14, E18, P1 and P16) according to the sections of **Materials and Methods** in Chapter III. The sequence specific primers (Life Technologies, NY, USA) for P2X receptors (Shibuya et al., 1999; see **Appendix**) were then added to the reaction mixtures and the PCR cycling parameters were 95°C for 30 s, 58°C for 1 min (58°C for P2X<sub>1</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>7</sub>; 61°C for P2X<sub>2</sub> and 64°C for P2X<sub>6</sub>), 72°C for 1.5 min for 35 cycles, followed by a further cycle of 10-min extension at 72°C. The resulting PCR products were resolved in a 2% agarose gel and observed under ultraviolet illumination. At least 3 separate RT-PCR experiments were performed for each P2X receptor on each individual embryonic tissue.

### *Tissue processing and immunohistochemistry*

Please refer to the sections of **Materials and Methods** on Chapter II. The primary antibodies used were rabbit polyclonal antibodies against P2X<sub>1-6</sub> receptors (gifts from Roche Bioscience, USA, 1:200; see **Appendix**) and P2X<sub>7</sub> receptor (Alomone, Israel, 1:500 see

**Appendix).** For control experiments, the sections were incubated with the primary antibodies pre-adsorbed with the control peptide antigens that used in raising the antibodies or with normal horse serum only. Double labeling experiment of P2X<sub>3</sub> and Islet-1 antibody (1:700, Developmental Studies Hybridoma Bank, DSHB) was performed as previously described in the section of Materials and Methods in Chapter III.

### *Photomicroscopy*

Images of DAB immunohistochemical staining were taken with a Leica DC 200 digital camera (Leica, Switzerland) attached to a Zeiss Axioplan microscope (Zeiss, Germany). Images were imported into a graphics package (Adobe Photoshop 5.0, USA).

### *Neural tube explant culture*

Rat embryos were obtained at E12. The hindbrain neural tube explants used were taken between rhombomere 1 (r1) to r4 axial levels (Caton et al., 2000). Motor neuron-containing explants were dissected using Dispase (Roche Bioscience) and tungsten needles. The bilateral explants were cut open at the dorsal midline and flattened. Only the medial one-third of each side of the neural tube was used for culture to avoid contamination of the roof plate and dorsal neural tube. Tissues were washed in Hank's Balanced Salt Solution (HBSS, Gibco, UK) and kept on ice until needed. Collagen gel was freshly made by mixing the rat tail

collagen (Roche Bioscience, USA) with 7.5% sodium bicarbonate solution and 10X Minimum Essential Medium (MEM) in a ratio of 8:1:1 (collagen: sodium bicarbonate: 10X MEM). A thin layer of collagen gel was laid and allowed to set in the culture well of 4-well plates (Nunc). The neural tube explant was transferred onto the thin collagen layer and a large drop of collagen gel was added to embed the explants. The collagen gel with embedded neural tube explant was covered with high glucose-Dulbecco's modified Eagle medium (DMEM) with Glutamax I (Gibco) supplemented with 1X antibiotic/antimycotic solution and insulin-transferrin-selenium supplements (Gibco). To examine the effects of extracellular purines on the axon outgrowth, 100 $\mu$ M of ATP,  $\alpha\beta$ -meATP or UTP (Sigma, USA) was added to the medium at the beginning of the culture period. The collagen-embedded explants were cultured for 4 days in a humidified atmosphere of 5% CO<sub>2</sub> at 37°C. The culture medium was replaced with fresh medium containing same concentration of the nucleotides every 2 days.

#### *Immunostaining of collagen gels and quantitation of axon outgrowth*

Collagen gels were fixed for immunostaining according to Guthrie and Lumsden (1994) using monoclonal antibody 2H3 (Developmental Studies Hybridoma Bank), which recognizes the 165 kDa neurofilament protein. Gels were mounted under propped coverslips in 90% glycerol/10% PBS and photographed. Images were imported into both NeuroLucida (MicroBrightField, Inc, USA) for analysis of neurite length and an analytical package



(Metamorphs, Universal Imaging Corporation, USA) for comparison of the number of neurites projecting from the explants between treatment groups. A total of 50 longest neurites from each explant were taken for comparison of neurite length. The pixels occupied by immunostained neurites were taken as a representative of the number of neurites projecting from the explants for comparison. The pixels occupied by total neurites were then divided by the pixel occupied by the explants to determine the neurite/explant ratio. Neural tube explants together with the collagen gel were cryoembedded, sectioned and stained for neural cell adhesion molecule (NCAM) expression using monoclonal NCAM antibody (1:4000; Sigma).

## RESULTS

### *Expression pattern of P2X receptors during rat brain development*

Previously, we have shown that P2X<sub>3</sub> was the first purinoceptor to express during neurogenesis. It was detected in the cranial motor neurons early at E11, whereas P2X<sub>2</sub> receptor protein was found in the nucleus tractus solitarius at E14 (Cheung and Burnstock, 2002). Here we examined the expression pattern of all the known P2X receptor subtypes during rat brain development using RT-PCR and immunohistochemistry. The mRNA transcripts of receptor subtypes P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub> and P2X<sub>7</sub> were detected as early as E14 brain (Fig. 1) and they continued to express, though to different extents, from this stage onward into the postnatal period (E14 to P16). The abundance of the P2X<sub>2</sub> and P2X<sub>7</sub> receptor transcripts appeared approximately the same throughout the stages examined. A gradual decrease in expression of P2X<sub>3</sub> receptor was observed, where the expression was high at E14 and E18 but appeared to be lower at P1 and P16. In contrast, the intensity of P2X<sub>4</sub> receptor transcripts amplified was gradually increased from E14 to P16. P2X<sub>5</sub> and P2X<sub>6</sub> receptor transcripts started to express weakly at E18 and P1, respectively. P2X<sub>1</sub> receptor transcript was not detected in the brain at all the stages examined although in the positive control using uterine tissues, the primers for P2X<sub>1</sub> receptor showed strong positive signals (data not shown).

P2X<sub>3</sub> receptor was expressed in the neurons and the outgrowing axons in the hindbrain neural tubes as early as in E11 confirming our earlier report (Cheung and Burnstock, 2002). Immunoreactivities of other P2X receptor subtypes were not observed at this early stage. P2X<sub>2</sub> receptor was expressed in the nucleus tractus solitarius at E14. To obtain the spatial information of expression of the P2X receptors, we used immunohistochemistry to examine the distribution of the P2X<sub>1</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> and P2X<sub>7</sub> receptor protein during rat brain development. Consistent with the RT-PCR results, P2X<sub>7</sub> immunoreactivity was observed at E14. Expression was localized in the lateral hypothalamus (Fig. 2) and the isthmus. At E18, P2X<sub>7</sub> receptor was detected in the lateral olfactory tract and the optic tract, and widespread throughout the diencephalon (thalamus and lateral hypothalamus), cerebellum and brainstem (midbrain, pons and medulla) and the expression persisted after birth (data not shown). The P2X<sub>4</sub> immunoreactivity was not observed until P1, although its mRNA transcript was expressed early at E14. P2X<sub>4</sub> receptor was expressed in distinct populations of cells instead of a widespread expression in adult (see review Nörenberg and Illes, 2000) (Fig. 3). P2X<sub>4</sub> immunopositive cells showed cytoplasmic staining and were located in the striatal subventricular zone, mesencephalic trigeminal nucleus, parabrachial nucleus, lateral deep cerebellar nucleus and cuneate nucleus (Fig. 3). Likewise, both the receptor proteins of P2X<sub>5</sub> and P2X<sub>6</sub> receptors were also detected in P1 brain. P2X<sub>5</sub> receptor was expressed in the supraoptic nucleus, striatal subventricular zone and cuneate nucleus and in cells scattered over

the cortex and diencephalons (**Fig. 3**). Similar to P2X<sub>4</sub> receptor staining, the P2X<sub>5</sub>-immunopositive cells in the supraoptic nucleus showed cytoplasmic staining and round in shape, whereas the scattered P2X<sub>5</sub>-immunoreactive cells in the cortex and those in the striatal subventricular zone appeared pyramidal in shape (**Fig. 3**). P2X<sub>6</sub> receptor was, however, expressed weakly in the lateral hypothalamus (**Fig. 3**). Specific immunoreactivity for P2X<sub>1</sub> receptor was not detected at all the stages examined.

Based on the timing of the initial appearance of the receptors, the sequential expression for P2X receptors during brain development was summarized as in **Fig 4**.

#### ***Neural tube explant culture and axon outgrowth***

P2X<sub>3</sub> immunoreactivity was also localized in the motor neurons and its outgrowing nerves in the ventral neural tube at E11-E12 (**Fig 5C**). In order to investigate if ATP, the receptor ligand, also participated in motor axon outgrowth, the collagen-embedded cranial neural tubes containing motor neurons were treated with ATP and related compounds. In a control experiment where the collagen gel was bathed with medium only, motor axon outgrowth extended from the lateral sides as well as the rostral and caudal borders of the explants. The outgrowing motor axons were visualized with immunostaining using monoclonal 2H3 antibody. After staining, the axons appeared dark brown in color. In the ATP-treated group, the extent

of the axon outgrowth was significantly reduced compared to the control group (Fig 5, 6). There was a 46% reduction of neurite length in the ATP-treated group (Fig 6). Similarly,  $\alpha\beta$ -meATP, a stable analog of ATP and also the agonist for P2X<sub>3</sub> receptor, caused a 41% decrease in axon length (Fig 6). Application of UTP did not show significant inhibitory effect on neurite outgrowth from neural tube explants compared to control explants, eliminating the possibility of P2Y<sub>2</sub> and P2Y<sub>4</sub> receptor involvement (Fig 6). We subsequently compared the area occupied by all the outgrowing neurites (excluding the neural tube explants) between treatment groups. Both ATP and  $\alpha\beta$ -meATP caused a reduction of 61% and 62%, respectively, of the total area occupied by the neurites (Fig 6). To minimize the variation in neurite outgrowth due to the difference in the sizes of the neural tube explants, the neurites-occupied areas were then divided by the area occupied by the explants. Reduction of 47% of total neurite area was observed in both ATP-treated group and 46% in  $\alpha\beta$ -meATP-treated groups (Fig 6). ATP and  $\alpha\beta$ -meATP appeared to reduce the length and probably the number of extending neurites, too.

The neural tube explants were stained with P2X<sub>3</sub> receptor and NCAM, a marker for neural cell adhesion and neurite outgrowth. Results of immunofluorescence showed that both P2X<sub>3</sub> and NCAM were expressed in the neurons as well as the outgrowing neurites (Fig 5). Double labeling experiment showed that co-localization of P2X<sub>3</sub> receptor and NCAM was frequently

seen in the outgrowing neurites, although neurites showing NCAM but not P2X<sub>3</sub> receptor expression were also observed (**Fig 5**).

## DISCUSSION

The idea of extracellular ATP acting as a neurotransmitter or neuromodulator has been examined extensively in both the central and peripheral nervous system in adult animals, and a large body of evidence shows that the ATP-induced fast synaptic response is mediated by activation of ATP-gated ion channels, the P2X receptors (Burnstock, 1972; Burnstock and Kennedy, 1985; Nörenberg and Illes, 2000; North, 2002; Burnstock, 2003b). We have previously found that ATP-gated P2X<sub>3</sub> purinoceptor was expressed in the early embryonic nervous system (Cheung and Burnstock, 2002). The present study shows for the first time the developmental expression of six of the seven P2X receptor subtypes during prenatal brain development, and the possible role of ATP and the P2X<sub>3</sub> receptor during embryonic neurogenesis.

We demonstrated that the neuronal P2X<sub>3</sub> and P2X<sub>2</sub> receptors start to express in the embryonic rat central nervous system (CNS) at E11 and E14, respectively, in confirmation of our earlier findings (Cheung and Burnstock, 2002). Here we showed that in addition to the P2X<sub>2</sub> receptor, the P2X<sub>7</sub> receptor in the brain was also expressed from E14 onwards. P2X<sub>7</sub> receptors have been shown to be involved in programmed cell death or to induce cytotoxicity at a high concentration of ATP released during inflammation or upon tissue trauma (reviewed

by Le Feuvre et al., 2002). Sperlágh et al. (2002) demonstrated that ATP regulates glutamate release via activation of P2X<sub>7</sub> receptor, and excessive glutamate release altered the Ca<sup>2+</sup> homeostasis, resulted in activation of apoptosis-related gene (e.g caspase) (see review by Le Feuvre et al., 2002). Since apoptosis is a common event in developing brain, it is therefore likely that the activation of P2X<sub>7</sub> receptor is also involved in cell death during neurogenesis, but this possibility awaits further investigation.

Although the expression of P2X<sub>4</sub>, P2X<sub>5</sub> and P2X<sub>6</sub> receptors appeared late during development, P2X<sub>4</sub> and P2X<sub>5</sub> receptors were both expressed in the subventricular zone, the site of postnatal neurogenesis (see review Conover and Allen, 2002). It has been claimed that astrocytes in the subventricular zone served as neural stem cells (Doetsch et al., 1999) that give rise to both neurons and glia. An opposing report by Johansson et al (1999), however, suggests that it is the ependymal cells adjacent to subventricular zone that generate multipotent neurospheres. It is as yet unknown whether the P2X receptor-positive cells present in the subventricular zone are neural stem cells or migrating neuroblasts. P2X<sub>4</sub> and P2X<sub>5</sub> may constitute two different types of cells in terms of the morphology and area of expression. P2X<sub>4</sub> receptor-expressing cells appeared round and resided in the subventricular zone, while cells positive for P2X<sub>5</sub> receptor looked pyramidal in shape and were scattered throughout different layers of the cortex as well as being located in the subventricular zone. An



investigation of the identity of the P2X<sub>4</sub> and P2X<sub>5</sub> receptor-expressing cells in the subventricular zone is in progress. Little is known about the role of P2X<sub>6</sub> receptors in the neonatal hypothalamus, but the P2X<sub>6</sub> receptor has been implicated in hormone release from axon terminals as well as membrane recycling of the granular vesicles and microvesicles in the adult hypothalamo-neurohypophysial system (Loesch and Burnstock, 2001). It is therefore believed that such expression may not relate to development. The P2X<sub>1</sub> receptor, according to the present results, did not express throughout the perinatal stages examined. However, previous studies have shown P2X<sub>1</sub> receptor expression in the cerebellum (Loesch and Burnstock, 1998) and P2X<sub>1</sub> receptor up-regulation in the CNS after injury (Florenzano et al., 2002; Franke et al., 2001).

The presence of molecules that are involved in both embryonic neurogenesis and regeneration after injury is not unusual (Waschek, 2002). However, the possibility that ATP is involved in both processes is yet to be established. Among all the P2X receptors examined, homomeric P2X<sub>3</sub> receptor was the first to express during neurogenesis in both central and peripheral nervous system. P2X<sub>3</sub> immunoreactivity is detected in the cranial motor neurons as early as E11, by the time when the neurons finish their final mitosis, exit the cell cycle, and start axon outgrowth (Ericson et al., 1992; Yamada et al., 1993). Based on the locations of immunoreactivities which are overlapping with dorsal axon trajectories and the dorsal

migratory pathway of motor neurons from the ventral neural tube, it was suggested that the P2X<sub>3</sub> receptors expressing cells are the BM and/or VM neurons, instead of somatomotor (SM) neurons (see review Jacob et al., 2001). Although the P2X<sub>3</sub> immunoreactivity in the spinal neural tube suggests that the VM neurons express the receptor, the intense staining in the hindbrain neural tube compared to the weak staining in the spinal neural tube suggests that the BM neurons also express the receptor.

We have shown that both ATP and  $\alpha\beta$ -meATP significantly reduced neurite extension from motor neuron-containing neural tube explants at E12. ATP is a non-selective agonist for most of the P2X and P2Y receptor subtypes. Although it is possible that P1 adenosine receptors may also be involved after adenosine is produced following ectoenzymatic breakdown of ATP, adenosine receptors were not included in our present study. Instead, the  $\alpha\beta$ -meATP was used in the present study as a stable analog of ATP to exclude any possible P1 receptor involvement. In addition, since  $\alpha\beta$ -meATP is a selective agonist only for P2X<sub>1</sub>, P2X<sub>2/3</sub> and P2X<sub>3</sub> receptors. Since neither RT-PCR and immunohistochemical data showed any P2X<sub>1</sub> receptor expression in embryonic and postnatal brains and P2X<sub>2</sub> receptor expression was not observed in the brain until E14, it is most likely that the effect of  $\alpha\beta$ -meATP was mediated via P2X<sub>3</sub> receptor. In addition to the P2X<sub>3</sub> receptor, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors, which are UTP-activated receptors, have also been demonstrated previously in motor neurons in the ventral neural tube (Cheung et

al., 2003). However, the P2Y receptors reside mainly in the spinal instead of cranial neural tube. Furthermore, the present result also showed that the inhibitory effect was not observed when UTP was used instead of ATP, thus excluding the involvement of P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors.

ATP has previously been shown to inhibit neurite outgrowth in hippocampal neurons transfected with NCAM, a marker for neural cell adhesion and neurite outgrowth, and the inhibitory effect of ATP was lost when the hippocampal neurons did not express NCAM, suggesting that ATP regulates neurite extension via NCAM (Skladchikova et al., 1999). Immunohistochemical studies showed that axons growing out from the neural tube at E12 expressed NCAM. Some but not all of the outgrowing axons showed NCAM and P2X<sub>3</sub> receptor coexpression, implicating that ATP-mediated inhibition in neurite outgrowth might act, at least partly, through the NCAM signaling system.


In summary, we present the first report to show the developmental expression profile of P2X receptors subtypes during prenatal brain development in the rat. Results from the present study indicated that different P2 receptor subtypes may participate in different developmental processes such as neurite outgrowth (involving P2X<sub>3</sub> receptor), postnatal neurogenesis (relating to P2X<sub>4</sub> and P2X<sub>5</sub> expression) and cell death (possibly involving P2X<sub>7</sub>

receptor), whereas others might not be involved in development (P2X<sub>1</sub> and P2X<sub>6</sub> receptors). Furthermore, extracellular ATP may function as a signaling molecule to inhibit motor axon outgrowth in the embryonic neural tube, most likely via the interaction between P2X<sub>3</sub> receptor and NCAM.

## FIGURES & LEGENDS:





**Figure 1** RT-PCR analysis on P2X receptor mRNA expression during prenatal rat brain development. Total RNA from brain samples of four developmental ages (E14, E18, P1 and P16) was reverse-transcribed, and the resulting cDNA was PCR-amplified using gene-specific P2X receptor primers (see Experimental Procedure). Lane L represents 100bp-DNA ladder. The amplified products are arranged in 4 lanes corresponding to RT-PCR products of E14, E18, P1 and P16 rat brains (from left to right) for each P2X receptor examined, i.e. P2X<sub>1</sub> (lane 1-4); P2X<sub>2</sub> (lane 5-8); P2X<sub>3</sub> (lane 9-12); P2X<sub>4</sub> (lane 13-16); P2X<sub>5</sub> (lane 17-20); P2X<sub>6</sub> (lane 21-24) and P2X<sub>7</sub> (lane 25-28). The P2X<sub>1</sub> receptor primers that detects no expression in brain samples shows strong positive signals using rat uterus as positive control (data not shown). Note the gradual decline in P2X<sub>3</sub> mRNA expression from E14 to P16. The expression pattern shown here represents results from at least three independent experiments.

**Fig 1**



**Figure 2** Immunoreactivity of P2X<sub>7</sub> receptor protein in the developing brain. P2X<sub>7</sub> immunoreactivity is detected in: (A), the lateral hypothalamus (lh) at E14 (B), the lateral olfactory tract (lot) and optic tract (opt). Diagram inserted in B outlines the region represented (arrows). (C) cerebellum and midbrain (cb and mb) and (D) medulla (md) at E18. 3v, third ventricle; 4v, fourth ventricle; aq, aqueduct. Insert in B outline the structure shown in B. Scale bar = 250µm (A, C, D) and 500µm (B).


**Fig 2**





**Figure 3** Immunoreactivity of P2X receptors in neonatal (P1) brain. Rectangular boxes in the inserts outline the regions shown in the corresponding pictures and the black dots in some of the inserts represent P2X immunoreactivity. (A) P2X<sub>4</sub> receptor-positive cells (arrows) are detected in regions along the striatal subventricular zone. (B) A high magnification of the rectangular box is shown in (A). (C) P2X<sub>4</sub> receptor immunoreactivity is also detected in mesencephalic trigeminal nucleus and (D) lateral deep nucleus of the cerebellum. (E) P2X<sub>5</sub> receptor expression is located in the supraoptic nucleus and (F) the cells along the striatal subventricular zone. (G) Scattered P2X<sub>5</sub> immunoreactive cells are also observed throughout the cortex (G). Note that the whole cell bodies of the P2X<sub>5</sub> receptor-positive cells shown in F and G are labeled. (H) P2X<sub>6</sub> receptor expression is detected in the lateral hypothalamus. Scale bar = 750µm (A), 100µm (B, E, H) and 200µm (C, D, F, G).


**Fig 3**



**Figure 4** Summary of the sequential expression of P2X receptors during rat neurogenesis


P2X receptors are arranged from top to bottom according to the chronological order of expression during rat brain development from E11 to Adult. While P2X<sub>3</sub> receptors appear early, they decline in the stages that follow. P2X<sub>2</sub> and P2X<sub>7</sub> receptors are expressed from the same day (E14) onwards, while P2X<sub>4</sub>, P2X<sub>5</sub> and P2X<sub>6</sub> are also expressed from P1 onwards. Dotted line for P2X<sub>1</sub> receptor represents unknown starting point, since expression of P2X<sub>1</sub> receptor was not observed in any of the developmental ages examined in this study.

**Fig 4**



**Figure 5** Neural tube explants in collagen gel after treatment with 100 $\mu$ M of (A) ATP and (B) control. (C) Cross section from E12 hindbrain neural tube showing P2X<sub>3</sub> receptor immunoreactivities (red) in the motor neurons and the motor fibers in the ventral neural tube. (D and E) Neural tube explants are cryosectioned and immunostained with the P2X<sub>3</sub> receptor (red) and NCAM (green). (F) Image merged from D and E showing co-localization (yellow/orange) of P2X<sub>3</sub> and NCAM (arrows). Scale bar = 500 $\mu$ m (A-B) and 100 $\mu$ m (C-F).


**Fig 5**




**Figure 6** Quantitation of neurite outgrowth from collagen embedded neural tube explant culture. Neural tube explants were bathed with 100 $\mu$ M of extracellular nucleotides (ATP,  $\alpha\beta$ -meATP and UTP). Control explants were treated with medium only. Images of treated neural tube explants were imported into Neurolucida and neurite outgrowth was analyzed by measuring the 50 longest neurites from each explant. (A) Results expressed as the average length of neurites counted with error bar represents standard error. (B) Images of treated neurite tube explants were imported into Metamorph and the total pixel area (arbitrary units) of the neurites (excluding the explants) were computed (B). (C) To minimize the variations of the neurite outgrowth due to the differences in individual explant size, the total pixel area occupied by the neurites (excluding the explants) were divided by the total pixel area occupied by the corresponding explants and the ratios were compared between groups. Significant difference is represented by \*\* ( $p < 0.001$ ) or \* ( $p < 0.05$ ) analyzed by unpaired t-test.

**Fig 6**


**A**



**B**



**C**





# **Chapter V Pharmacological and molecular characterization of functional P2 receptors in rat embryonic cardiomyocytes**

## **ABSTRACT**

Purinergic receptors activated by extracellular nucleotides (ATP, ADP, UTP and UDP) are well known to exert physiological effects on the cardiovascular system, including cardiomyocytes. However, the possibility that nucleotides participate in embryonic heart development is not clear. We have investigated the responsiveness of embryonic cardiomyocytes to P2 agonists by means of the fluorometric imaging plate reader (FLIPR), which measures  $\text{Ca}^{2+}$  influx. Cardiomyocytes taken from embryonic day (E) 12 did not respond to P2 agonists, but responses were detected in cardiomyocytes taken from E14 and E18 rats. ATP, 2MeSADP, UTP, UDP and BzATP, but not  $\alpha\beta$ -meATP, were able to induce  $\text{Ca}^{2+}$  mobilization. PPADS blocked the ATP-induced responses of E14 embryonic cardiomyocytes but not those produced in E18 hearts. RT-PCR showed a dominant presence of P2X<sub>2</sub> and P2X<sub>4</sub> mRNA transcripts on E14 cardiomyocytes with a lower expression of P2X<sub>3</sub> and P2X<sub>7</sub>. P2X<sub>1</sub> and a low level of P2X<sub>5</sub> receptor mRNA were also

expressed at E18. Immunocytochemical data indicated that only P2X<sub>2</sub> and P2X<sub>4</sub> receptor protein was expressed in E14 cardiomyocytes. All the P2X receptor subtype protein was expressed in E18 cardiomyocytes except for P2X<sub>3</sub> and P2X<sub>6</sub>. Responses mediated by agonists specific for P2Y receptors subtypes (2MeSADP, UTP and UDP) showed that P2Y receptors (P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub>) were also present in both E14 and E18 cardiomyocytes. Our results provide evidence that specific P2 receptor subtypes are present in embryonic cardiomyocytes, including P2X<sub>7</sub> and P2Y<sub>4</sub> receptors which have not been identified in adult rat cardiomyocytes. Some of the receptors have shown responsiveness to the ATP stimulation even before birth, suggesting that ATP may be an important messenger in embryonic as well as adult hearts.

## INTRODUCTION

Extracellular purines and pyrimidines (ATP, ADP and UTP) are well known to act as agonists in regulating a variety of physiological functions in many different cell types (Burnstock, 1997). In 1978, Burnstock proposed that there were specific receptors for adenine nucleosides (P1) and nucleotides (P2 receptors). Based on cloning and second messenger systems P2 receptors were divided into two receptor families, ionotropic P2X receptors and metabotropic P2Y receptors (Abbracchio and Burnstock, 1994). P2X receptors are ligand-gated ion channels formed from either homomeric or heteromeric association of 7 receptor subunits (P2X<sub>1-7</sub>) (North, 2002). P2Y receptors are G protein-coupled receptors, with 8 mammalian subtypes (P2Y<sub>1,2,4,6,11,12,13,14</sub>) being cloned (Burnstock, 2003a).

ATP is known to mediate various physiological activities in the adult heart of different species (Olsson and Pearson, 1990; Ralevic and Burnstock, 1991; Vassort, 2001). However, only a few studies focused specifically on P2 receptor expression in cardiomyocytes (Vulchanova et al., 1996; Webb et al., 1996; Nori et al., 1998; Hansen et al., 1999). The mRNA transcripts of P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptors are all expressed in the neonatal cardiomyocytes, whereas P2Y<sub>4</sub> receptor transcript is no longer detected in the adult myocytes

(Webb et al., 1996), suggesting that dynamic changes in expression of P2Y receptors were occurring during heart development. While it was demonstrated that the P2X<sub>1</sub> receptor protein was specifically expressed in the intercalated disks of cardiac muscle (Vulchanova et al., 1996), Nori et al (1998) also detected the mRNA transcripts for P2X<sub>1</sub>, P2X<sub>2</sub> and P2X<sub>4</sub> receptors from the micro-dissected tissues in various areas of the heart, with strong signals in the atria and only the typical band for P2X<sub>4</sub> receptor transcripts in ventricles. In addition, Hansen et al (1999) showed an abundance of colocalized P2X<sub>2</sub> and P2X<sub>5</sub> receptor clusters on the sarcolemma of neonatal heart.

The heart is the first organ to function in developing embryos (Fishman and Chien, 1997). The tubular heart undergoes sequential morphological changes such as looping, segmentation, trabeculation, septation etc (Franco et al., 1998). As with skeletal or smooth muscle, the arrangement of the myocardial cells is not random, but shows certain patterns which change during ontogenetic development. Such arrangement is of great importance to ensure the efficiency of the myocardial pump. It is therefore considered that dynamic changes in spatiotemporal patterns of gene expression resulting in complex structural changes during heart ontogeny are involved in the developing embryo (Olson and Srivastava, 1996; Zhao and Rivkees, 2000); thus the gene expression may be different between different developmental stages and from that of the adult (Franco et al., 1998). Nevertheless, identifying the presence

of gene expression may not provide the information of whether the gene products are in functional status or not. There have been some studies of P2 receptors gene expression in embryonic heart. Previously, the expression of some of the purinergic receptors subtypes (P2X<sub>2</sub> and P2Y<sub>1,2,4,6</sub>) in the embryonic rat heart have been identified (Cheung and Burnstock, 2002; Cheung et al., 2003), yet the functional status of the receptors remained unclear. There have also been reports of the expression of P2X receptor subtypes in the chick embryonic heart where P2X<sub>4</sub> and P2X<sub>5</sub> mRNA has identified (Ruppelt et al., 1999, 2001; Hu et al., 2002) and in the human embryonic heart, where mRNA for P2X<sub>1</sub>, P2X<sub>3</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptors were expressed (Bogdanov et al., 1998a). However, information on the developmental expression profile together with the functional status of other P2X receptor subunits in rat embryo is lacking. To fill this gap, we have used the fluorometric imaging plate reader (FLIPR) together with RT-PCR analysis and immunocytochemistry to study the expression profile of the purinergic receptors during the development of rat cardiomyocytes. Such combinatorial information on the gene expression and pharmacological analysis may clarify the specific receptors responsible for ATP-mediated activities during cardiac embryogenesis.

## MATERIALS AND METHODS

### *Cell Culture and Ca<sup>2+</sup> mobilization analysis*

Cardiomyocytes were prepared from embryonic Sprague-Dawley rats according to Burton et al (1999). Briefly, female time-mated rats were sacrificed using carbon dioxide inhalation and cervical dislocation. The day of identification of the presence of a vaginal plug was designated as day zero (E0). Embryos were removed and placed into ice-cold phosphate-buffered saline (PBS, pH 7.4). The hearts were dissected out, placed in Ca<sup>2+</sup>-free PBS at 4°C, washed, and the heart tissues were digested in type II collagenase (Worthington; 1 mg/ml in the same medium) at 37°C. The hearts were then gently triturated until all tissue fragments disappeared. The cell suspension was then mixed with Dulbecco's modified Eagle's medium (DMEM) with GLUTAMAX I containing 10% (v/v) fetal calf serum (FCS) and centrifuged at 700g for 6 min. The cell pellet was resuspended in DMEM-FCS containing penicillin (100U/ml), streptomycin (0.1mg/ml), and amphotericin B (0.25 µg/ml) and passed sequentially through a 21- and 25-gauge needle. Cells were allowed to preplate (twice, 1 hr each) and the nonadherent cells were then plated at  $1 \times 10^4$  cells per well into 96-well black-wall, clear bottom microtitre plates (BD Biosciences, Franklin Lakes, NJ), which had been previously coated with a solution of 1% (w/v) gelatin in water. These cardiomyocyte preparations were >98% pure as judged by immunocytochemical staining with

monoclonal antibodies against sacromeric actin (Sigma; diluted 1/500). The myocytes were cultured in the same medium plus insulin-transferrin-selenium supplement at 37°C in 5% CO<sub>2</sub> for one day. The growth medium was then aspirated and replaced with 100 µl of loading medium (PBS containing 1mM Fluo-4-AM, 10 % pluronic acid and 2.5 mM probenidol) and incubated for one hour at room temperature. The cells were subsequently washed three times with PBS, and 100 µl of PBS supplemented with 1 mM CaCl<sub>2</sub> were added to each well. The cells were then placed in a Fluorometric Imaging Plate Reader (FLIPR; Molecular Devices Corp., Sunnyvale, CA), and changes in cellular fluorescence were recorded after the addition of 50 µl control buffer or 50 µl of the ATP diluted in PBS. Maximum change in fluorescence over baseline was used to determine the response towards ATP. In addition, P2 agonists such as 2',3'-O-(4-benzoylbenzoyl)-ATP (BzATP), αβ-methylene ATP (αβ-meATP), 2-Methylthio-ATP (2MeSADP), uridine 5'-triphosphate (UTP) and uridine 5'-diphosphate (UDP) were also used for examining the Ca<sup>2+</sup> mobilizing response on the cardiomyocytes. To investigate if pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS), a P2 receptor selective antagonist, blocked the ATP-induced response, cells were treated with PPADS (30µM) for 30 min before addition of ATP. ATP and related nucleotides were obtained from Sigma Chemical Co. (UK) except for PPADS, which was from Tocris Cookson, UK.

#### *Double labeling immunocytochemistry*

Cardiomyocytes were grown on gelatin-coated 8-well chambered slides (Nunc). The cells were fixed in 4% paraformaldehyde in phosphate buffer (PB, pH 7.4) for 2 hr at room temperature. Cells were washed with PBS, blocked with 10% normal horse serum in 0.1% Triton, and the cells were stained with the monoclonal antibody against sarcomeric actin (1:500; Sigma), together with the polyclonal antibodies against P2X<sub>1-6</sub> (1:200; Roche Bioscience) and P2X<sub>7</sub> receptors (1:500; Alomone) followed by an FITC-conjugated donkey anti-mouse IgG antibody and cy3-coupled donkey anti-rabbit IgG antibody (1:200; Jackson ImmunoResearch Lab) for 1 hr. Please refer to the sections of **Materials and Methods** on Chapter II for the details for Photomicroscopy

### *RT-PCR analysis*

Embryonic hearts at E14 and E18 were dissected and total RNA was extracted from the dissected hearts according to the sections of **Materials and Methods** on Chapter III. The sequence specific primers (Life Technologies, NY, USA) for P2X receptors (Shibuya et al., 1999) were then added to the reaction mixtures and the PCR cycling parameters were 95°C for 30 s, 58°C for 1 min (58°C for P2X<sub>1</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>7</sub>; 61°C for P2X<sub>2</sub> and 64°C for P2X<sub>6</sub>), 72°C for 1.5 min for 35 cycles, followed by a further stage of 10-min extension at 72°C.



## RESULTS

### *Effects of agonists on $Ca^{2+}$ mobilization of cardiomyocytes*

We used FLIPR to study the responses of purinergic receptors that are present in cultured embryonic cardiomyocytes upon exposure to ATP and its derivatives. Positive responses were represented by an increase in fluorescence units, indicating  $Ca^{2+}$  mobilization in response to receptor activation. Cardiomyocytes from three embryonic ages (E12, E14 and E18) were taken for analysis. All the agonists were in a concentration of  $100\mu\text{M}$ . No apparent change was observed in control group when  $Ca^{2+}$ -containing PBS was added into the cells (**Fig 1B, D, G**). Cardiomyocytes taken from E12 did not show any significant response in  $Ca^{2+}$  mobilization against ATP (**Fig 1A**) or any of the ligands tested. In contrast, significant responses were detected with cardiomyocytes taken from E14 and E18 embryonic hearts when the cells were treated with rapid application of ATP (**Fig 1C, 1F**). Rapid increase in fluorescence occurred in a second. We then investigated if the P2 antagonist PPADS blocked the ATP-triggered response. The ATP-induced response on E14 cardiomyocytes was antagonized by PPADS at a concentration of  $30\mu\text{M}$  (**Fig 1D**), whereas the antagonizing effects of PPADS on E18 cardiomyocytes was not significant (**Fig 1H**). On the other hand, the P2Y receptor agonists such as 2MeSADP, UTP and UDP all induced significant response in  $Ca^{2+}$  mobilization on cardiomyocytes taken at both embryonic ages (**Fig 2A-F**). BzATP induced a

weak response on E14 cardiomyocytes, and the response was increased in E18 cardiomyocytes (**Fig 3A, 3B**).  $\alpha\beta$ -meATP did not induce a significant response on E14 cardiomyocytes (**Fig 3C**). The response by  $\alpha\beta$ -meATP, though very weak, was observed in E18 cardiomyocytes (**Fig 3D**).

#### *RT-PCR analysis*

Two developmental ages of embryonic heart at E14 and E18 were studied for mRNA expression of all the seven P2X receptors (P2X<sub>1-7</sub>). Results of the mRNA expression were summarized in **Fig 4**. For all the P2X receptors examined, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub> and P2X<sub>7</sub> receptors showed mRNA expression in the heart at both E14 and E18. P2X<sub>1</sub> and P2X<sub>5</sub> receptor was expressed at E18 but not at E14, though the expression of P2X<sub>5</sub> in the heart was barely detectable at E18. The P2X<sub>6</sub> receptor, however, was not expressed in either E14 or E18 hearts.

#### *Double-labeling immunocytochemistry*

Fluorescence immunocytochemical staining has shown that among all the P2X receptors examined, only P2X<sub>2</sub> and P2X<sub>4</sub> receptors were expressed in the cardiomyocytes at E14 (**Fig 5A-F**), as were shown in the double-labeled immunocytochemical staining with  $\alpha$ -sarcomeric actin. None of the other P2X receptor subunits was coexpressed with  $\alpha$ -sarcomeric actin (**Fig**

**5G-K).** Similar to E14, P2X<sub>2</sub> and P2X<sub>4</sub> receptors were detectable in E18 cardiomyocytes labeled with  $\alpha$ -sarcomeric actin shown by double-labeling (**Fig 6A-F**). P2X<sub>1</sub>, P2X<sub>5</sub> and P2X<sub>7</sub> receptors were also expressed in E18 cultured cardiomyocytes (**Fig 6G-O**). However, immunoreactivity of P2X<sub>3</sub> and P2X<sub>6</sub> was not detected in any of the stages examined.

## DISCUSSION

It is well known that extracellular ATP exerts a wide range of activities on the adult myocardium (for reviews, see Olsson and Pearson, 1990; Ralevic and Burnstock, 1991; Pelleg and Belardinelli, 1998; Vassort, 2001). However, combined functional, molecular and immunocytochemical information about P2 receptor expression in the embryonic heart is lacking, which is needed for our understanding of purinergic signaling during embryonic development. The present study focused on the expression pattern of P2 receptors in the rat heart during embryonic development.

With the use of FLIPR, the responsiveness of cardiomyocytes taken at different embryonic ages towards ATP was analyzed. Indeed, cells at different embryonic ages responded differently to ATP. In addition to the previous reports demonstrating the presence of functional P1 adenosine receptors in mammalian embryonic cardiomyocytes (Hofman et al., 1997; Zhao and Rivkees, 2001; Zhao et al., 2002), the results of the present study clearly indicated the presence of functional P2X and P2Y receptors in rat cardiomyocytes from E14 onwards. Taken together the results of RT-PCR and immunocytochemical staining showed that P2X<sub>2</sub> and P2X<sub>4</sub> receptors were the most likely P2X receptor subtypes responding to ATP at E14. The discriminating feature between the P2X<sub>2</sub>- and the P2X<sub>4</sub>-receptor is the blockade of

the latter but not the former by PPADS (Ralevic and Burnstock, 1998). However, the ATP-induced response at E14 was almost completely blocked by PPADS, which suggested that it was mostly the P2X<sub>2</sub> receptor that accounted for the ATP-mediated response at E14 cardiomyocytes. RT-PCR studies were consistent with this conclusion, with the P2X<sub>2</sub> mRNA band dominant. In addition, the P2X<sub>2</sub> receptor was also expressed in the embryonic rat heart as early as at E12 (Cheung and Burnstock, 2002), the stage at which none of the other P2X receptors were detected (unpublished data). In contrast, the ATP-induced response at E18 cardiomyocytes was sustained after treating with PPADS, suggesting the involvement of P2X<sub>4</sub>, P2X<sub>6</sub> and P2X<sub>7</sub> receptors (see Ralevic and Burnstock, 1998). However, absence of P2X<sub>6</sub> mRNA transcript in the present study ruled out the possibility of P2X<sub>6</sub> receptor involvement. RT-PCR and immunocytochemistry indicated the presence of P2X<sub>1</sub>, P2X<sub>3</sub>, P2X<sub>4</sub> and P2X<sub>7</sub> receptors at E18 hearts. In addition, BzATP, a P2X<sub>1</sub> and P2X<sub>7</sub> receptor-sensitive agonist, triggered Ca<sup>2+</sup> mobilization in E18 cardiomyocytes. Although P2X<sub>1</sub> receptor is also sensitive to BzATP,  $\alpha\beta$ -meATP, a P2X<sub>1</sub>-specific agonist, did not induce significant responses in both E14 and E18 cardiomyocytes. It is therefore suggested that the BzATP-induced response is mostly contributed by activation of functional P2X<sub>7</sub> rather than P2X<sub>1</sub> receptors; this has not been reported previously. In contrast, P2X<sub>4</sub> receptor expression has been reported in human fetal and chick embryonic heart (Bogdanov et al., 1998a; Ruppelt et al., 1999; Hu et al., 2002). ATP is known to stimulate a large increase in cytosolic calcium transient and myocyte

contractile amplitude (see review by Vassort, 2001). Transgenic mouse overexpressing human P2X<sub>4</sub> receptors demonstrated an increase in contractility in cardiomyocytes subject to ATP stimulation (Hu et al., 2001). In contrast to P2X<sub>4</sub> receptor, little is known about the function of P2X<sub>2</sub> and P2X<sub>7</sub> receptor in the myocardium, although it has been shown previously that activation of P2X<sub>7</sub> receptors induced contraction of human saphenous vein smooth muscle (Cario-Toumaniantz et al., 1998). It is still not clear what factors underlie early embryonic changes in contractility in rat, as both changes in Ca<sup>2+</sup> sensitivity and troponin isoforms occur after 7 days postnatal (Reiser et al., 1994; Jin, 1996). However, the possibility of increase in contractility in embryonic rat as a result of P2X<sub>4</sub> and P2X<sub>7</sub> receptor activation (and probably P2X<sub>2</sub> receptor as well) mediated by ATP is worth investigating.

The presence of receptor transcripts of P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptors in embryonic rat heart has been demonstrated previously (Cheung et al., 2003), as well as in human fetal heart for P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub> receptors (Bogdanov et al., 1998a). The present study helps to uncover the functional status of the receptors on cardiomyocytes during heart development. The P2Y receptor agonists all induced Ca<sup>2+</sup> mobilization on cardiomyocytes at E14. 2MeSADP, which is a stable analog to ADP, induced a P2Y<sub>1</sub>-specific response on Ca<sup>2+</sup> mobilization on cardiomyocytes. The uracil nucleotides that preferentially activate P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors (by UTP) and P2Y<sub>6</sub> receptor (by UDP) also induced Ca<sup>2+</sup> mobilization on

cardiomyocytes. Although the receptor proteins were expressed as early as in E12 (Cheung et al., 2003), the receptors were shown to be responsive to the agonists in the cardiomyocytes from E14 onwards. We have previously shown that the P2Y receptor proteins expressed initially all over the heart but soon restricted to the trabeculated layers; the expression was absent in compact myocardium after E14 (Cheung et al., 2003). Trabeculation differs from compact myocardium in terms of extent of differentiation, rate of contractions and impulse conduction (Franco et al., 1998). P2Y receptor expression in the trabeculated layer, and the responsiveness towards agonists from E14 onwards suggested that the receptor may have something to do with either the differentiation or contraction. Small spontaneous responses were occasionally observed in E14 and E18 cardiomyocytes. Such responses appeared to be artifacts, as the spontaneous responses retained in the presence of PPADS. It is probably due to the contractile property of the cardiomyocytes that generate the responses.

Bogdanov et al (1998a) have shown the presence of P2X<sub>1</sub> and P2X<sub>3</sub> mRNA transcripts in human fetal heart. Here we were also able to amplify the mRNA transcripts of P2X<sub>1</sub> and P2X<sub>3</sub> receptors in E18 hearts. However, compared to ATP, BzATP and the P2Y receptor agonists,  $\alpha\beta$ -meATP only triggered a very small response in E18 cardiomyocytes. It is therefore unlikely that P2X<sub>1</sub> and P2X<sub>3</sub> receptors are highly involved in the development of cardiomyocytes in rats.

Ruppelt et al. (2001) demonstrated the mRNA expression of the chick P2X<sub>5</sub> receptor subtypes in the embryonic chick heart. Although the results of RT-PCR from the present study showed very weak P2X<sub>5</sub> mRNA transcript expression in E18 rat heart, double labeling experiments confirmed the presence of P2X<sub>5</sub> receptor protein in the cardiomyocytes.









Although expression profile of P2 receptors on heart development has been examined previously, expression pattern together with functional analysis on embryonic cardiomyocytes have not been studied previously. Our observations support the hypothesis that ATP acts on particular P2 receptor subtypes during different stages of development, suggesting that complex mechanisms are involved in governing sequential P2 receptor subtype expression. In summary, we have identified P2X receptor subtypes (P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>5</sub> and P2X<sub>7</sub>) and P2Y receptor subtypes (P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> and P2Y<sub>6</sub>) in rat embryonic cardiomyocytes. All these receptor subtypes, except for P2X<sub>7</sub> and P2Y<sub>4</sub> have been described in adult rat cardiomyocytes. Therefore it appears that P2X<sub>7</sub> and P2Y<sub>4</sub> play additional roles in the embryo. Complex remodeling occurs during embryonic development of the heart, but further investigations are needed to uncover the precise roles played by the various P2 receptor subtypes.



## FIGURES & LEGENDS







**Figure 1**  $\text{Ca}^{2+}$  mobilization of embryonic cardiomyocytes. The response of  $\text{Ca}^{2+}$  mobilization is represented by an increase in the mean of fluorescent units ( $n = 3$ ; error bars represent standard error of the mean). ATP-induced response in cultured cardiomyocytes taken from E12 (A), E14 (C), E18 (F) and the corresponding controls (B, D, G, respectively). E and H show the ATP-induced response after the preincubation with PPADS.

**Fig 1**







**Figure 2**  $\text{Ca}^{2+}$  mobilization of embryonic cardiomyocytes. The response of  $\text{Ca}^{2+}$  mobilization is represented by an increase in the mean of fluorescent units ( $n = 3$ ; error bars represent standard error of the mean). **A, C, E** show responses of E14 cardiomyocytes induced by 2MeSADP, UTP and UDP, respectively; whereas **B, D, F** show responses of E18 cardiomyocytes induced by corresponding agonists.

**Fig 2**




**Figure 3**  $\text{Ca}^{2+}$  mobilization of embryonic cardiomyocytes. The response of  $\text{Ca}^{2+}$  mobilization is represented by an increase in the mean of fluorescent units ( $n = 3$ ; error bars represent standard error of the mean). **A, B** show responses induced by BzATP on E14 and E18 cardiomyocytes, respectively. **C, D** show responses induced by  $\alpha\beta$ -meATP on E14 and E18 cardiomyocytes, respectively.

**Fig 3**



**Figure 4** RT-PCR analysis for P2X<sub>1-7</sub> receptors on E14 and E18 heart tissues. Primers for P2X<sub>6</sub> receptors that gave negative results at both stages showed positive signals using rat brain tissue extract (data not shown).


**Fig 4**






**Figure 5** P2X receptor subtype expression in cultured E14 cardiomyocytes. Cardiomyocytes were identified by monoclonal antibody against  $\alpha$ -sacromeric actin ( $\alpha$ -SMA, green) (**A** and **D**). P2X receptor-immunoexpressing cells were shown in red (**B** and **E**). Cardiomyocytes showing coexpression (yellow) of P2X receptors (P2X<sub>2</sub> and P2X<sub>4</sub>) with the  $\alpha$ -SMA (**C** and **F**). Cardiomyocytes at this stage did not express P2X<sub>1</sub>, P2X<sub>3</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> and P2X<sub>7</sub> receptors (**G-K**, respectively). Scale bar = 25 $\mu$ m.

**Fig 5**



**Figure 6** P2X receptor expression in cultured E18 cardiomyocytes. Cardiomyocytes were identified by monoclonal antibody against  $\alpha$ -sacromeric actin ( $\alpha$ -SMA, green) (A, D, G, J and M). P2X receptor-expressing cells are shown in red (P2X<sub>2</sub> (B), P2X<sub>4</sub> (E), P2X<sub>1</sub> (H), P2X<sub>5</sub> (K) and P2X<sub>7</sub> (N)). P2X receptor subtypes coexpressing with  $\alpha$ -SMA on cardiomyocytes were shown in yellow (C, F, I, L and O). P2X<sub>3</sub> and P2X<sub>6</sub> receptors were not expressed in E18 cardiomyocytes (data not shown). Scale bar = 50 $\mu$ m.

**Fig 6**



## **Chapter VI Early expression of ATP-gated P2X<sub>7</sub> receptor in the developing rat pancreas**

### **ABSTRACT**

Extracellular ATP modulates the functions of the adult pancreas via two nucleotide receptor families, the P2X and P2Y receptors. Recently, expression of the P2X<sub>7</sub> receptor was demonstrated in islet cells of the pancreas, particularly the mature  $\alpha$  cells that secrete glucagon. In streptozotocin-induced diabetic model, loss of insulin-secreting cells was accompanied by an increase in  $\alpha$  cells that expressed the P2X<sub>7</sub> receptor. In the present study we have examined the expression of P2X<sub>7</sub> receptor in the developing pancreas from embryonic days (E) 11-18. We detected P2X<sub>7</sub>-immunoreactive cells in pancreatic islets cells as early as at E11, prior to glucagon expression. Subsequently P2X<sub>7</sub> receptor was expressed in glucagon-secreting cells at E12 and complete colocalization was observed at E14. Occasional colocalization of P2X<sub>7</sub> receptor and insulin was observed in scattered cells at E12 and E14 but not at E18, when the glucagon-secreting and insulin-secreting cells were almost completely segregated. In summary, it was found that P2X<sub>7</sub> receptor was expressed early in a subpopulation of glucagon- and insulin-immunopositive cells in developing islets and subsequently became restricted to glucagon-expressing cells as development proceeded.

## INTRODUCTION

The functional units of the endocrine pancreas are the islets of Langerhans composed of four cell types:  $\alpha$ ,  $\beta$ ,  $\delta$  and PP cells. The insulin-secreting  $\beta$  cells constitute the majority of the endocrine cell population and form the core of the islet, whereas  $\alpha$ ,  $\delta$  and PP cells secreting glucagon, somatostatin and a pancreatic polypeptide respectively make up the rest of the islet cell population. In mammals the embryonic pancreas develops from the primitive foregut as two outpocketings (the dorsal and ventral buds), each of which consists of an inner endodermal epithelium surrounded by the mesenchyme (Pictet and Rutter, 1972). Both buds subsequently proliferate to form multiple branches and fuse together to make a functional organ. Among the hormones secreted from the endocrine portion of the pancreas, glucagon is the first peptide expressed in the developing pancreatic epithelium at embryonic day (E) 9.5 in the mouse (Rall et al., 1973; Guz et al., 1995). The functional significance of this early appearance of glucagon in the pancreas has not been resolved, although a recent study suggests that glucagon regulates the differentiation of insulin-secreting cells (Prasadan et al., 2002). However, the relationship of these endocrine cells in embryos and how the differentiation of these various types of pancreatic cells is regulated is still far from clear. The histogenesis of pancreatic endocrine cells requires complex and dynamic gene expression (Larsson, 1998; St-Onge et al., 1999).

Receptors responsible for ATP-mediated activities are subdivided into ionotropic P2X and metabotropic P2Y receptor families (Ralevic and Burnstock, 1998). P2X receptors mediate rapid non-selective passage of small cations across the cell membrane resulting in an increase in intracellular Ca<sup>2+</sup> and depolarization (see Ralevic and Burnstock, 1998). Among all the P2X receptors cloned, the P2X<sub>7</sub> receptor is structurally and functionally unique in that the cation channel of the P2X<sub>7</sub> receptor, under the continuous presence of ATP and a low level of divalent cations, converts to a pore permeable to small molecules as well as ions (North, 2002). The significantly longer intracellular C-terminus than other P2X receptors is associated with the induction of the non-selective pore (Surprenant et al., 1996). In addition, the P2X<sub>7</sub> receptor is the only P2X receptor subunit that is unable to form heteromeric assemblies with other P2X receptor subunits (Torres et al., 1999), and thus the P2X<sub>7</sub> receptor only exists as a homomer. P2X<sub>7</sub> receptor has also been implicated in mediating apoptosis in some tissues (Surprenant et al., 1996; Di Virgilio, 2000; North, 2002).

Exogenous nucleotides modulate the functions of the adult pancreas (Loubatières-Mariani and Chapal, 1988; Petit et al., 2001; Novak et al., 2002). It has been demonstrated that ATP stimulates insulin secretion, while adenosine inhibits insulin secretion from  $\beta$  cells and stimulates glucagon secretion from  $\alpha$  cells.

The P2X<sub>7</sub> receptor has been recently detected in  $\alpha$  cells but not the other pancreatic endocrine cell types (Coutinho-Silva et al., 2001, 2003). In the present study, we have investigated the developmental expression pattern of the P2X<sub>7</sub> receptor. We have made use of specific antibodies and an immunofluorescent double labeling method to study the spatial-temporal expression of P2X<sub>7</sub> receptor in the early developing pancreas in order to find out its relationship with the glucagon and insulin secreting cells.



## **MATERIALS AND METHODS**

### *Tissue preparation*

Please refer to the section **Materials and Methods** on Chapter II.

### *Immunofluorescence double labeling*

Please refer to the section **Materials and Methods** on Chapter III. The primary antibodies used were rabbit anti-P2X<sub>7</sub> (1:200; Roche Bioscience), goat anti-glucagon (1:50; Santa Cruz Biotechnology) and guinea pig anti-insulin (1:500; Inestar Stillwater).

## RESULTS

P2X<sub>7</sub> receptor immunoreactivity was detected in pancreatic islets at E11-E18. The P2X<sub>7</sub> receptor was first expressed at E11 (**Fig 1A**), the stage at which glucagon and insulin immunoreactivities were not yet detectable (also see Roberts et al., 2001). P2X<sub>7</sub> receptor-immunoreactive cells were found in the islets, which appear as ovoid cell clusters in the pancreas. At E12, both glucagon and insulin started to express in the islets (**Figs 1B, 1C**). Double immunofluorescence labeling showed that all the insulin-expressing cells were glucagon-positive, whereas some pancreatic cells expressed glucagon only (**Fig 1D**). Insulin-expressing cells constituted only a small fraction of cells within the glucagon-expressing population at E12 (**Fig 1D**). Double labeling also showed that all the P2X<sub>7</sub> receptor-expressing cells were glucagon positive (**Fig 1F**). Some of the glucagon-expressing cells, however, were P2X<sub>7</sub> receptor-negative (**Fig 1F**). At this stage, a small number of islet cells were observed co-expressing P2X<sub>7</sub> receptor and insulin, whereas some populations expressing either P2X<sub>7</sub> receptor or insulin only were also identified (**Fig 1J**).

At E14, expression of glucagon and insulin was detected. Unlike E12, where all the insulin-expressing cells were glucagon-immunopositive, cells that express insulin but not glucagon were first appeared at this stage (**Fig 2A-2C**). All the glucagon-immunoreactive

cells showed complete co-localization with the P2X<sub>7</sub> receptor (Fig 2D-2F). Similar to that observed at E12, some but not all of the P2X<sub>7</sub> receptor-expressing cells were colocalized with insulin-immunopositive cells. Cells expressing either P2X<sub>7</sub> receptor or insulin were also observed.

A sharp increase in the population of insulin-expressing cells took place after E14 (Larsson, 1998). At E18, when insulin-secreting  $\beta$  cells became the dominant endocrine cell type and outnumbered the glucagon-immunoreactive cells (Fig 3A-3B), the glucagon-positive and insulin-positive cells were completely segregated (Fig 3C). The P2X<sub>7</sub> receptor was expressed in the glucagon-expressing islet cells, indicated by colocalization of P2X<sub>7</sub> receptor and glucagon (Fig 3D-3F). Glucagon-positive, P2X<sub>7</sub> receptor negative cells, though present, were very rare (Fig 3F). At this stage, none of the insulin-expressing cells were P2X<sub>7</sub> receptor-immunopositive (Fig 3G-3I).

## DISCUSSION

The current experiments used a double immunohistochemical method to examine the expression of ATP-gated P2X<sub>7</sub> receptor in glucagon and insulin expressing cells during early development in the rat pancreas. Glucagon and insulin are secreted hormonal peptides as well as common markers for  $\alpha$  cells and  $\beta$  cells respectively in both adult and embryonic islets in pancreas. Surprisingly, we found that the P2X<sub>7</sub> receptor, which has previously been shown to be expressed specifically in glucagon-expressing cells in postnatal as well as in adult pancreas (Coutinho-Silva et al., 2001), was detected as early as at E11, the stage at which pancreatic cells are still glucagon- and insulin-negative. The early appearance of P2X<sub>7</sub> immunoreactivity prior to glucagon expression indicates that expression of the P2X<sub>7</sub> receptor does not require the presence of glucagon. Whether or not the P2X<sub>7</sub> receptor participates in regulation of glucagon expression, however, is not known. Subsequent expression of the P2X<sub>7</sub> receptor was shown to be largely associated with glucagon-positive cells but some insulin staining cells also expressed P2X<sub>7</sub> receptors. Eventually, P2X<sub>7</sub> receptor expression was only detected in mature  $\alpha$  cells containing glucagon (Coutinho-Silva et al., 2001). It has been shown that the early islet cell population (before E14-E15) consists of glucagon-positive cells and glucagon/insulin-coexpressing cells (Larsson, 1998). Our present study and also other reports (Herrera et al., 1991; Teitelman et al., 1993; Larsson, 1998) show that all insulin

expressing cells prior to E14 belong to the glucagon/insulin-coexpressing cell subpopulation. Our results also show that the P2X<sub>7</sub> receptor was expressed in both glucagon-positive and glucagon/insulin-coexpressing cells. In view of the finding in the adult pancreas that the P2X<sub>7</sub> receptor was restricted to mature  $\alpha$  cells that secrete glucagon only (Coutinho et al., 2001, 2003), the expression of the P2X<sub>7</sub> receptor in glucagon/insulin expressing cells appears to be novel. It is however known that while the glucagon-positive cells will give rise to the mature  $\alpha$  cells, the glucagon/insulin expressing cells will not give rise to any of the mature  $\alpha$ - or  $\beta$ -cells (Herrera, 2000), which are thought to be eliminated by apoptosis (Larsson, 1998). Whether the P2X<sub>7</sub> receptor is involved in the elimination of the glucagon/insulin expressing cells through apoptosis needs further investigation, but the finding that the P2X<sub>7</sub> receptor are not found in all of the glucagon/insulin expressing cells and are observed in glucagon-positive cells indicates that the involvement of the P2X<sub>7</sub> receptor in the pancreatic cell death is highly unlikely.


Previous studies demonstrated the first appearance of ultrastructurally recognizable  $\beta$  cells with a characteristic of insulin-positive and glucagon-negative immunoreactivity at E14-E15 (Larsson, 1998). Our present study also found that the insulin-positive and glucagon-negative cells first appeared at E14.

In summary, we have shown the expression of the P2X<sub>7</sub> receptor early in the embryonic pancreas even before expression of hormone peptides, suggesting that expression of P2X<sub>7</sub> receptor did not depend on the presence of glucagon. Subsequent expression was detected in islet cells expressing different endocrine markers. Thus the P2X<sub>7</sub> receptor appears to be one of the earliest markers during islet cell development. Besides, transient expression of P2X<sub>7</sub> receptors in the glucagon and insulin co-expressing cells offers additional insight into whether ATP is involved during pancreatic development, in addition to its role in modulating insulin secretion.

**FIGURES & LEGENDS**

**Figure 1** Immunohistochemistry of P2X<sub>7</sub> receptor, glucagon and insulin in islets of the E11-E12 pancreas. (A) P2X<sub>7</sub> receptor-immunoreactive cells (red) are expressed in clusters in E11 pancreas. (B) Immunoreactivity of glucagon-expressing cells (red); (C) insulin-expressing cells (green), and (D) colocalization of glucagon and insulin (yellow). (E-G) Double labeling of glucagon and P2X<sub>7</sub> receptor. (E) Glucagon expression (red) and (F) P2X<sub>7</sub> receptor expression (green). (G) Colocalization of glucagon and P2X<sub>7</sub> receptor (yellow). (H) P2X<sub>7</sub> receptor expression (red); (I) insulin expression (green) and (J) colocalization of P2X<sub>7</sub> receptor and insulin (yellow). Scale bar = 100µm (A, E-J) and 114µm (B-D).


**Fig 1**






**Figure 2** Immunohistochemistry of P2X<sub>7</sub> receptor, glucagon and insulin in islets of the *E14 pancreas*. (A) Immunoreactivity of glucagon-expressing cells (red), (B) insulin-expressing cells (green). (C) Colocalization of glucagon- and insulin-expressing cells (yellow). (D) P2X<sub>7</sub> receptor immunoreactive cells (red). (E) Glucagon-expressing cells (green) and (F) colocalization of glucagon and P2X<sub>7</sub> receptor (yellow). (G) P2X<sub>7</sub> immunostaining (red), (H) insulin immunostaining (green). (I) Colocalization of P2X<sub>7</sub> receptor (yellow). Scale bar = 100µm.

**Fig 2**



**Figure 3** Immunohistochemistry of P2X<sub>7</sub> receptor, glucagon and insulin in islets of the *E18 pancreas*. (A) Immunoreactivity of glucagon-expressing cells (red), (B) insulin-expressing cells (green), and (C) colocalization of glucagon and insulin (yellow); (D) P2X<sub>7</sub> receptor immunoreactive cells (red), (E) glucagon and insulin expressing cells (green), and (F) colocalization of P2X<sub>7</sub> and glucagon (yellow); (G) P2X<sub>7</sub> immunoreactive cells (red), (H) Insulin expressing cells (green) and (I) colocalization of P2X<sub>7</sub> and insulin (yellow). Scale bar = 100µm.

**Fig 3**



## **Chapter VII. General Discussion and Conclusion**

### **VII.1 Introduction**

Fundamental questions in developmental biology concern (1) what genes are expressed; (2) where and when they are expressed and turned off; (3) the regulatory programs that govern the gene expression; (4) and ultimately, why they are expressed. The vast majority of events take place in embryos, with many genes expressed in a dynamic sequential manner, making development a complex and highly integrated process. ATP has an intracellular role in energy storage and release, as well as extracellular roles in mediating wide ranges of physiological activities (see review Abbracchio and Burnstock, 1998; Burnstock, 2002b). Extracellular activities of ATP and related nucleotides (ADP, UTP and UDP) are mediated by activation of two families of P2 receptors, the ionotropic P2X receptors and the metabotropic P2Y receptors (Abbracchio and Burnstock, 1994). Cloning of over 50 P2 receptor subtypes in different species for the past decade (Burnstock, 2003a) has increased our knowledge of the P2 receptor-mediated signaling. It is expected that purinergic signaling pathways would be involved in embryonic development (see Burnstock, 2001).

During development of the early mammalian embryos, the process of gastrulation determines the embryonic body axis and, in addition, generates three distinctive germ layers, namely ectoderm, mesoderm and endoderm. There are two types of ectodermal tissues, the

neuroectoderm and the surface ectoderm. While the neuroectoderm gives rise to tissues of both the central and peripheral nervous system, the surface ectoderm will form the skin. Mesoderm gives rise to several types of tissues, such as musculo-skeletal, cardiovascular and urogenital tissues. Endoderm gives rise mainly to the tissues of the viscera, including those of the digestive and respiratory systems. The results of the present study have demonstrated that P2 receptors are widely expressed throughout the three germ layers during development. The spatial-temporal expression pattern of the P2 receptors in each germ layer, together with the possible roles during development, will be discussed below.

## **VII. 2 P2 receptors in ectoderm-derived tissues**

### ***Nervous system***

Activation of P2X receptors involves depolarization of plasma membrane and activation of voltage-dependent  $\text{Ca}^{2+}$  influx, resulting in an increase in intracellular free  $\text{Ca}^{2+}$  concentration. In addition, during early development changes in intracellular  $\text{Ca}^{2+}$  can alter growth cone motility and the rate of neurite outgrowth (Mattson and Kater, 1987), neural migration (Komuro and Rakic, 1996) and neural phenotype (Marty et al., 1996). Therefore, we investigated the expression pattern of P2X receptors during embryonic neurogenesis. Surprisingly, the P2X<sub>2</sub>, P2X<sub>4</sub> and P2X<sub>6</sub> receptors, which are widely distributed in adult brains (see Burnstock, 2003b), were absent in early embryonic neural tube. It was the homomeric

P2X<sub>3</sub> receptor that showed early expression in embryonic branchiomotor/visceromotor (BM/VM) neurons in the neural tube as well as in cranial ganglia. As development proceeded, the P2X<sub>3</sub> receptor was detected in the facial motor nucleus in the hindbrain, which raised the question of whether the cranial motor neurons showing P2X<sub>3</sub>-immunoreactivity were the facial branchiomotor neurons. The spatial-temporal expression pattern of P2X<sub>3</sub> receptors in the cranial motor neurons suggested that it might be involved in neurite outgrowth. Both  $\alpha\beta$ -meATP and ATP, agonists to the P2X<sub>3</sub> receptor, showed significant inhibition of neurite extension. UTP did not mimic the inhibitory effect of ATP; therefore, it is unlikely that P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors were involved, even though these receptors were expressed in the embryonic spinal nerves. The stability of  $\alpha\beta$ -meATP also ruled out the possibility of an adenosine-mediated response. ATP has been shown to inhibit NCAM-expressing neurites (Skladchikova et al., 1999). Our results showed that the embryonic cranial motor axons expressed NCAM, and the ATP-mediated inhibitory effects on NCAM-expressing axons further indicated that ATP might interact with NCAM in the process of axon outgrowth in embryonic cranial motor neurons, most likely via P2X<sub>3</sub> receptor. The process of axon guidance appears to be very complex, involving different types of signaling molecules acting in concert to direct pathfinding (Tessier-Lavigne and Goodman, 1996). Our results demonstrated that ATP has an inhibitory effect on neurite outgrowth from cranial neural tube. However, no experiments were carried out to see if ATP had any effect on axon guidance.

Several questions arise: does the inhibitory effect of ATP reflect the rejection of cranial motor axons to particular tissues from the environment that release ATP? What is the source of ATP surrounding the neural tube? Is this inhibitory effect due to a reduction in length of BM/VM axons? Identifying the *in vivo* source of ATP together with the use of specific markers for different types of motor axons will be crucial in uncovering the role of purinergic signaling in embryonic axon pathfinding.

The expression of P2X<sub>3</sub> receptor was also prominent in a number of neural crest-derived tissues, including trigeminal, facioacoustic, glossopharyngeal-vagal, dorsal root and sympathetic ganglia, mesencephalic trigeminal nucleus. Enteric neurons in the adult guinea pig also show P3X<sub>3</sub> receptor expression (Van Nassauw, et al., 2002; see Burnstock, 2003b). Other neural-crest derived tissues which are non-neural, such as melanocytes, dermal bones of skull, odontoblasts and the pharyngeal arches cartilages, all show absence of P2X<sub>3</sub> receptor expression throughout life. It seems that the onset of P2X<sub>3</sub> receptor expression begins after the migrating neural crest cells arrive at their presumptive destination and are committed into a neural fate. P2X<sub>3</sub> receptor-deficient mice showed an impaired response towards inflammatory pain (Cockayne et al., 2000) and peristalsis (Bian et al., 2003), whereas loss or atrophy of neurons was never reported in the transgenic model, suggesting that P2X<sub>3</sub> receptor expression is important for the function, but not the survival of neurons.



The P2X<sub>2</sub> and receptor expression was detected in the nucleus tractus solitarius in E14 rat brain. Results from double labeling experiments indicated that the P2X<sub>2</sub> receptor was largely, if not entirely, colocalized with the P2X<sub>3</sub> receptor. It is very likely that the two receptors formed P2X<sub>2/3</sub> heteromers in the nucleus tractus solitarius. In contrast, the nodose and the dorsal root ganglia showed an incomplete colocalization of P2X<sub>2</sub> and P2X<sub>3</sub> receptors. It is known that the P2X<sub>2/3</sub> heteromers differ from the homomeric P2X<sub>2</sub> and P2X<sub>3</sub> receptors in the response towards ATP, especially in the aspects of desensitization (Liu et al., 2001, Koshimizu et al., 2002). The variable extent of involvement between the P2X<sub>2</sub> and P2X<sub>3</sub> in the formation of the P2X<sub>2/3</sub> heteromers may thus contribute to different effects of ATP-mediated activities.

The P2X<sub>7</sub> receptor was expressed in the rat hypothalamus from E14 onwards, slightly earlier than the appearance of the functional glutamate receptor in the embryonic hypothalamus (at E15) (van den Pol et al., 1995). Sperlágh et al. (2002) demonstrated that ATP regulates glutamate release via activation of P2X<sub>7</sub> receptors, and excessive glutamate release altered the Ca<sup>2+</sup> homeostasis, resulting in activation of apoptosis-related gene (e.g caspase) (see review Le Feuvre et al., 2002). In vitro studies on the embryonic hippocampal neurons also showed that glutamate release upon reactive oxygen species induced activation of glutamate receptor

(NMDA receptor), which then activated caspases and in turn triggered apoptosis (Ishikawa et al., 1999). Given that ATP-mediated apoptosis involved activation of P2X<sub>7</sub> receptor (see review Le Feuvre et al., 2002), it seems likely that the activation of P2X<sub>7</sub> receptor is also involved in cell death during neurogenesis, but this possibility awaits further investigation.

The P2X<sub>4</sub>, P2X<sub>5</sub> and P2X<sub>6</sub> receptors were not detected in the developing brain until the late embryonic period, between E18-P1. P2X<sub>6</sub> receptor expression was shown in the lateral hypothalamus of P1 brain. P2X<sub>6</sub> receptors have been implicated in hormone release from axon terminals as well as recycling of the granular vesicles and microvesicles in the adult hypothalamo-neurohypophysial system (Loesch and Burnstock, 2001). P2X<sub>4</sub> and P2X<sub>5</sub> receptors were both detected in the subventricular zone (SVZ) of the embryonic striatum. The SVZ was previously demonstrated to be a site of postnatal neurogenesis (Conover and Allen, 2002). P2X<sub>4</sub> and P2X<sub>5</sub> receptors labeled two different types of cells in the SVZ; the round-shaped, cytoplasmic-stained, P2X<sub>4</sub> receptor immunoreactive cells, and the pyramidal-shaped, nuclear and cytoplasmic-stained, P2X<sub>5</sub> receptor immunoreactive cells. Doetsch et al. (1999) and Laywell et al. (2000) showed that the subventricular (SV) astrocytes are the neural stem cells that give rise to both neurons and glia. Other results suggest that it is the ependymal cells that generate multipotent neurospheres (Johansson et al., 1999). It would be interesting to use double-labeling to examine the identity of the P2X<sub>5</sub>

receptor-immunoreactive cells in the SVZ to see if they are SV astrocytes or ependymal cells. P2X<sub>4</sub> receptor-immunoreactive cells, however, resemble migrating neuroblasts rather than the morphologically distinctive astrocytes or ependymal cells. The P2X<sub>1</sub> receptor, according to our result, was not expressed before P16. It has been demonstrated previously that P2X<sub>1</sub> receptors are expressed in the adult rat cerebellum (Loesch and Burnstock, 1998; Florenzano et al., 2002) and upregulation of the receptor was observed in the precerebellar neurons that survived after cerebellar injury (Florenzano et al., 2002). It is not clear whether the upregulation is important for post-injured cell survival or a consequence of axotomy. Although P2X<sub>1</sub> receptor expression was unlikely to be involved in embryonic neurogenesis, its potential role in either cell survival or regeneration after injury would be worth investigating.

In addition, the P2X receptor involvement in embryonic neurogenesis, G-protein coupled P2Y receptor expression was also detected in the embryonic nervous system. We have observed an early expression of P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors in the ventral neural tube. The P2Y<sub>2</sub> receptor was expressed in the spinal motor neurons and the ventrally migrating motor axons. The P2Y<sub>4</sub> receptors, however, were only found in the spinal motor neurons. Absence of inhibitory effects by UTP suggested that ATP-induced effects were not mediated by P2Y<sub>2</sub> or P2Y<sub>4</sub> receptors. Nevertheless, the distinct expression pattern of P2X<sub>3</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors in the ventral neural tube raises the question of whether there is any interaction

between ATP signaling and the well known ventral-patterning signals such as Sonic Hedgehog (Shh) and Pax 6 (Goulding et al., 1993; Mansouri et al., 1996; Dodd et al., 1998, Litingtung and Chiang, 2000). Among the P2Y receptor examined, the P2Y<sub>4</sub> receptor appeared to be the dominant receptor in the developing brain. Although the exact function of the P2Y<sub>4</sub> receptor during neurogenesis was unknown, the transient expression (at least in the medulla) suggests a role during development.

Taken together, our results suggest that ATP is involved during neurogenesis in both prenatal and postnatal animals. While the P2X<sub>2</sub>, P2X<sub>4</sub> and P2X<sub>6</sub> receptors are dominant in the neonatal as well as adult brain, P2X<sub>3</sub> receptors appeared to play a more important role during embryonic neurogenesis. Despite a transient and dynamic expression of P2X<sub>3</sub> receptors in the embryonic brain especially in the motor neurons, the early expression in the cranial sensory ganglia persists after birth. Nevertheless, purinergic signaling via P2X receptor activation appears to be complex and fine-tuned, for each of the receptors are expressed in a spatial-temporal manner.

The present study also showed distinct localization of P2X<sub>2</sub> and P2Y<sub>1</sub> receptors in the notochord and the floor plate, respectively. The notochord is situated just beneath the neural tube, while the floor plate is at the ventral midline. Although the notochord and the floor

plate were not considered to be neuronal structures, they are known to exert major effects on neurogenesis (Placzek, 1995; Bronner-Fraser and Fraser, 1997). Both the notochord and the floor plate secrete Shh, which is a powerful signaling molecule involved in ventral patterning of the neural tube (Goulding et al., 1993; Dodd et al., 1998, Litingtung and Chiang, 2000). Shh first secretes from the notochord and then from the floor plate. Shh regulates one of the transcription factors *Pax 6* gene, and both of them act in a concentration dependent manner in promoting the differentiation of the neurons in the ventral neural tube to become motor neurons. This is the first report demonstrating P2 receptor expression in the notochord and floor plate. It would be interesting to look at the interaction between the Shh, Pax and purinergic signaling.

### **VII.3 P2 receptors in mesoderm-derived tissues**

#### ***VII.3.a Somites and skeletal muscles***

Following gastrulation, the paraxial mesodermal tissues on either side of the embryos in a position lateral to the neural tube segregate from the rest of the mesoderm and form the well-defined tissue blocks, the somites. Shortly after it has formed, each somite undergoes a mesenchyme-to-epithelial transition, and the epithelialized somite becomes partitioned into presumptive sclerotome (ventromedial) and dermomyotome (dorsolateral) regions, in a rostral-caudal direction. The dermomyotome will give rise to myotome (forming skeletal

muscle) and the dermatome (forming dermis).

Although the P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors in our study were all expressed early in the myotome and later in the developing skeletal muscle, their fate appeared to be quite different. Whereas P2Y<sub>4</sub> receptor expression was sustained in postnatal skeletal muscle, the P2Y<sub>1</sub> and P2Y<sub>2</sub> receptors were no longer expressed. Instead, P2Y<sub>1</sub> receptor was located in the smooth muscle of the blood vessels and P2Y<sub>2</sub> receptors appeared to be expressed in satellite cells. Neonatal satellite cells showed a concentration-dependent proliferation upon UTP treatment (Ryten et al., 2002), suggesting that P2Y<sub>2</sub> receptor activation by UTP was likely to participate in satellite cell proliferation, which is very important in the response to muscle damage. It is equally possible that UTP (and possibly ADP via P2Y<sub>1</sub> receptors) are also involved in proliferation during embryonic myogenesis. The present results suggest future studies of the interaction between extracellular nucleotides and myogenic signaling molecules such as Pax 3, MyoD and Myf5 (Tajbakhsh et al., 1997; Buckingham, 2001; Chi and Epstein, 2002; Buckingham et al., 2002).

Choi et al (2002) showed a colocalization of P2Y<sub>1</sub> receptor with the acetylcholine receptor. In the present study, however, colocalization of P2Y receptor subtypes with acetylcholine receptors in the neuromuscular junction was not observed. It may be that the

difference in the antibodies used in the two studies accounts for the discrepancy. We used a commercial rat-specific antibody, while the one used by Choi et al (2002) was prepared against chick receptor. The P2Y<sub>1</sub> receptor expression in our study was downregulated in the embryonic skeletal muscle as development proceeded, which was in agreement with a downregulation of chick P2Y<sub>1</sub> receptor mRNA transcript in embryonic skeletal muscle reported by Meyer et al. (1999a).

In addition to expression studies, functional studies also showed that upon ATP treatment, the isolated skeletal muscle cells from mouse embryos demonstrated P2X receptor-like responses (Collet et al., 2002). The response to ATP was developmentally regulated, as the amplitude of responses was decreased during early postnatal stages. The responses were completely lost in adult skeletal muscle cells, indicating that the ATP-induced responses were stage-specific. Altogether, the dynamic expression of P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors in somites and in the developing skeletal muscle, the transient expression of the P2X<sub>5</sub> receptor in the embryonic skeletal muscle tissue and its role in inducing satellite cell differentiation (Ryten et al., 2001; 2002), strongly suggests that ATP is involved in regulation of skeletal muscle development as well as regeneration.

### **VII.3.b Heart**

The heart originates from paired cardiac mesodermal primordia which fuse in the midline to produce a primitive heart tube (Yutzey and Bader, 1995). The heart tube then undergoes a series of remodeling steps, including looping, trabeculation, septation, and development of spiral outflow tracts (Larsen, 1998). Extracellular ATP and adenosine are known to have powerful actions on cardiomyocytes (Olsson and Pearson, 1990; Ralevic and Burnstock, 1991; Pelleg and Belardinelli, 1998; Vassort, 2001). Previous studies showed that subtypes of P1 adenosine receptors were expressed in the embryonic cardiomyocytes (Hofman et al., 1997; Zhao and Rivkees, 2001; Zhao et al., 2002). It was therefore interesting to investigate if subtypes of P2 receptor were also expressed in particular stages of heart development. The present results showed that P2X<sub>2</sub> and P2Y<sub>1</sub>, P2Y<sub>2</sub>, and P2Y<sub>4</sub> receptors were expressed in the myocardium at E12, the stage at which trabeculation and septation are in progress (Franco et al., 1998). Studies on Ca<sup>2+</sup> influx, together with RT-PCR and immunocytochemistry, have identified particular subtypes of P2X (P2X<sub>2</sub>, P2X<sub>4</sub>, P2X<sub>7</sub>) and P2Y (P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub>, P2Y<sub>6</sub>) receptors in embryonic cardiomyocytes at E14, followed by P2X<sub>1</sub>, P2X<sub>3</sub> and P2X<sub>5</sub> receptors at E18. Identification of P2X<sub>7</sub> receptor in the cardiomyocytes appears to be novel. Although P2Y receptor-mediated responses were observed in the cardiomyocytes at both E14 and E18, immunohistochemical studies showed that the P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub> receptor subtypes, while widely expressed throughout the myocardium, gradually became restricted to the trabeculated myocardium but not to the compact myocardium. Differences in the proliferation capacity



between the compact layer and the trabeculated layer of the myocardium (Sedmera et al., 2000) may provide a clue to the functional role of P2Y receptor activation. Trabeculations are important in enhancing contractility (Chalice and Viragh, 1973) and in coordinating intraventricular conduction (de Jong et al., 1992). However, preliminary results have shown that treatment of cultured embryonic cardiomyocytes with ATP, ADP, UTP and UDP did not affect cell proliferation (unpublished data). P2X receptors are expressed in embryonic as well as adult cardiomyocytes. Persistent expression of P2X receptors did not necessarily reflect the absence of dynamic expression patterns. *In situ* labeling of the P2X receptors in the embryonic hearts during development should further be examined. It is possible that P2X receptors regulate particular physiological activities which are important in embryonic as well as in adult cardiomyocytes (Pelleg and Belardinelli, 1998).

#### **VII.4 P2 receptors in endodermal-derived tissues**

##### ***Pancreas***

We have shown in the present study that one of the P2X receptors, the P2X<sub>7</sub> receptor, was expressed in developing endodermal tissue, the embryonic pancreas. The study was focused on the endocrine tissues, i.e. the islets of Langerhans. The major hormones present are insulin secreted from  $\beta$  cells, somatostatin from  $\delta$  cells and glucagon from  $\alpha$  cells. Previously, our group has demonstrated the expression of P2X<sub>7</sub> receptor to be restricted to  $\alpha$  cells raising the

question of whether P2X<sub>7</sub> receptor expression depends upon the presence of glucagon. The present results showed that i) the possibility of glucagon-driven P2X<sub>7</sub> receptor expression was ruled out; ii) P2X<sub>7</sub> receptor expression was not limited to glucagon-expressing cells during early development; and iii) colocalization of P2X<sub>7</sub> receptor with insulin was transient. It is reasonable to speculate that the P2X<sub>7</sub> and glucagon positive cells (insulin negative) at both E12 and E14 would give rise to  $\alpha$  cells, whereas the insulin-positive and P2X<sub>7</sub> negative (also glucagon negative) cells would give rise to  $\beta$  cells. Given that the early islet cells are all glucagon-positive (at E12), two additional types of cells were identified which were the glucagons/insulin/P2X<sub>7</sub> receptor coexpressing cells (i.e. P2X<sub>7</sub> receptor-positive) and glucagons/insulin coexpressing cells (i.e. P2X<sub>7</sub> receptor-negative). Information is missing regarding to the identity of these cells, although these multihormonal cells would not give rise to either mature  $\alpha$  or  $\beta$  cells and appeared to be eliminated in later development (Larsson, 1998; Herrera, 2000). The possibility of P2X<sub>7</sub> receptor control of glucagon-release appears to be unlikely, and previous studies have shown that glucagon release is regulated by adenosine, while insulin secretion is stimulated by ATP via P2Y receptor-mediated pathway (Loubatières-Mariani and Chapal, 1988; Loubatières-Mariani et al., 1997). Previous studies on P2X<sub>7</sub> receptor-deficient mice did not report any pancreatic-related abnormalities (Labasi et al., 2002; Ke et al., 2003). Further studies using in vitro culture systems would be an appropriate approach, together with the application of ATP or manipulation of P2X<sub>7</sub> receptor

expression (either overexpressed receptor transcripts, or suppressed transcripts by means of RNA interference techniques) to examine the roles of P2X<sub>7</sub>-mediated signaling. Coutinho et al (2003) have demonstrated the expression of the P2Y<sub>4</sub> receptor in both  $\alpha$  and  $\beta$  cells in adult pancreas. Examination on the P2Y<sub>4</sub> receptor expression in the developing pancreas will probably provide a more complete picture about how ATP regulates the development of pancreatic islets.

## **VII.5 Concluding Remarks**

In conclusion, our study has demonstrated for the first time the widespread expression pattern of P2X and P2Y receptor subtypes during rat embryonic development. The expression pattern of P2 receptor subtypes was not restricted to a particular tissue or system but included all the three germ layers. Dynamic and transient expression for particular receptors was observed in different tissues (for example, the P2X<sub>3</sub> receptor in cranial motor neurons; the P2X<sub>2</sub> receptor in notochord; the P2X<sub>7</sub> receptor in pancreatic insulin-expressing cells; the P2Y<sub>1</sub> receptor in the floor plate; the P2Y<sub>4</sub> receptor in the brainstem; the P2X<sub>5</sub>, P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors in somites in developing skeletal muscle; and the P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors in the compact layer of myocardium). It appears that ATP acting on P2X and P2Y receptor subtypes regulates organogenesis during embryonic development.

**REFERENCES**

- Abbracchio, M.P., Boeynaems, J.M., Barnard, E.A., Boyer, J.L., Kennedy, C., Miras-Portugal, M.T., King, B.F., Gachet, C., Jacobson, K.A., Weisman, G.A. and Burnstock, G. (2003). Characterization of the UDP-glucose receptor (re-named here the P2Y(14) receptor) adds diversity to the P2Y receptor family. *Trends Pharmacol Sci.* **24**:52-55.
- Abbracchio, M.P. and Burnstock, G. (1994). Purinoceptors: are there families of P2X and P2Y purinoceptors? *Pharmacol Ther.* **64**: 445-475.
- Abbracchio, M.P. and Burnstock, G. (1998). Purinergic signaling: pathophysiological roles. *Jpn J Pharmacol.* **78**: 113-145.
- Abe, Y., Sorimachi, M., Itoyama, Y., Furukawa, K. and Akaike, N. (1995). ATP responses in the embryo chick ciliary ganglion cells. *Neuroscience* **64**: 547-551.
- Abood, L.G., Koketsu, K. and Miyamoto, S. (1962). Outflux of various phosphates during membrane depolarization of excitable tissues. *Am J Physiol.* **202**:469-474.
- Bailey, M.A., Imbert-Teboul, M., Turner, C., Marsy, S., Srai, K., Burnstock, G. and Unwin, R.J. (2000). Axial distribution and characterization of basolateral P2Y receptors along the rat renal tubule. *Kidney Int.* **58**:1893-1901.
- Bailey, M.A., Imbert-Teboul, M., Turner, C., Srai, S.K., Burnstock, G. and Unwin, R.J. (2001). Evidence for basolateral P2Y(6) receptors along the rat proximal tubule: functional and molecular characterization. *J Am Soc Nephrol.* **12**:1640-1647.
- Barnard, E.A. (1992). Receptor classes and the transmitter-gated ion channels. *Trends Biochem Sci.* **17**:368-374.
- Barnard, E.A., Skolnick, P., Olsen, R.W., Mohler, R.W., Sieghart, W., Biggio, G., Braestrup, C., Bateson, A.N. and Langer, S.Z. (1998). International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acid A receptors: classification on the basis of subunit structure and receptor function. *Pharmacol Rev.* **50**:291-313.

- Bean, B.P. (1992). Pharmacology and electrophysiology of ATP-activated ion channels. *Trends Pharmacol Sci.* **13**:87-90.
- Bergfeld, G.R. and Forrester, T. (1989). Efflux of adenosine triphosphate from human erythrocytes in response to a brief pulse of hypoxia. *Proc Physiol Soc.* **418**:88.
- Bian, X., Ren, J., DeVries, M., Schnegelsberg, B., Cockayne, D.A., Ford, A.P. and Galligan, J. (2003). Peristalsis is impaired in the small intestine of mice lacking the P2X<sub>3</sub> subunits. *J Physiol.* **551**:309-322.
- Bo, X., Alavi, A., Xiang, Z., Oglesby, I., Ford, A. and Burnstock, G. (1999). Localization of ATP-gated P2X<sub>2</sub> and P2X<sub>3</sub> receptor immunoreactive nerves in rat taste buds. *Neuroreport* **10**: 1107-1111.
- Bo, X., Zhang, Y., Nassar, M., Burnstock, G. and Schoepfer, R. (1995). A P2X purinoceptor cDNA conferring a novel pharmacological profile. *FEBS Lett.* **375**:129-133.
- Boarder, M.R. and Hourani, S.M. (1998). The regulation of vascular function by P2 receptors: multiple sites and multiple receptors. *Trends Pharmacol Sci.* **19**:99-107.
- Bodin, P., Bailey, D.J. and Burnstock, G. (1991). Increased flow-induced ATP release from isolated vascular endothelial but not smooth muscle cells. *Br J Pharmacol.* **103**:1203-1205.
- Bodin, P. and Burnstock, G. (1996). ATP-stimulated release of ATP by human endothelial cells. *J Cardiovasc Pharmacol.* **27**:872-875.
- Bodin, P. and Burnstock, G. (2001a). Purinergic signaling: ATP release. *Neurochem Res.* **26**: 959-969.
- Bodin, P. and Burnstock, G. (2001b). Evidence that release of ATP from endothelial cells during increased shear stress is vesicular. *J Cardiovasc Pharmacol.* **38**: 900-908.
- Bogdanov, Y.D., Dale, L., King, B.F., Whittock, N. and Burnstock, G. (1997). Early expression of a novel nucleotide receptor in the neural plate of *Xenopus* embryos. *J Biol Chem.* **272**:12583-12590.

- Bogdanov, Y., Rubino, A. and Burnstock, G. (1998a). Characterization of subtypes of the P2X and P2Y families of ATP receptors in the foetal human heart. *Life Sci.* **62**:697-703.
- Bogdanov, Y.D., Wildman, S.S., Clements, M.P., King, B.F. and Burnstock, G. (1998b). Molecular cloning and characterization of rat P2Y<sub>4</sub> nucleotide receptor. *Br J Pharmacol.* **124**:428-430.
- Brake, A.J., Wagenbach, M.J. and Julius, D. (1994). New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. *Nature (Wash. DC)*. **371**:519-523
- Brändle, U., Güenther, E., Irrle, C. and Wheeler-Schilling, T.H. (1998). Gene expression of the P2X receptors in the rat retina. *Brain Res Mol Brain Res.* **59**:269-272.
- Brändle, U., Zenner, H-P. and Ruppertsberg, J.P. (1999). Gene expression of P2X receptors in the developing inner ear of the rat. *Neurosci Lett.* **273**:105-108.
- Briscoe, J., Sussel, L., Serup, P, Hartigan-O'Connor, D., Jessell, T.M., Rubenstein, J.L. and Ericson, J. (1999). Homeobox gene Nkx2.2 and specification of neuronal identity by graded Sonic hedgehog signaling. *Nature* **398**:622-627.
- Bronner-Fraser, M. and Fraser, S.E. (1997). Differentiation of the vertebrate neural tube. *Curr Opin Cell Biol.* **9**:885-891.
- Buckingham, M. (2001). Skeletal muscle formation in vertebrates. *Curr Opin Genet Dev.* **11**:440-448.
- Buckingham, M., Bajard, L., Chang, T., Daubas, P., Hadchouel, J., Meilhac, S., Montarras, D., Rocancourt, D. and Relaix, F. (2003). The formation of skeletal muscle: from somite to limb. *J Anat.* **202**:59-68.
- Buell, G., Lewis, C., Collo, G., North, R.A. and Surprenant, A. (1996). An antagonist-insensitive P2X receptor expressed in epithelia and brain. *EMBO J.* **15**:55-62.
- Burnstock, G. (1972). Purinergic nerves. *Pharmacol Rev.* **24**:509-581.
- Burnstock, G. (1976). Do some nerve cells release more than one transmitter? *Neuroscience*

- 1:239-248.
- Burnstock, G. (1978). A basis for distinguishing two types of purinergic receptor. In: *Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach*. Eds. R.W. Straub & L. Bolis, Raven Press, New York. pp. 107-118.
- Burnstock, G. (1979). The purinergic nerve hypothesis. In: *Physiological and regulatory functions of adenosine and adenosine nucleotides*. Eds. H.P. Baer & G.I. Drummond, Raven Press, New York. pp. 3-32.
- Burnstock, G. (1986). The changing face of autonomic neurotransmission. (The First von Euler Lecture in Physiology). *Acta Physiol Scand.* **126**:67-91.
- Burnstock, G. (1990). Co-transmission. The Fifth Heymans Lecture - Ghent, February 17, 1990. *Arch Int Pharmacodyn Ther.* **304**:7-33.
- Burnstock, G. (1996). Purinoceptors: ontogeny and phylogeny. *Drug Dev Res.* **39**:204-242.
- Burnstock, G. (1997). The past, present and future of purine nucleotides as signaling molecules. *Neuropharmacology* **36**:1127-1139.
- Burnstock, G. (1999a). Purinergic cotransmission. *Brain Res. Bull.* **50**, 355-357.
- Burnstock, G. (1999b). Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. *J Anat.* **194**: 335-342.
- Burnstock, G. (2001). Purinergic signalling in development. In: *Handbook of Experimental Pharmacology, Volume 151/I. Purinergic and Pyrimidinergic Signalling I - Molecular, Nervous and Urinogenitary System Function*, Eds. Abbracchio, M.P. & Williams, M., Springer-Verlag, Berlin. pp. 89-127.
- Burnstock, G. (2002a). Purinergic signaling and vascular cell proliferation and death. *Arterioscler Thromb Vasc Biol.* **22**:364-373.
- Burnstock G. (2002b). Potential therapeutic targets in the rapidly expanding field of purinergic signalling. *Clin Med.* **2**:45-53.

- Burnstock, G. (2003a). Introduction: ATP and its metabolites as potent extracellular agonists. In: *Current Topics in Membranes Vol 54. 'Purinergic Receptors and Signalling.'* Ed E.M. Schwiebert. Academic Press, San Diego, pp. 1-27.
- Burnstock, G. (2003b). Purinergic receptors in the nervous system. In: *Current Topics in Membranes, Vol 54. 'Purinergic Receptors and Signalling.'* Ed E.M. Schwiebert. Academic Press, San Diego, pp. 307-368.
- Burnstock, G., Campbell, G., Bennett, M. and Holman, M.E. (1963). Inhibition of the smooth muscle of the taenia coli. *Nature* **200**:581-582.
- Burnstock, G., Campbell, G., Bennett, M. and Holman, M.E. (1964). Innervation of the guinea-pig taenia coli: are there intrinsic inhibitory nerves which are distinct from sympathetic nerves? *Int J Neuropharmacol.* **3**: 163-166.
- Burnstock, G., Campbell, G., Satchell, D. and Smythe, A. (1970). Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. *Br J Pharmacol.* **40**:668-688.
- Burnstock, G., Cocks, T., Kasakov, L. and Wong, H.K. (1978). Direct evidence for ATP release from non-adrenergic, non-cholinergic ("purinergic") nerves in the guinea-pig taenia coli and bladder. *Eur J Pharmacol.* **49**:145-149.
- Burnstock, G. and Kennedy, C. (1985). Is there a basis for distinguishing two types of P<sub>2</sub>-purinoceptor? *Gen. Pharmacol.* **16**:433-440.
- Burton, P.B.J., Raff, M.C., Kerr, P., Yacoub, M.H. and Barton, P.J.R. (1999). An intrinsic timer that controls cell-cycle withdrawal in cultured cardiac myocytes. *Dev Biol.* **216**:659-670.
- Cario-Toumaniantz, C., Loirand, G., Ladoux, A. and Pacaud, P. (1998). P<sub>2</sub>X<sub>7</sub> receptor activation-induced contraction and lysis in human saphenous vein smooth muscle. *Circ Res.* **83**:196-203.
- Caton, A., Hacker, A., Naeem, A., Livet, J., Maina, F., Bladt, F., Klein, R., Birchmeier, C. and Guthrie, S. (2000). The branchial arches and HGF are growth-promoting and



- chemoattractant for cranial motor axons. *Development* **127**:1751-1760.
- Chakfe, Y., Seguin, R., Antel, J.P., Morissette, C., Malo, D., Henderson, D. and Séguéla, P. (2002). ADP and AMP induce interleukin-1 release from microglial cells through activation of ATP-primed P2X<sub>7</sub> receptor channels. *J Neurosci.* **22**:3061-3069.
- Chalice, C.E. and Viragham S. (1973) The architectural development of the early mammalian heart. *Tissue Cell.* **6**:447-462.
- Chambers, J.K., Macdonald, L.E., Sarau, H.M., Ames, R.S., Freeman, K., Foley, J.J., Zhu, Y., McLaughlin, M.M., Murdock, P., McMillan, L., Trill, J., Swift, A., Aiyar, N., Taylor, P., Vawter, L., Naheed, S., Szekeres, P., Hervieu, C., Scott, C., Watson, J.M., Murphy, A.J., Duzic, E., Klein, C., Bergsma, D.J., Wilson, S. and Livi, G.P. (2000). A G protein-coupled receptor for UDP glucose. *J Biol Chem.* **275**:10767-10771.
- Chang, K., Hanaoka, K., Kumada, M. and Takuwa, Y. (1995). Molecular cloning and functional analysis of a novel P<sub>2</sub> nucleotide receptor. *J Biol Chem.* **270**:26152-26158.
- Charlton, M.E., Williams, A.S., Fogliano, M., Sweetnam, P.M. and Duman, R.S. (1997). The isolation and characterization of a novel G protein-coupled receptor regulated by immunologic challenge. *Brain Res.* **764**:141-148.
- Chaudry, I.H. (1982). Does ATP cross the cell plasma membrane. *Yale J Biol Med.* **55**:1-10.
- Chen, C.C., Akopian, A.N., Sivilotti, L., Colquhoun, D., Burnstock, G. and Wood, J.N. (1995). A P2X purinoceptor expressed by a subset of sensory neurons. *Nature* **377**:428-431.
- Cheung, K. K. and Burnstock, G. (2002). Localization of P2X<sub>3</sub> receptor and the coexpression of with P2X<sub>2</sub> receptor during rat embryonic neurogenesis. *J Comp Neurol.* **443**:368-382.
- Cheung, K.K., Ryten, M. and Burnstock, G (2003). Abundant and dynamic expression of G protein-coupled P2Y receptors in mammalian development. *Dev Dyn.* (in press).
- Chi, N. and Epstein, J.A. (2002). Getting your Pax straight: Pax proteins in development and disease. *Trends Genet.* **18**:41-47.
- Choi, R.C., Man, M.L., Ling, K.K. Ip, N.Y., Simon, J., Barnard, E.A. and Tsim, K.W. (2001).

- Expression of the P2Y<sub>1</sub> nucleotide receptor in chick muscle: its functional role in the regulation of acetylcholinesterase and acetylcholine receptor. *J Neurosci.* **21**:9224-9234.
- Churchill, G.C. and Louis, C.F. (1997). Stimulation of P<sub>2U</sub> purinergic or  $\alpha_{1A}$ adrenergic receptors mobilizes calcium in the lens cells. *Invest Ophthalmol Vis Sci.* **38**:855-865.
- Cockayne, D.A., Hamilton, S.G., Zhu, Q.M., Dunn, P.M., Zhong, Y., Novakovic, A., Malmberg, A.B., Cain, G., Berson, A., Kassotakis, L., Hedley, L., Lachnit, W.G., Burnstock, G., McMahon, S.B. and Ford, A.P.D.W. (2000). Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X<sub>3</sub>-deficient mice. *Nature* **407**: 1011-1015.
- Collet, C., Strube, C., Csernoch, L., Mallouk, N., Ojeda, C., Allard, B. and Jacquemond, V. (2002). Effects of extracellular ATP on freshly isolated mouse skeletal muscle cells during pre-natal and post-natal development. *Pflugers Arch.* **443**:771-778.
- Collison, D.J. and Duncan, G. (2001). Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. *Invest Ophthalmol Vis Sci.* **42**:2355-63.
- Collo, G., Neidhart, S., Kawashima, E., Kosco-Vilbois, M., North, R.A. and Buell, G. (1997). Tissue distribution of the P2X<sub>7</sub> receptor. *Neuropharmacology* **36**: 1277-1283.
- Collo, G., North, R.A., Kawashima, E., Merlo-Pich, R., Neidhart, S., Surprenant, A. and Buell, G. (1996). Cloning of P2X<sub>5</sub> and P2X<sub>6</sub> receptors and the distribution and properties of an extended family of ATP-gated ion channels. *J Neurosci.* **16**:2495-2507.
- Communi, D., Janssens, R., Robaye, B., Zeelis, N. and Boeynaems, J.M. (2000). Rapid up-regulation of P2Y messengers during granulocytic differentiation of HL-60 cells. *FEBS Lett.* **475**:39-42.
- Communi, D., Motte, S., Boeynaems, J.M. and Piroton, S. (1996). Pharmacological characterization of the human P2Y<sub>4</sub> receptor. *Eur J Pharmacol.* **317**:383-389.
- Communi, D., Robaye, B. and Boeynaems, J.M. (1999). Pharmacological characterization of the human P2Y<sub>11</sub> receptor. *Br J Pharmacol.* **128**:1199-1206.

- Conigrave, A.D., Lee, J.Y., van der Weyden, L., Jiang, L., Ward, P., Tasevski, V., Lettrell, B.M. and Morris, M.B. (1998). Pharmacological profile of a novel cyclic AMP-linked P2 receptor on undifferentiated HL-60 leukemia cells. *Br J Pharmacol.* **124**:1580-1585.
- Conover, J.C. and Allen, R.L. (2002). The subventricular zone: new molecular and cellular developments. *Cell Mol Life Sci.* **59**:2128-2135.
- Contrina, M.L., Lin, J.H., Alves-Rodrigues, A., Liu, S., Li, J., Azmi-Ghadimi, H., Kang, J., Naus, C.C. and Nedergaard, M. (1998). Connexin regulate calcium signaling by controlling ATP release. *Proc Natl Acad Sci USA.* **95**:15735-15740.
- Cook, S.P. and McCleskey, E.W. (1997). Desensitization, recovery and Ca<sup>2+</sup> dependent modulation of ATP-gated P2X receptors in nociceptors. *Neuropharmacology* **36**:1303-1308.
- Cook, S.P., Rodland, K.D. and McCleskey, E.W. (1998). A memory for extracellular Ca<sup>2+</sup> by speeding recovery of P2X receptors from desensitization. *J Neurosci.* **18**:9238-9244.
- Cook, S.P., Vulchanova, L., Hargreaves, K.M., Elde, R. and McCleskey, E.W. (1997). Distinct ATP receptors on pain-sensing and stretch-sensing neurons. *Nature* **387**:505-508.
- Coutinho-Silva, R., Parsons, M., Robson, T. and Burnstock, G. (2001). Changes in expression of P2 receptors in rat and mouse pancreas during development and ageing. *Cell Tissue Res.* **306**:373-383.
- Coutinho-Silva, R., Parsons, M., Robson, T., Lincoln, J. and Burnstock, G. (2003). P2X and P2Y purinoceptor expression in pancreas from streptozotocin-diabetic rats. *Mol Cell Endocrinol.* **204**:141-154.
- Czajkowski, R., Lei, L., Sabala, P. and Baranska, J. (2002). ADP-evoked phospholipase C stimulation and adenylyl cyclase inhibition in glioma C6 cells occur through two distinct nucleotide receptors, P2Y(1) and P2Y (12). *FEBS Lett.* **513**:179-183.
- D'Ambrosi, N., Murra, B., Cavaliere, F., Amadio, S., Bernardi, G., Burnstock, G. and Volonte, C. (2001). Interaction between ATP and nerve growth factor signaling in the survival and neuritic outgrowth from PC12 cells. *Neuroscience* **108**:527-534.

- De Jong, F., Opthof, T., Wilde, A.A.M., Janse, M.J., Charles, R., Lamers, W.H. and Moorman, A.F.M. (1992). Persisting zones of slow conduction in the developing chicken hearts. *Circ Res.* **71**:240-250.
- Detwiler, T.C. and Feinman, R.D. (1973). Kinetics of the thrombin-induced release of adenosine triphosphate by platelets. Comparison with release of calcium. *Biochemistry* **12**:2462-2468.
- Deuchars, S.A., Atkinson, L., Brooke, R.E., Musa, H., Milligan, C.J., Batten, T.F.C., Buckley, N.J., Parson, S.H. and Deuchars, J. (2001). Neuronal P2X<sub>7</sub> receptors are targeted to presynaptic terminals in the central and peripheral nervous systems. *J Neurosci.* **21**:7143-7152.
- Ding, S. and Sachs, F. (1999). Ion permeability and block of P2X<sub>2</sub> purinoceptors: single channel recordings. *J Membr Biol.* **172**:215-223.
- Ding, S. and Sachs, F. (2000). Inactivation of P2X<sub>2</sub> purinoceptors by divalent cations. *J Physiol.* **522**:199-214.
- Di Virgilio, F. (2000). Dr. Jekyll/Mr. Hyde: the dual role of extracellular ATP. *J Auton Nerv Syst.* **81**, 59-63.
- Dixon, C.J., Woods, N.M., Webb, T.E. and Green, A.K. (2000). Evidence that rat hepatocytes co-express functional P2Y<sub>1</sub> and P2Y<sub>2</sub> receptors. *Br J Pharmacol.* **129**:764-770.
- Dodd, J., Jessell, T.M. and Placzek, M. (1998). The when and where of floor plate induction. *Science* **282**:1654-1657.
- Doetsch, F., Caille, I., Lim, D.A., Garcia-Verdugo, J.M. and Alvarez-Buylla, A. (1999). Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. *Cell* **97**:703-716.
- Dranoff, J.A., Masyuk, A.I., Kruglov, E.A., LaRusso, N.F. and Nathanson, M.H. (2001). Polarized expression and function of P2Y ATP receptors in rat bile duct epithelia. *Am J*

- Physiol Gastrointest Liver Physiol.* **281**:1059-1067.
- Drury, A.N. and Szent-Györgyi, A. (1929). The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. *J Physiol. (Lond)* **68**:213-237.
- Dubyak, G.R. and el-Moatassim, C. (1993). Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. *Am J Physiol.* **265**:C577-C606.
- Dunn, P.M., Liu, M., Zhong, Y., King, B.F. and Burnstock, G. (2000). Diinosine pentaphosphate: an antagonist which discriminates between recombinant P2X<sub>3</sub> and P2X<sub>2/3</sub> receptors and between two P2X receptors in rat sensory neurones. *Br J Pharmacol.* **130**: 1378-1384.
- Ericson, J., Thor, S., Jessell, T.M., Edlund, T. and Yamada, T. (1992). Early stages of motor neuron differentiation revealed by expression of homeobox gene *Islet-1*. *Science* **256**:1555-1560.
- Evans, R.J., Lewis, C., Virginio, C., Lundstrom, K., Buell, G., Surprenant, A. and North, R.A. (1996). Ionic permeability of, and divalent cation effects on, two ATP-gated cation channels (P2X receptors) expressed in mammalian cells. *J Physiol (Lond)*. **497**:413-422.
- Fam, S.R., Gallagher, C.J. and Salter, M.W. (2000). P2Y(1) purinoceptor-mediated Ca<sup>(2+)</sup> signaling and Ca<sup>(2+)</sup> wave propagation in dorsal spinal cord astrocytes. *J Neurosci.* **15**:2800-2808.
- Ferguson, D.R., Kennedy, I. and Burton, T.J. (1997). ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes—a possible sensory mechanism? *J Physiol.* **505**:503-511.
- Fishman, M.C. and Chien, K.R. (1997). Fashioning the vertebrate heart: earliest embryonic decisions. *Development* **124**:2099-2117.
- Fiske, C.H. and Subbarow, Y. (1929). Phosphorous compounds of muscle and liver. *Science*

- 70:381-384.
- Florenzano, F., Viscomi, M.T., Cavaliere, F., Volonte, C. and Molinari, M. (2002). Cerebellar lesion up-regulates P2X<sub>1</sub> and P2X<sub>2</sub> purinergic receptors in precerebellar nuclei. *Neuroscience* **115**:425-434.
- Forrester, T. and Lind, A.R. (1969). Identification of adenosine triphosphate in human plasma and the concentration in the venous effluent of forearm muscles before, during and after sustained contractions. *J Physiol.* **204**:347-364.
- Franco, D., Lamers, W.H. and Moorman, A.F. (1998). Patterns of expression in the developing myocardium: towards a morphologically integrated transcriptional model. *Cardiovasc Res.* **38**:25-53.
- Franke, H., Grosche, J., Schadlich, H., Krugel, U., Allgaier, C. and Illes, P. (2001). P2X receptor expression on astrocytes in the nucleus accumbens of rats. *Neuroscience* **108**:421-429.
- Fu, W.M. (1994). Potentiation by ATP of the postsynaptic acetylcholine response at developing neuromuscular synapses in *Xenopus* cell cultures. *J Physiol (Lond)*. **447**:449-458.
- Fu, W.M. and Huang, F.L. (1994). Potentiation by endogenously released ATP of spontaneous transmitter secretion at developing neuromuscular synapses in *Xenopus* cell cultures. *Br J Pharmacol.* **111**:880-886.
- Fu, W.M. and Poo, M.M. (1991). ATP potentiates spontaneous transmitter release at developing neuromuscular synapses. *Neuron* **6**:837-843.
- Fu, W.M., Chen Y.H., Lee, K.F. and Liou, J.C. (1997). Regulation of quantal transmitter secretion by ATP and protein kinases at developing neuromuscular synapses. *Eur J Neurosci.* **9**:676-685.
- Garzia-Guzman, M., Soto, F., Laube, B. and Stühmer, M. (1996). Molecular cloning and functional expression of a novel rat heart P2X purinoceptor. *FEBS Lett.* **388**:123-127.
- Gassmann, M., Casagrande, F., Orioli, D., Simon, H., Lai, C., Klein, R. and Lemke, G. (1995).

- Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. *Nature* **378**:390-384.
- Glass, R. and Burnstock, G. (2001). Immunohistochemical identification of cells expressing ATP-gated cation channels (P2X receptors) in the adult rat thyroid. *J Anat.* **198**:569-579.
- Glass, R., Townsend-Nicholson, A. and Burnstock, G. (2000). P2 receptors in the thymus: expression of P2X and P2Y receptors in adult rats, an immunohistochemical and in situ hybridization study. *Cell Tissue Res.* **300**: 295-306.
- Glynn, I.M. (1968). Membrane adenosine triphosphatase and cation transport. *Br Med Bull.* **24**:165-169.
- Goulding, M.D., Lumsden, A. and Gruss, P. (1993). Signals from the notochord and floor plate regulate the region-specific expression of two *Pax* genes in the developing spinal cord. *Development* **117**:1001-1016.
- Graff, R.D., Lazarowski, E.R., Banes, A.J. and Lee, G.M. (2000). ATP release by mechanically loaded porcine chondrons in pellet culture. *Arthritis Rheum.* **43**:1571-1579.
- Greenwood, D., Yao, W.P. and Housley, G.D. (1997). Expression of the P2X<sub>2</sub> receptor subunit of the ATP-gated ion channel in the retina. *Neuroreport* **8**:1083-1088.
- Gröschel-Stewart, U., Bardini, M., Robson, T. and Burnstock, G. (1999a). Localization of P2X<sub>5</sub> and P2X<sub>7</sub> receptors by immunohistochemistry in rat stratified squamous epithelia. *Cell Tissue Res.* **296**:599-605.
- Gröschel-Stewart, U., Bardini, M., Robson, T. and Burnstock, G. (1999b). P2X receptors in the rat duodenal villus. *Cell Tissue Res.* **297**:111-117.
- Guthrie, S. and Lumsden, A. (1994). Collagen gel coculture of neural tissue. *Neuroprotocol* **4**:116-120.
- Guz, Y., Montminy, M.R., Stein, R., Leonard, J., Gamer, L.W., Wright, C.V.E. and Teitelman, G. (1995). Expression of murine STF-1, a putative insulin gene transcription factor, in cells of

- pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. *Development* **121**:11-18.
- Haines, W.R., Torres, G.E., Voigt, M.M. and Egan, T.M. (1999). Properties of the novel ATP-gated ionotropic receptor composed of the P2X<sub>1</sub> and P2X<sub>5</sub> isoforms. *Mol Pharmacol.* **56**:720-727.
- Hansen, M.A., Bennett, M.R. and Barden, J.A. (1999). Distribution of purinergic P2X receptors in the rat heart. *J Auton Nerv Syst.* **78**:1-9.
- Harada, H., Chan, C.M., Loesch, A., Unwin, R. and Burnstock, G. (2000). Induction of proliferation and apoptotic cell death via P2Y and P2X receptors, respectively, in rat glomerular mesangial cells. *Kidney Int.* **57**:949-958.
- Hazama, A., Hayashi, S. and Okada, Y. (1998). Cell surface measurements of ATP release from single pancreatic  $\beta$  cells using a novel biosensor technique. *Pflugers Arch.* **437**:31-35.
- Hede, S.E., Amstrup, J., Christoffersen, B.C. and Novak, I. (1999). Purinoceptors evoke different electrophysiological responses in pancreatic ducts. P2Y inhibits K (+) conductance, and P2X stimulates cation conductance. *J Biol Chem.* **274**:31784-31791.
- Herrera, P. L. (2000). Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. *Development* **127**:2317-2322.
- Herrera, P.L., Huarte, J., Sanvito, F., Meda, P., Orci, L. and Vassalli, J.D. (1991). Embryogenesis of the murine endocrine pancreas, early expression of pancreatic polypeptide gene. *Development* **113**:1257-1265.
- Hilfer, S.R., Palmatier, B.Y. and Fithian, E.M. (1977). Precocious evagination of the embryonic chick thyroid in ATP-containing medium. *J Embryol Exp Morphol.* **42**:163-175.
- Hoebertz, A., Meghji, S., Burnstock, G. and Arnett, T.R. (2001). Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y(1) receptor on bone cells. *FASEB J.* **15**:1139-1148.
- Hoebertz, A., Townsend-Nicholson, A., Glass, R., Burnstock, G. and Arnett, T.R. (2000).



- Expression of P2 receptors in bone and cultured bone cells. *Bone* **27**:503-510.
- Hofman, P.L., Hiatt, K., Yoder, M.C. and Rivkees, S.A. (1997). A<sub>1</sub> adenosine receptors potently regulate heart rate in mammalian embryos. *Am J Physiol.* **273**:R1374-R1380.
- Hollopeter, G., Jantzen, H.M., Vincent, D., Li, G., England, L., Ramakrishnan, V., Yang, R.B., Nurden, P., Nurden, A., Julius, D. and Conley, P.B. (2001). Identification of the platelet ADP receptor targeted by antithrombotic drugs. *Nature* **409**:202-207.
- Holton, P. (1959). The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves. *J Physiol. (Lond)* **145**:494-504.
- Hou, M., Malmsjo, M., Moller, S., Pantev, E., Nergdahl, A., Zhao, X.H., Sum, X.Y., Hedner, T., Edvinsson, L. and Erlinge, D. (1999). Increase in cardiac P2X<sub>1</sub>-and P2Y<sub>2</sub>-receptor mRNA levels in congestive heart failure. *Life Sci.* **65**:1195-1206.
- Housley, G.D., Kanjhan, R., Raybould, N.P., Greenwood, D., Salih, S.G., Jarlebark, L., Burton, L.D., Setz, V.C., Cannell, M.B., Soeller, C., Christie, D.L., Usami, S., Matsubara, A., Yoshie, H., Ryan, A.F. and Thorne, P.R. (1999). Expression of the P2X(2) receptor subunit of the ATP-gated ion channel in the cochlea: implications for sound transduction and auditory neurotransmission. *J Neurosci.* **19**:8377-8388.
- Hu, B., Mei, Q.B., Yao, X.J., Smith, E., Barry, W.H. and Liang, B.T. (2001). A novel contractile phenotype with cardiac transgenic expression of the human P2X<sub>4</sub> receptor. *FASEB J.* **15**:2739-2741.
- Hu, B., Senkler, C., Yang, A., Soto, F. and Liang, B. T. (2002). P2X<sub>4</sub> receptor is a glycosylated cardiac receptor mediating a positive inotropic response to ATP. *J Biol Chem.* **277**:15752-15757.
- Hughes, J. and Vane, J.R. (1967). An analysis of the responses of the isolated portal vein of the rabbit to electrical stimulation and to drugs. *Br J Pharmacol Chemother.* **30**:46-66.
- Hume, R.I. and Höning, M.G. (1986). Excitatory action of ATP on embryonic chick muscle. *J Neurosci.* **6**:681-690.

- Idzko, M., Dichmann, S., Ferrari, D., Di Virgilio, F., la Sala, A., Girolomoni, G., Panther, E. and Norgauer, J. (2002). Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2Y receptors. *Blood* **100**:925-32.
- Ishikawa, Y., Satoh, T., Enokido, Y., Nishio, C., Ikeuchi, T. and Hatanaka, H. (1999). Generation of reactive oxygen species, release of L-glutamate and activation of caspases are required for oxygen-induced apoptosis of embryonic hippocampal neurons in culture. *Brain Res.* **824**:71-80.
- Jacob, J., Hacker, A. and Guthrie, S. (2001). Mechanisms and molecules in motor neuron specification and axon pathfinding. *Bioessays* **23**:582-595.
- Jiang, L., Foster, F.M., Ward, P., Tasevski, V., Luttrell, B.M. and Conigrave, A.D. (1997). Extracellular ATP triggers cyclic AMP-dependent differentiation of HL-60 cells. *Biochem Biophys Res Commun.* **236**:626-630.
- Jin, J. P. (1996). Alternative RNA splicing-generated cardiac troponin T isoform switching: a non-heart-restricted genetic programming synchronized in developing cardiac and skeletal muscles. *Biochem Biophys Res Commun.* **225**:883-889.
- Johansson, C.B., Momma, S., Clarke, D.L., Risling, M.I., Lendahl, U. and Frisén, J. (1999). Identification of a neural stem cell in the adult mammalian central nervous system. *Cell* **96**:25-34.
- Kalckar, H.M. (1969). *Biological Phosphorylations: Development of Concepts*. Prentice Hall, Englewood Cliffs, NJ.
- Kanjhan, R., Housley, G.D., Burton, L.D., Christie, D.L., Kippenberger, A., Thorne, P.R., Luo, L. and Ryan, A.F. (1999). Distribution of the P2X<sub>2</sub> receptor subunit of the ATP-gated ion channels in the rat central nervous system. *J Comp Neurol.* **407**: 11-32.
- Kaufman, M.H. (1992). *The atlas of mouse development*. London: Academic Press.

- Kaufman, M.H. and Bard, J.B.L. (1999). The anatomical basis of mouse development. London: Academic Press.
- Ke, H.Z., Qi, H., Weidema, A.F., Zhang, Q., Panupinthu, N., Crawford, D.T., Grasser, W.A., Paralkar, V.M., Li, M., Audoly, L.P., Gabel, C.A., Jee, W.S., Dixon, S.J., Sims, S.M. and Thompson, D.D. (2003). Deletion of the P2X<sub>7</sub> nucleotide receptor reveals its regulatory roles in bone formation and resorption. *Mol Endocrinol.* 17:1356-1367.
- Kellerman, D.J. (2002). P2Y<sub>2</sub> receptor agonists: a new class of medication targeted at improved mucociliary clearance. *Chest* 121:201S-205S.
- Kennedy, C. and Burnstock, G. 1985. Evidence for the presence of two types of P2 purinoceptor in the longitudinal muscle of rabbit portal vein. *Eur J Pharmacol* 111: 49-56.
- Kidd, E.J., Grahames, C.B.A, Simon, J., Michel, A.D., Barnard, E.A. and Humphrey, P.P.A. (1995). Localization of P2X purinoceptor transcript in the rat nervous system. *Mol Pharmacol.* 48:569-573.
- Kidd, E.J., Miller, K.J., Sansum, A.J. and Humphrey, P.P. (1998). Evidence for P2X<sub>3</sub> receptors in the developing rat brain. *Neuroscience* 87:533-539.
- King, B.F., Townsend-Nicholson, A., Wildman, S.S., Thomas, T., Spyer, K.M. and Burnstock, G. (2000). Coexpression of rat P2X<sub>2</sub> and P2X<sub>6</sub> subunits in *Xenopus* oocytes. *J Neurosci.* 20:4871-4877.
- King, B.F., Ziganshina, L.E., Pintor, J. and Burnstock, G. (1996). Full sensitivity of P2X<sub>2</sub> purinoceptor to ATP revealed by changing extracellular pH. *Br J Pharmacol.* 117:1371-1373.
- Kolb, H-A. and Wakelam, M.J.O. (1983). Transmitter-like action of ATP on patched membranes of cultured myoblasts and myotubes. *Nature* 303:621-623.
- Komuro, H. and Rakic, P. (1996). Intracellular Ca<sup>2+</sup> fluctuations modulate the rate of neuronal migration. *Neuron* 17:275-285.

- Koshimizu, T.A., Ueno, S., Tanoue, A., Yanagihara, N., Stojilkovic, S.S. and Tsujimoto, G. (2002). Heteromultimerization modulates P2X receptor functions through participating extracellular and C-terminal subdomains. *J Biol Chem.* **277**:46891-46899.
- Kukley, M., Barden, J.A., Steinhauser, C. and Jabs, R. (2001). Distribution of P2X receptors on astrocytes in juvenile rat hippocampus. *Glia* **36**:11-21.
- Kulick, M.B. and von Kügelgen, I. (2002). P2Y-receptors mediating an inhibition of the evoked entry of calcium through N-type calcium channels at neuronal processes. *J Pharmacol Exp Ther.* **303**:520-526.
- Kunapuli, S. P. and Daniel, J. L. (1998). P2 receptor subtypes in the cardiovascular system. *Biochem J.* **336**:513-523.
- Laasberg, T. 1990. Ca<sup>2+</sup>-mobilizing receptors of gastrulating chick embryo. *Comp Biochem Physiol. C* **97**: 1-12
- Labasi, J.M., Petrushova, N., Donovan, C., McCurdy, S., Lira, P., Payette, M.M., Brissette, W., Wicks, J.R., Audoly, L. and Gabel, C.A. (2002). Absence of the P2X<sub>7</sub> receptor alters leukocyte function and attenuates an inflammatory response. *J Immunol.* **168**:6436-6445.
- Labrakakis, C., Gerstner, E. and Macdermott, A.B. (2000). Adenosine triphosphate-evoked currents in cultured dorsal root ganglion neurons obtained from rat embryos; desensitization kinetics and modulation of glutamate release. *Neuroscience* **101**:1117-1126.
- Lalevée, N., Rogier, C., Becq, F. and Joffre, M. (1999). Acute effects of adenosine triphosphates, cyclic 3',5'-adenosine monophosphates, and follicle-stimulating hormone on cytosolic calcium level in cultured immature rat Sertoli cells. *Biol Reprod.* **61**:343-352.
- Langer, S.Z. and Pinto, J.E. (1976). Possible involvement of a transmitter different from norepinephrine in the residual responses to nerve stimulation of the cat nictitating membrane after pretreatment with reserpine. *J Pharmacol. Exp Ther.* **196**:697-713.
- Langley, J.N. and Anderson, H.K. (1895). *J Physiol. (Lond)* **19**:122-130.
- Larsen, W.J. (1998). *Essentials of Human Embryology*. Churchill Livingstone. New York.

- Larsson, L. I. (1998). On the development of the islets of Langerhans. *Microsc Res Tech.* **43**:284-291.
- Laywell, E.D., Rakic, P., Kukekov, V.G., Holland, E.C. and Steindler, D.A. (2000). Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. *Proc Natl Acad Sci USA.* **97**:13883-13888..
- Le, K.T., Babinski, K. and Séguéla, P. (1998). Central P2X<sub>4</sub> and P2X<sub>6</sub> channel subunits coassemble into a novel heteromeric ATP receptor. *J Neurosci.* **18**:7152-7159.
- Le Douarin, N.M. and Kalcheim, C. 1999. *The neural crest.* 2nd ed. Cambridge: Cambridge University Press.
- Le Feuvre, R., Brough, D. and Rothwell, N. (2002). Extracellular ATP and P2X<sub>7</sub> receptors in neurodegeneration. *Eur J Pharmacol.* **447**:261-269.
- Lee, K.F., Simon, H., Chen, H., Bates, B., Hung, M.C., Hauser, C. (1995). Requirement for neuregulin receptor erbB2 in neural and cardiac development. *Nature* **378**:394-398.
- Lewis, C.J., Neidhart, S., Holy, C., North, R.A., Buell, G. and Surprenant, A. (1995). A coexpression of P2X<sub>2</sub> and P2X<sub>3</sub> receptor subunits can account for ATP-gated currents in sensory neurones. *Nature* **377**:432-434.
- Litingtung, Y. and Chiang, C. (2000). Control of Shh activity and signaling in the neural tube. *Dev Dyn.* **219**:143-154.
- Liu, M., King, B., Dunn, P.M., Rong, W., Townsend-Nicholson, A. and Burnstock, G. (2001). Coexpression of P2X<sub>3</sub> and P2X<sub>2</sub> receptor subunits in varying amounts generates heterogeneous populations of P2X receptors that evoke a spectrum of agonist responses comparable to that seen in sensory neurons. *J Pharmacol Exp Ther.* **296**:1043-1050.
- Llewellyn-Smith, I.J. and Burnstock, G. (1998). Ultrastructural localization of P2X<sub>3</sub> receptors in rat sensory neurons. *Neuroreport* **9**: 2545-2550.
- Loesch, A. and Burnstock, G. (1998). Electron-immunocytochemical localization of the P2X<sub>1</sub>

- receptors in the rat cerebellum. *Cell Tissue Res.* **294**:253-260.
- Loesch, A. and Burnstock, G. (2001). Immunoreactivity to P2X(6) receptors in the rat hypothalamo-neurohypophysial system: an ultrastructural study with extravidin and colloidal gold-silver labeling. *Neuroscience* **106**:621-631.
- Lohmann, K. (1929). Über die pyrophosphat fraction in muskel. *Naturwissenschaften.* **17**:624-628.
- Loubatières-Mariani, M.M. and Chapal, J. (1988). Purinergic receptors involved in the stimulation of insulin and glucagon secretion. *Diabete Metabolism (Paris).* **14**:119-126.
- Lustig, K.D., Shiau, A.K., Brake, A.J. and Julius, D. (1993). Expression cloning of an ATP receptor from mouse neuroblastoma cells. *Proc Natl Acad Sci USA.* **90**:5113-5117.
- Mansouri, A.S., Hallonet, M. and Gruss, P. (1996). Pax genes and their roles in cell differentiation and development. *Curr Biol.* **8**:851-857.
- Marty, S., Berninger, B., Carroll, P. and Thoenen, H. (1996). GABAergic stimulation regulates the phenotype of hippocampal interneurons through the regulation of brain-derived neurotrophic factor. *Neuron* **16**:565-570.
- Maruyama, K. (1991). The discovery of adenosine triphosphate and the establishment of its structure. *J History Biol.* **24**:145-154.
- Mathews, C.K. and van Holde, K.E. (1990). Biochemistry. The Benjamin/Cummings Publishing Company, Inc.
- Mattson, M.P. and Kater, S.B. (1987). Calcium regulation of neurite elongation and growth cone motility. *J Neurosci.* **7**:4034-4043.
- Maugeri, N., Bermejo, E. and Lazzari, M.A. (1990). Adenosine triphosphate released from human mononuclear cells. *Thromb Res.* **59**:887-890.
- McConalogue, K. and Furness, J.B. (1994). Gastrointestinal neurotransmitters. *Baillieres Clin Endocrinol Metab.* **8**:51-76.
- McLachlan, J. (1994). Medical Embryology. Addison-Wesley, Wokingham.

- McMurtry, I.F. (2002). Introduction: pre- and postnatal lung development, maturation, and plasticity. *Am J Physiol Lung Cell Mol Physiol.* **282**:L341-L344.
- Merriman-Smith, R., Tinstall, M., Kistler, J., Donaldson, P., Housley, G. and Eckert, R. (1998). Expression profiles of P2-receptor isoforms P2Y1 and P2Y2 in the rat lens. *Invest Ophthalmol Vis Sci.* **39**:2791-2796.
- Meyer, M.P., Clarke, J.D.W., Patel, K., Townsend-Nicholson, A. and Burnstock, G. (1999a). Selective expression of purinoceptor cP2Y<sub>1</sub> suggests a role for nucleotide signaling in development of the chick embryo. *Dev Dyn.* **214**:152-158.
- Meyer, M.P., Gröschel-Stewart, U., Robson, T. and Burnstock, G. (1999b). Expression of two ATP-gated ion channels, P2X<sub>5</sub> and P2X<sub>6</sub>, in developing chick skeletal muscle. *Dev Dyn.* **216**:442-449.
- Meyer, M.P., Swann, K., Burnstock, G. and Clarke, J.D.W. (2001). The extracellular ATP receptor, cP2Y<sub>1</sub>, inhibits cartilage formation in micromass cultures of chick limb mesenchyme. *Dev Dyn.* **222**:494-505.
- Moore, D.J., Chambers, J.K., Wahlin, J-P., Tan, K.B., Moore, G.B., Jenkins, O., Emson, P.C. and Murdock, P.R. (2001). Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription-polymerase chain reaction study. *Biochim Biophys Acta.* **1521**:107-119.
- Nagasawa, J. (1977). The common release mechanism of secretory granules in glandular cells, neurosecretory cells, neurons and paraneurons. *Arch Histol Jpn.* **40**Suppl:31-47.
- Narayanan, C.H. and Narayanan, Y. (1978). Determination of the embryonic origin of the mesencephalic nucleus of the trigeminal nerve in birds. *J Embryol Exp Morphol.* **43**: 85-105.
- Neary, J.T. (2000). Trophic actions of extracellular ATP: gene expression profiling by DNA array analysis. *J Auton Nerv Syst.* **81**:200-204.

- Neary, J.T., Kang, Y., Bu, Y., Yu, E., Akong, K. and Peters, C.M. (1999). Mitogenic signaling by ATP/P2Y purinergic receptors in astrocytes: involvement of a calcium-independent protein kinase C, extracellular signal-regulated protein kinase pathway distinct from the phosphatidylinositol-specific phospholipase C/calcium pathway. *J Neurosci.* **19**:4211-4220.
- Neary, J.T., McCarthy, M., Kang, Y. and Zuniga, S. (1998). Mitogenic signaling from P1 and P2 purinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures. *Neurosci Lett.* **242**:159-162.
- Neary, J.T., Rathbone, M.P., Cattabeni, F., Abbracchio, M.P. and Burnstock, G. (1996). Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. *Trends Neurosci.* **19**:13-18.
- Nicholas, R.A., Watt, W.C., Lazarowski, E.R., LI, Q. and Harden, K. (1996). Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective and an ATP- and UTP-specific receptor. *Mol Pharmacol.* **50**:224-229.
- Nikolic, P., Housley, G.D. and Thorne, P.R. (2003). Expression of the P2X<sub>7</sub> receptor subunit of the adenosine 5'-triphosphate-gated ion channel in the developing and adult rat cochlea. *Audiol Neurootol.* **8**:28-37.
- Nomura, N., Nagase, T., Miyajima, N., Sazuka, T., Tanaka, A., Sato, S., Seki, N., Kawarabayasi, Y., Ishikawa, K. and Tabata, S. (1994). Prediction of the coding sequences of unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1 (supplement). *DNA Res.* **1**:251-262.
- Nörenberg, W. and Illes, P. (2000). Neuronal P2X receptors: localization and functional properties. *Naunyn-Schmiedeberg's Arch Pharmacol.* **362**:324-339.
- Nori, S., Fumagalli, L., Bo, X., Bogdanov, Y. and Burnstock, G. (1998). Coexpression of mRNAs for P2X<sub>1</sub>, P2X<sub>2</sub> and P2X<sub>4</sub> receptors in rat vascular smooth muscle: an in situ hybridization and RT-PCR study. *J Vasc Res.* **35**:179-185.



- North RA. (1996). P2X purinoceptor plethora. *Semin Neurosci* **8**: 187-194.
- North, R.A. (2002). Molecular physiology of P2X receptors. *Physiol Rev.* **82**:1013-1067.
- Norton, W.H., Rohr, K.B. and Burnstock, G. (2000). Embryonic expression of a P2X(3) receptor encoding gene in zebrafish. *Mech Dev.* **99**:149-152.
- Novak, I., Nitschke, R. and Amstrup, J. (2002). Purinergic receptors have different effects in rat exocrine pancreas. Calcium signals monitored by Fura-2 using confocal microscopy. *Cell Physiol Biochem.* **12**:83-92.
- Oglesby, I.B., Lachnit, W.G., Burnstock, G. and Ford, A.P.D.W. (1999). Subunit specificity of polyclonal antisera to the carboxy terminal regions of P2X receptors, P2X<sub>1</sub> through P2X<sub>7</sub>. *Drug Dev Res.* **47**: 189-195.
- Olsson, R.A. and Pearson, J.D. (1990). Cardiovascular purinoceptors. *Physiol Rev.* **70**:761-845.
- Olson, E.N. and Srivastava, D. (1996). Molecular pathways controlling heart development. *Science* **272**:671-676.
- Olson, E.N. and Williams, R.S. (2000a). Calcineurin signaling and muscle remodeling. *Cell* **101**:689-92.
- Olson, E.N. and Williams, R.S. (2000b). Remodeling muscles with calcineurin. *Bioessays* **22**:510-9.
- Pattyn, A., Morin, X., Cremer, H., Golidis, C. and Brunet, J.F. (1997). Expression and interactions of the two closely related homeobox genes Phox2a and Phox2b during neurogenesis. *Development* **124**:4065-4075.
- Pearson, J.D. and Gordon, J.L. (1979). Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotide. *Nature* **281**:384-386.
- Pelleg, A. and Belardinelli, L. (1998). Effects of extracellular adenosine and ATP on cardiomyocytes. R.G. Landes Company, Biomedical Publishes, Austin, Texas, pp1-225.

- Petit, P., Hillaire-Buys, D., Loubatieres-Mariani, M.M. and Chapal, J. (2001). Purinergic and Pyrimidinergic Signalling II - Cardiovascular, Respiratory, Immune, Metabolic and Gastrointestinal Tract Function *In: Handbook of Experimental Pharmacology, Volume 151/II.*, Eds. Abbracchio, M.P. & Williams, M., Springer-Verlag, Berlin. pp.377-391.
- Pictet, R. and Rutter, W. J. (1972). Development of the embryonic endocrine pancreas. *In. Handbook of Physiology/Endocrinology vol. 7.* Steiner, D.F., Frenkel, N. Eds Washington DC, American Physiological Society, pp. 25-66.
- Placzek, M. (1995). The role of the notochord and floor plate in inductive interactions. *Curr Opin Genet Dev.* 5:499-506.
- Pillois, X., Chaulet, H., Belloc, I., Dupuch, F., Desgranges, C. and Gadeau, A.P. (2002). Nucleotide receptors involved in UTP-induced rat arterial smooth muscle cell migration. *Circ Res.* 90:678-81.
- Prasadan, K., Daume, E., Preuett, B., Spilde, T., Bhatia, A., Kobayashi, H., Hembree, M., Manna, P. and Gittes, G.K. (2002). Glucagon is required for early insulin-positive differentiation in the developing mouse pancreas. *Diabetes* 51:3229-3236.
- Queiroz, G., Meyer, D.K., Meyer, A., Starke, K. and von Kügelgen, I. (1999). A study of the mechanism of the release of ATP from rat cortical astroglial cells evoked by activation of glutamate receptors. *Neuroscience* 91:1171-1181.
- Radford, K.M., Virginio, C., Surprenant, A., North, R.A. and Kawashima, E. (1997). Baculovirus expression provides direct evidence for heteromeric assembly of P2X<sub>2</sub> and P2X<sub>3</sub> receptors. *J Neurosci.* 17:6529-6533.
- Ralevic, V. and Burnstock, G. (1991). Roles of P2-purinoceptors in the cardiovascular system. *Circulation* 84:1-14.
- Ralevic, V. and Burnstock, G. (1998). Receptors for purines and pyrimidines. *Pharmacol Rev.* 50:413-492.

- Rall, L. B., Pictet, R. L., Williams, R. H. and Rutter, W. J. (1973).** Early differentiation of glucagon-producing cells in embryonic pancreas: a possible developmental role for glucagon. *Proc Natl Acad Sci USA.* **70**:3478-3482.
- Reiser, P. J., Westfall, M. V., Schiaffino, S. and Solaro, R. J. (1994).** Tension production and thin-filament protein isoforms in developing rat myocardium. *Am J Physiol Heart Circ Physiol.* **267**:H1589-1596.
- Rice, W.R., Burton, F.M. and Fiedeldey, D.T. (1995).** Cloning and expression of the alveolar Type II cell P2U-purinergic receptor. *Am J Respir Cell Mol Biol.* **12**:27-32.
- Rice, W.R. and Singleton, F.M. (1987).** P2Y-purinoceptor regulated surfactant secretion from rat isolated alveolar type II cells is associated with mobilization of intracellular calcium. *Br J Pharmacol.* **91**:833-838.
- Roberts, C., Roberts, G. A., Lobner, K., Bearzatto, M., Clark, A., Bonifacio, E. and Christie, M. R. (2001).** Expression of the protein tyrosine phosphatase-like protein IA-2 during pancreatic islet development. *J Histochem Cytochem.* **49**:767-775.
- Roberts, D.J. (2000).** Molecular mechanisms of development of the gastrointestinal tract. *Dev Dyn.* **219**:109-120.
- Roelink, H., Augsburger, A., Heemskerk, J., Korzh, V., Norlin, S., Ruiz, I., Altaba, A., Tanabe, Y., Placzek, M., Edlund, T., Jessell, T.M. and Dodd, J. (1994).** Floor plate and motor neuron induction by vhh-1, a vertebrate homolog of hedgehog expressed by the notochord. *Cell* **76**: 761-775.
- Ruppelt, A., Liang, B.T. and Soto, F. (1999).** Cloning, functional characterization and developmental expression of a P2X receptor from chick embryo. *Prog Brain Res.* **120**:81-90.
- Ruppelt, A., Ma, W., Borchardt, K., Sillberberg, S. D. and Soto, F. (2001).** Genomic structure, developmental distribution and functional properties of the chicken P2X<sub>5</sub> receptor. *J*

- Neurochem.* **77**:1256-1265.
- Ryten, M., Dunn, P., Neary, J.T. and Burnstock, G. (2002). ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X<sub>5</sub> receptor on satellite cells. *J Cell Biol.* **158**:345-355.
- Ryten, M., Hoebertz, A. and Burnstock, G. (2001). Sequential expression of three receptor subtypes for extracellular ATP in developing rat skeletal muscle. *Dev Dyn.* **221**:331-341.
- Sak, K. and Webb, T.E. (2002). A retrospective of recombinant P2Y receptor subtypes and their pharmacology. *Arch Biochem Biophys.* **397**:131-136.
- Sanes, J.R. and Lichtman, J.W. (2001). Induction, assembly, maturation and maintenance of a postsynaptic apparatus. *Nat Rev Neurosci.* **2**:791-805.
- Sawtell, N.M. and Lessard, J.L. (1989). Cellular distribution of smooth muscle actins during mammalian embryogenesis: expression of the  $\alpha$ -vascular but not the Y-enteric isoform in differentiating striated myocytes. *J Cell Biol.* **109**: 2929-2937.
- Schadlich, H., Wirkner, K., Franke, H., Bauer, S., Grosche, J., Burnstock, G., Reichenbach, A., Illes, P. and Allgaier, C. (2001). P2X(2), P2X(2-2) and P2X(5) receptor subunit expression and function in rat thoracolumbar sympathetic neurons. *J Neurochem.* **79**:997-1003.
- Schlenk, F. (1987). The ancestry, birth, and adolescence of adenosine triphosphate. *Trends Biochem Sci.* **12**:367-368.
- Schwiebert, E.M. (1999). ABC transporter-facilitated ATP conductive transport. *Am J Physiol.* **276**:C1-C8.
- Sedaa, K.O., Bjur, R.A., Shinozuka, K. and Westfall, D.P. (1990). Nerve and drug-induced release of adenine nucleosides and nucleotides from rabbit aorta. *J Pharmacol Exp Ther.* **252**:1060-1067.
- Sedmera, D., Pexieder, T., Vuillemin, M., Thompson, R.P. and Anderson, R.H. (2000). Developmental patterning of the myocardium. *Anat Rec.* **258**:319-337.

- Séguéla, P., Haghghi, A., Soghomonian, J-J. and Cooper, E. (1996). A novel neuronal P<sub>2X</sub> ATP receptor ion channel with widespread distribution in the brain. *J Neurosci.* **16**:448-455.
- Seifert, R. and Schultz, G. (1989). Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracil nucleotides. *Trends Pharmacol Sci.* **10**:365-369.
- Shibuya, I., Tanaka, K., Hattori, Y., Uezono, Y., Nobuya, H., Noguchi, J., Ueta, Y., Izumi, F. and Yamashita, H. (1999). Evidence that multiple P<sub>2X</sub> purinoceptors are functionally expressed in rat supraoptic neurons. *J. Physiol.* **514**:351-367.
- Simon, J., Filippov, A.K., Goransson, S., Wong, Y.H., Frelin, C., Michel, A.D., Brown, D.A. and Barnard, E.A. (2002). Characterization and channel coupling of the P<sub>2Y</sub>(12) nucleotide receptor of brain capillary endothelial cells. *J Biol Chem.* **277**:31390-31400.
- Skladchikova, G., Ronn, L. C., Berezin, V. and Bock, E. (1999). Extracellular adenosine triphosphate affects neural cell adhesion molecule (NCAM)-mediated cell adhesion and neurite outgrowth. *J. Neurosci. Res.* **57**:207-218.
- Smart, M.L., Gu, B., Panchal, R.G., Wiley, J., Cromer, B., Williams, D.A. and Petrou, S. (2003). P<sub>2X</sub><sub>7</sub> receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. *J Biol Chem.* **278**:8853-8860.
- Sneddon, P. and Burnstock, G. (1984). ATP as a co-transmitter in rat tail artery. *Eur J Pharmacol.* **106**:149-152.
- Soto, F., Garcia-Guaman, M., Gomez-Hernandez, J.M., Hollmann, M., Karschin, C. and Stühmer, P. (1996). P<sub>2X</sub><sub>4</sub>; an ATP-activated ionotropic receptor cloned from rat brain. *Proc Natl Acad Sci USA.* **93**:3684-3688.
- Sperlágh, B., Köfalvi, A., Deuchars, D., Atkinson, L., Milligan, C. J., Buckley, N. J. and Vizi, E. S. (2002). Involvement of P<sub>2X</sub><sub>7</sub> receptors in the regulation of neurotransmitter release in the rat hippocampus. *J. Neurochem.* **81**:1196-1211.
- St-Onge, L., Wehr, R. and Gruss, P. (1999). Pancreas development and diabetes. *Curr Opin Genet Dev.* **9**:295-300.

- Su, C., Bevan, J.A. and Burnstock, G. (1971). [<sup>3</sup>H]adenosine triphosphate; release during stimulation of enteric nerves. *Science* **173**:337-339.
- Sugioka, M., Fukuda, Y. and Yamashita, M. (1996). Ca<sup>2+</sup> responses to ATP via purinoceptors in the early embryonic chick retina. *J Physiol (Lond)*. **493**:855-863.
- Surprenant, A., Rassendren, F., Kawashima, E., North, R.A. and Buell, G. (1996). The cytolytic P<sub>2Z</sub> receptor for extracellular ATP identified as a P2X receptor (P2X<sub>7</sub>). *Science* **272**:735-738.
- Surprenant, A., Schneider, D.A., Wilson, H.L., Galligan, J.J. and North, R.A. (2000). Functional properties of heteromeric P2X<sub>1/5</sub> receptors expressed in HEK cells and excitatory junction potentials in guinea pig submucosal arterioles. *J Auton Nerv Syst*. **81**:249-263.
- Tajbakhsh, S., Rocancourt, D., Cossu, G. and Buckingham, M. (1997). Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. *Cell* **89**:127-138.
- Teitelman, G., Alpert, S., Polak, J. M., Martinez, A. and Hanahan, D. (1993). Precursor cells of mouse endocrine pancreas coexpress insulin, glucagon and the neuronal proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic polypeptide. *Development* **118**:1031-1039.
- Tenneti, L., Gibbons, S.J. and Talamo, B.R. (1998). Expression and trans-synaptic regulation of P2X<sub>4</sub> and P2z receptors for extracellular ATP in parotid acinar cells. Effects of parasympathetic denervation. *J Biol Chem*. **273**:26799-26808.
- Teixeira, M., Butlen, D., Ferrary, E., Sterkers, O. and Escoubet, B. (2000). Identification of uridine 5'-triphosphate receptor mRNA in rat cochlear tissues. *Acta Otolaryngol*. **120**:156-159.
- Torres, G.E., Egan, T.M. and Voigt, M.M. (1999). Hetero-oligomeric assembly of P2X receptor subunits. *J Biol Chem*. **274**:6653-6659.
- Torres, G.E., Haines, W.R., Egan, T.M. and Voigt, M.M. (1998). Co-expression of P2X<sub>1</sub> and

- P2X<sub>5</sub> receptor subunits reveals a novel ATP-gated ion channel. *Mol Pharmacol.* **54**:989-993.
- Ueno, S., Tsuda, M., Iwanaga, T. and Inoue, K. (1999). Cell type-specific ATP-activated responses in rat dorsal root ganglion neurons. *Br J Pharmacol* **126**: 429-436.
- Unterberger, U., Moskvina, E., Scholze, T., Freissmuth, M. and Boehm, S. (2002). Inhibition of adenylyl cyclase by neuronal P2Y receptors. *Br J Pharmacol.* **135**:673-684.
- Vainio, S. and Lin, Y. (2002). Coordinating early kidney development: lessons from gene targeting. *Nat Rev Genet.* **3**:533-543.
- Valera, S., Hussy, N., Evans, R.J., Adami, N., North, R.A., Surprenant, A. and Buell, G. (1994). A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP. *Nature* **371**:516-519.
- van den Pol, A.N., Obrietan, K., Cao, V. and Trombley, P.Q. (1995). Embryonic hypothalamic expression of functional glutamate receptors. *Neuroscience* **67**:419-439.
- Van Nassauw, L., Brouns, I., Adriaensen, D., Burnstock, G. and Timmermans, J.P. (2002). Neurochemical identification of enteric neurons expressing P2X(3) receptors in the guinea-pig ileum. *Histochem Cell Biol.* **118**:193-203.
- Van Rhee, A.M., Fischer, B., Van Galen, P.J.M. and Jacobson, K.A. (1995). Modelling the P<sub>2Y</sub> purinoceptor using rhodopsin as template. *Drug Res Discov.* **13**:133-154.
- Varela-Echavarria, A., Pfaff, S.L. and Guthrie, S. (1996). Differential expression of LIM homeobox genes among motor neuron subpopulations in the developing chick brain stem. *Mol Cell Neurosci.* **8**:242-257.
- Vassort, G. (2001). Adenosine 5'-triphosphate: a P2-purinergic agonist in the myocardium. *Physiol Rev.* **81**:767-806.
- Virginio, C., North, R.A. and Surprenant, A. (1998). Calcium permeability and block at homomeric and heteromeric P2X<sub>2</sub> and P2X<sub>3</sub> receptors and receptors in rat nodose neurons. *J Physiol.* **510**:27-35.

- Vizi, E.S. and Burnstock, G. (1988). Origin of ATP release in the rat vas deferens; concomitant measurement of [<sup>3</sup>H]noradrenaline and [<sup>14</sup>C]ATP. *Eur J Pharmacol.* **158**:69-77.
- Vöhringer, C., Schfer, R. and Reiser, G. (2000). A chimeric rat brain P2Y1 receptor tagged with green-fluorescent protein: high affinity ligand recognition of adenosine diphosphates and triphosphates and selectivity identical to that of the wild-type receptor. *Biochem Pharmacol.* **59**:791-800.
- Von Kügelgen, I. and Wetter, A. (2000). Molecular pharmacology of P2Y receptors. *Naunyn-Schmiedeberg's Arch Pharmacol.* **362**:310-323.
- Vulchanova, L., Arvidsson, U., Riedl, M., Wang, J., Buell, G., Surprenant, A., North, R.A. and Elde, R. (1996). Differential distribution of two ATP-gated channels (P2X receptors) determined by immunocytochemistry. *Proc Natl Acad Sci USA.* **93**, 8063-8067.
- Vulchanova, L., Riedl, M.S., Shuster, S.J., Buell, G., Surprenant, A., North, R.A. and Elde, R. (1997). Immunohistochemical study of the P2X<sub>2</sub> and P2X<sub>3</sub> receptor subunits in rat and monkey sensory neurons and their central terminals. *Neuropharmacology* **36**: 1229-1242.
- Vulchanova, L., Riedl, M.S., Shuster, S.J., Stone, L.S., Hargreaves, K.M., Buell, G., Surprenant, A., North, R.A. and Elde, R. (1998). P2X<sub>3</sub> is expressed by DRG neurons that terminate in inner lamina II. *Eur J Neurosci.* **10**:3470-3478.
- Wang, C-Z., Namba, N., Gono, T., Inagaki, N. and Seino, S. (1996). Cloning and pharmacological characterization of a fourth P2X receptor subtype widely expressed in brain and peripheral tissues including various endocrine tissues. *Biochem Biophys Res Commun.* **220**:196-202.
- Waschek, J.A. (2002). Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. *Dev Neurosci.* **24**:14-23.
- Webb, T.E., Boluyt, M.O. and Barnard, E.A. (1996). Molecular biology of P2Y purinoceptors: expression in rat heart. *J Auton Pharmacol.* **16**:303-307.



- Webb, T.E., Henderson, D.J., Roberts, J.A. and Barnard, E.A. (1998). Molecular cloning and characterization of the rat P2Y4 receptor. *J Neurochem.* **71**:1348-1357.
- Webb, T.E., Simon, J., Krishek, B.J., Bateson, A.N., Smart, T.G., King, B.F., Burnstock, G. and Barnard, E.A. (1993). Cloning and functional expression of a brain G-protein-coupled ATP receptor. *FEBS Lett.* **324**:219-225.
- Wells, D.G., Zawisa, M.J. and Hume, R.I. (1995). Changes in responsiveness to extracellular ATP in chick skeletal muscle during development and upon denervation. *Dev Biol.* **172**:585-590.
- Westfall, D.P., Stitzel, R.E. and Rowe, J.N. (1978). The postjunctional effects and neural release of purine compounds in the guinea-pig vas deferens. *Eur J Pharmacol.* **50**:27-38.
- Wheeler-Schilling, T.H., Marquardt, K., Kohler, K., Güenther, E. and Jabs, R. (2001). Identification of purinergic receptors in retinal ganglion cells. *Brain Res Mol Brain Res.* **92**:177-180.
- Wheeler-Schilling, T.H., Marquardt, K., Kohler, K., Jabs, R. and Güenther, E. (2000). Expression of purinergic receptors in bipolar cells of the rat retina. *Brain Res Mol Brain Res.* **76**:415-418.
- Wittenberger, T., Schaller, H.C. and Hellerbrand, S. (2001). An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors. *J Mol Biol.* **307**:799-813.
- Woodcock-Mitchell, J., Mitchell, J.J., Low, R.B., Kieny, M., Sengel, P., Rubbia, L., Skalli, O., Jackson, B. and Gabbiani, G. (1988).  $\alpha$ -Smooth muscle actin is transiently expressed in embryonic rat cardiac and skeletal muscles. *Differentiation* **39**: 161-166.
- Xiang, Z., Bo, X. and Burnstock, G. (1998). Localization of ATP-gated P2X receptor immunoreactivity in rat sensory and sympathetic ganglia. *Neurosci Lett.* **256**:105-108.
- Xiang, Z., Bo, X. and Burnstock, G. (1999). P2X receptor immunoreactivity in the rat cochlea,

- vestibular ganglion and cochlear nucleus. *Hearing Res.* **128**:190-196.
- Yamada, T., Pfaff, S.L., Edlund, T. and Jessell TM. (1993). Control of cell pattern in the neural tube: motor neuron induction by diffusible factors from notochord and floor plate. *Cell* **73**:673-686.
- Yao, S.T., Barden, J.A., Finkelstein, D.I., Bennett, M.R. and Lawrence, A.J. (2000). Comparative study on the distribution patterns of P2X<sub>1</sub>-P2X<sub>6</sub> receptor immunoreactivity in the brainstem of the rat and the common marmoset (*Callithrix jacchus*): association with catecholamine cell groups. *J Comp Neurol.* **427**: 485-507.
- Yutzey, K.E. and Bader, O. (1995). Diversification of cardiomyogenic cell lineages during early heart development. *Circ Res.* **77**:216-219.
- Zhang, F.L., Luo, L., Gustafson, E., Palmer, K., Qiao, X., Fan, X., Yang, S., Laz, T.M., Bayne, M. and Monsma, F. Jr. (2002). P2Y<sub>13</sub>: Identification and characterization of a novel G<sub>αi</sub>-coupled ADP receptor from human and mouse. *J Pharmacol Exp Ther.* **301**:705-713.
- Zhao, Z. and Rivkees, S.A. (2000). Programmed cell death in the developing heart: regulation by BMP4 and FGF2. *Dev Dyn.* **217**:388-400.
- Zhao, Z. and Rivkees, S.A. (2001). Inhibition of cell proliferation in the embryonic myocardium by A1 adenosine receptor activation. *Dev Dyn.* **221**:194-200.
- Zhao, Z., Yaar, R., Ladd, D., Cataldo, L.M. and Ravid, K. (2002). Overexpression of A3 adenosine receptors in smooth, cardiac, and skeletal muscle is lethal to embryos. *Microvasc Res.* **63**:61-69.
- Zhong, Y., Dunn, P.M. and Burnstock, G. (2000). Pharmacological comparison of P2X receptors on rat coeliac, mouse coeliac and mouse pelvic ganglion neurons. *Neuropharmacology* **39**: 172-180.

## Appendix

**Table 1: Primer sequence for P2X and P2Y receptors in RT-PCR analysis**

Receptor	Primer sequence (5' to 3')	Primer position	Product length (bp)
P2X <sub>1</sub> forward	GAAGTGTGATCTGGACTGGCACGT	776-801	452
P2X <sub>1</sub> reverse	GCGTCAAGTCCGGATCTCGACTAA	1203-1231	
P2X <sub>2</sub> forward	GAATCAGAGTGCAACCCCAA	826-845	357
P2X <sub>2</sub> reverse	TCACAGGCCATCTACTTGAG	1183-1164	
P2X <sub>3</sub> forward	TGGCGTTCTGGGTATTAAGATCGG	708-731	440
P2X <sub>3</sub> reverse	CAGTGGCCTGGTCACTGGCGA	1126-1147	
P2X <sub>4</sub> forward	GAGGCATCATGGGTATCCAGATCAAG	749-774	447
P2X <sub>4</sub> reverse	GAGCGGGGTGGAAATGTAAC TTAG	1170-1195	
P2X <sub>5</sub> forward	GCCGAAAGCTTCACCATTCCATAA	553-577	418
P2X <sub>5</sub> reverse	CCTACGGCATCCGCTTTGATGTGATAG	944-970	
P2X <sub>6</sub> forward	AAAGACTGGTCAGTGTGTGGCGTTC	444-468	520
P2X <sub>6</sub> reverse	TGCCTGCCAGTGACAAGAATGTCAA	938-963	
P2X <sub>7</sub> forward	GTGCCATTCTGACCAGGGTTGTATAAA	384-410	354
P2X <sub>7</sub> reverse	GCCACCTCTGTAAAGTTCTCTCCGATT	711-737	
P2Y <sub>1</sub> forward	ACGTCAGATGAGTACCTGCG	1235-1254	289
P2Y <sub>1</sub> reverse	CCCTGTCGTTGAAATCACAC	1504-1523	
P2Y <sub>2</sub> forward	CTGGTCCGCTTTGCCCGAGATG	1417-1438	311
P2Y <sub>2</sub> reverse	TATCCTGAGTCCCTGCCAAATGAGA	1703-1727	
P2Y <sub>4</sub> forward	TGTTCCACCTGGCATTGTCAG	1586-1586	294
P2Y <sub>4</sub> reverse	AAAGATTGGGCACGAGGCAG	1840-1859	
P2Y <sub>6</sub> forward	TGCTTGGGTGGTATGTGGAGTC	868-889	339
P2Y <sub>6</sub> reverse	CAATAGTCGAAGGACGGAAAGGT	1184-1206	

Shibuya et al (1999); Bailey et al. (2000, 2001)